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ABSTRACT 
 
Quinones are compounds present in nature with essential functions to the survival 
of living beings, such as defence or energy production. The great majority of quinones 
may be divided into three groups according to the number of aromatic rings: 
benzoquinones, naphthoquinones and anthraquinones. In the work developed for this 
thesis, naphthoquinones (diospyrin, diosquinone, juglone, menadione, naphthazarin and 
plumbagin) and ubiquinone analogues (idebenone and decylubiquinone), which are 
prenylated benzoquinones, were the studied compounds. Although several biological 
activities of naphthoquinones have been explored, little is known about their ability to 
modulate the immune system. On the other hand, ubiquinone analogues are promising 
drugs for the treatment of neurodegenerative disorders. Nevertheless, until now, 
idebenone and decylubiquinone were not studied in a model of mitochondrial dysfunction 
or in a model of Parkinsonism induced by MPP+ in zebrafish. Therefore, the main goals of 
this thesis were: naphthoquinones screening as potential anti-inflammatory and anti-
allergic drugs; the study of naphthoquinones’ toxicity in an in vivo model; and the study of 
the ubiquinone analogues’ potential in rescuing a Parkinsonian phenotype or a 
mitochondrial dysfunction in an in vivo model. 
In order to evaluate naphthoquinones’ anti-inflammatory properties, we studied 
their ability to reduce nitric oxide production in lipopolysaccharide-stimulated cells (RAW 
264.7 macrophages). Diosquinone was the only naphthoquinone that reduced nitric oxide 
production. However, as naphthoquinones may undergo redox cycles, they may generate 
superoxide anion that can react with nitric oxide, consuming it and forming peroxynitrite. 
Therefore, we quantified the superoxide radical and 3-nitrotyrosine, which is an important 
hallmark of peroxynitrite-induced toxicity. Both superoxide radical and 3-nitrotyrosine were 
not increased in the presence of diosquinone, with the diosquinone anti-inflammatory 
activity being confirmed by the associated reduction in pro-inflammatory cytokines’ 
production. Diosquinone anti-inflammatory properties might be valuable in the process of 
developing novel treatments for other pathologies with an associated inflammatory 
process, such as allergy. However, diosquinone was unable to inhibit RBL-2H3 basophils’ 
degranulation induced by either antibody-antigen complex or calcium ionophore. In 
contrast, diospyrin reduced calcium ionophore-induced degranulation and naphthazarin 
reduced antibody-antigen complex-induced degranulation. These results suggest that 
diospyrin and naphthazarin have different mechanisms of action. Also related to the study 
of naphthoquinones’ anti-allergic properties, results from this thesis suggest that the 
tested naphthoquinones are weak hyaluronidase inhibitors, but able to inhibit soybean 
lipoxidase, an enzyme structurally similar to 5-lipoxygenase. Menadione, diospyrin and 
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diosquinone were the naphthoquinones with strongest lipoxidase inhibitory activity. As 
these naphthoquinones were the most lipophilic among tested compounds, it is possible 
that they compete with natural lipoxidase substrates, which are also lipophilic. From these 
three naphthoquinones, only menadione inhibited leukotriene C4 production in intact cells. 
When tested in zebrafish embryos, most naphthoquinones were more toxic than in 
cell lines, such as RAW 264.7 or RBL-2H3 cells. Naphthoquinones showed different 
patterns of toxicity, which may be related with their lipophilic properties. Among 
monomeric naphthoquinones, naphthazarin and juglone directly killed zebrafish embryos 
without intermediate abnormalities, whereas menadione and plumbagin primarily evoked 
morphological/developmental abnormalities. Menadione in particular caused 
hyprochromic anaemia in zebrafish embryos, possibly via reduced hematopoiesis related 
with mitochondrial membrane potential disruption.  
In order to assess the putative protective effects of ubiquinone analogues in 
mitochondrial dysfunction and Parkinson’s disease models, we exposed zebrafish 
embryos/larvae to mitochondrial inhibitors and MPP+, a dopaminergic toxin inhibiting 
mitochondrial complex I. Inhibitors of complexes I and II induced abnormalities in 
zebrafish embryos, while complex III inhibitors were highly lethal without inducing prior 
abnormalities, likely due to lack of alternative downstream pathways to feed the 
mitochondrial respiratory chain. In fact, ubiquinone analogues delayed cardio-circulatory 
arrest in zebrafish larvae acutely exposed to rotenone (a mitochondrial complex I inhibitor), 
while failing to delay the arrest induced by complex III inhibition. Attending to these results 
and to the fact that oligomycin (an ATP synthase inhibitor) also delayed the heartbeat 
arrest of rotenone-treated larvae, the protection induced by ubiquinone analogues might 
be due to sustaining/delaying energy dissipation. Ubiquinone analogues may directly feed 
the complex III, provided they are firstly reduced by dehydrogenases, such as cytosolic 
NAD(P)H quinone-oxidoreductase. Ubiquinone analogues, however, failed to 
rescue/delay chronic rotenone toxicity, suggesting only transient effects at the respiratory 
chain, or additional toxicity pathways of chronic rotenone exposure.  
MPP+ (500 µM) induced an abnormal locomotor profile and sensorimotor reflexes, 
apparently without peripheral toxicity, as assessed by normal neuromast labelling; and no 
generalized mitochondrial toxicity, as assessed in mitochondrial extracts from whole-
larvae or even head/body splits. Despite the protective effect verified against an acute 
complex I dysfunction, the ubiquinone analogues did not rescue the MPP+-induced 
locomotor phenotype. One possible explanation is that MPP+ toxicity may rely on its 
mitochondrial membrane potential-dependent uptake, and with this being sustained by 
ubiquinone analogues, it would also sustain MPP+ incorporation and toxicity. 
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Summing up: diosquinone reduced nitric oxide and pro-inflammatory cytokine 
production; naphthazarin reduced basophils’ degranulation upstream from intracellular 
calcium increase, while diospyrin reduced calcium ionophore-induced basophils’ 
degranulation; menadione reduced leukotrienes levels in a cellular system; ubiquinone 
analogues were protective against an acute mitochondrial complex I dysfunction in 
zebrafish embryos, but they did not rescue the MPP+-induced Parkinsonian phenotype in 
zebrafish larvae. 
 
Keywords: Naphthoquinones, Ubiquinone analogues; Inflammation; Allergy; 
Neurodegenerative disorders; Mitochondria; Zebrafish.  
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RESUMO 
 
As quinonas são compostos presentes na Natureza com funções essenciais à 
sobrevivência dos seres vivos, tais como a defesa ou a produção energia. A maioria das 
quinonas pode ser dividida em três grupos de acordo com o número de anéis aromáticos: 
benzoquinonas, naftoquinonas e antraquinonas. As naftoquinonas (diospirina, 
diosquinona, juglona, menadiona, naftazarina e plumbagina) e os análogos de ubiquinona 
(idebenona e decilubiquinona), que são benzoquinonas preniladas, foram os compostos 
estudados no trabalho desenvolvido para esta tese. Várias atividades biológicas das 
naftoquinonas têm sido exploradas; contudo, o conhecimento sobre a sua capacidade 
para modularem o sistema imunitário é reduzido. Por outro lado, os análogos de 
ubiquinona são compostos promissores no tratamento de doenças neurodegenerativas, 
apesar de, até à data, a idebenona e a decilubiquinona não terem sido estudadas num 
modelo de disfunção mitocondrial ou num modelo de Parkinsonismo induzido pelo MPP+, 
em peixe-zebra. Deste modo, os principais objetivos desta tese foram: o screening de 
naftoquinonas como potenciais fármacos anti-inflamatórios e antialérgicos; o estudo da 
toxicidade das naftoquinonas num modelo in vivo; e o estudo do potencial de análogos de 
ubiquinona em resgatar um fenótipo Parkinsónico ou uma disfunção mitocondrial num 
modelo in vivo. 
Para avaliar as propriedades anti-inflamatórias das naftoquinonas, estudou-se a 
capacidade destas reduzirem a produção de óxido nítrico por um sistema celular 
(macrófagos RAW 264.7) sujeito à ação pró-inflamatória do lipopolissacarídeo. A 
diosquinona foi a única naftoquinona testada capaz de induzir um decréscimo na 
produção de óxido nítrico. Porém, as naftoquinonas podem sofrer ciclos de oxidação-
redução com geração do radical superóxido que, por sua vez, pode reagir com óxido 
nítrico, levando ao seu consumo e à formação de peroxinitrito. Assim, o radical 
superóxido e a 3-nitrotirosina, que constitui um dos principais marcadores de toxicidade 
do peroxinitrito, foram quantificados. Nenhum destes parâmetros estava aumentado na 
presença da diosquinona e a atividade anti-inflamatória desta foi confirmada pela redução 
da produção de citoquinas pró-inflamatórias. As propriedades anti-inflamatórias da 
diosquinona podem ser uma mais-valia para o tratamento de outras patologias com um 
processo inflamatório associado, como é o caso da alergia. Porém, a diosquinona não 
teve capacidade de inibir a desgranulação de basófilos RBL-2H3 quando estimulados por 
um complexo anticorpo-antigénio ou por um ionóforo de cálcio. Contrariamente à 
diosquinona, a diospirina reduziu a desgranulação induzida pelo ionóforo de cálcio, 
enquanto que a naftazarina reduziu a desgranulação induzida pelo complexo anticorpo-
antigénio. Estes resultados sugerem que a diospirina e a naftazarina apresentam 
RESUMO 	  
XXII 
diferentes mecanismos de ação. Ainda relacionado com o estudo da atividade 
antialérgica, resultados desta tese sugerem que as naftoquinonas testadas são fracos 
inibidores da hialuronidase, mas que apresentam capacidade para inibir a lipoxidase de 
soja, que é uma enzima estruturalmente semelhante à 5-lipoxigenase. As naftoquinonas 
que apresentaram uma maior atividade na inibição da lipoxidase foram a menadiona, a 
diospirina e a diosquinona. Como essas naftoquinonas são as que apresentam maior 
lipofilia entre as testadas, é provável que possam competir com os substratos naturais da 
lipoxidase, que são igualmente lipofílicos. Dessas três naftoquinonas, a menadiona foi a 
única que conseguiu inibir a produção de leucotrieno C4 num sistema celular. 
Quando testadas em embriões de peixe-zebra, as naftoquinonas foram, no geral, 
mais tóxicas do que quando testadas em linhas celulares, como nas células RAW 264.7 e 
RBL-2H3. As naftoquinonas mostraram diferentes perfis de toxicidade, que podem estar 
relacionados com as suas propriedades lipofílicas. Entre as naftoquinonas monoméricas, 
naftazarina e a juglona induziram diretamente a morte de embriões sem indução de 
anomalias, enquanto que a menadiona e a plumbagina promoveram inicialmente o 
desenvolvimento de anomalias. Em particular, a menadiona induziu uma anemia 
hipocrómica nos embriões de peixe-zebra, provavelmente devido a uma redução da 
hematopoiese relacionada com uma perturbação do potencial membranar mitocondrial. 
Para avaliar, os possíveis efeitos protetores dos análogos de ubiquinona num 
modelo de disfunção mitocondrial e num de Doença de Parkinson, embriões/larvas de 
peixe-zebra foram expostos a inibidores mitocondriais e ao MPP+, uma toxina 
dopaminérgica que inibe o complexo I mitocondrial. Os inibidores dos complexos I e II 
induziram anomalias nos embriões de peixe-zebra, enquanto que os inibidores do 
complexo III foram altamente letais, sem induzirem um estado de anormalidade, o que 
pode estar relacionado com a falta de alternativas ao complexo III na cadeia respiratória 
mitocondrial. De facto, os análogos de ubiquinona testados atrasaram a paragem 
cardiocirculatória de larvas de peixe-zebra tratadas de forma aguda com rotenona 
(inibidor do complexo I mitocondrial), enquanto que não foi verificada nenhuma proteção 
face à toxicidade induzida pelos inibidores do complexo III. Atendendo a estes resultados 
e ao facto da oligomicina (inibidor da ATP sintase) ter, igualmente, atrasado a perda de 
batimento cardíaco de larvas tratadas com rotenona, a proteção induzida pelos análogos 
de ubiquinona deve-se, provavelmente, a um atraso na depleção de energia. Os 
análogos de ubiquinona podem alimentar diretamente o complexo III mitocondrial, 
quando reduzidos previamente por desidrogenases, como a citosólica NAD(P)H quinona-
oxidoreductase. Contudo, os análogos de ubiquinona não induziram proteção contra a 
toxicidade crónica induzida pela rotenona, sugerindo que os análogos de ubiquinona 
possam ter apenas efeitos transientes na cadeia respiratória, ou que os efeitos tóxicos 
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decorrentes do tratamento crónico com rotenona não sejam apenas devido à inibição do 
complexo I. 
O MPP+ (500 µM) induziu um perfil de locomoção e de reflexos sensório-motores 
anormais, sem aparente toxicidade periférica (como foi avaliado pela normal marcação de 
neuromastos) e sem uma toxicidade mitocondrial generalizada (como foi verificado em 
extratos mitocondriais de larva-inteira ou mesmo em extratos mitocondriais da 
cabeça/corpo). Apesar do efeito protetor verificado face a uma disfunção aguda do 
complexo I, os análogos de ubiquinona não foram capazes de reverterem ou reduzirem a 
gravidade do fenótipo locomotor induzido pelo MPP+. Uma possível explicação para este 
resultado é que a acumulação do MPP+ na mitocôndria pode ser dependente do potencial 
de membrana mitocondrial, pelo que, como os análogos de ubiquinona são capazes de 
manterem esse potencial, podem contribuir para uma maior incorporação MPP+ na 
mitocôndria e consequentemente para o aumento da sua toxicidade. 
Retendo as principais observações/conclusões: a diosquinona diminuiu a 
produção de óxido nítrico, bem como de citoquinas pró-inflamatórias; a naftazarina inibiu 
a desgranulação de basófilos num passo da via metabólica anterior ao aumento de cálcio 
intracelular, enquanto que a diospirina reduziu a desgranulação de basófilos induzida por 
um ionóforo de cálcio; a menadiona reduziu os níveis de leucotrienos num sistema 
celular; os análogos de ubiquinona mostraram efeitos protetores contra uma disfunção 
aguda do complexo I mitocondrial em embriões de peixe-zebra, mas não resgataram o 
fenótipo Parkinsoniano induzido pelo MPP+ em larvas de peixe-zebra. 
 
Palavras-chave: Naftoquinonas; Análogos de ubiquinona; Inflamação; Alergia; Doenças 
neurodegenerativas; Mitocôndria; Peixe-zebra. 
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THESIS OUTLINE 	  
The present thesis contains four main sections: 
 
- CHAPTER I – INTRODUCTION AND OBJECTIVES 
This is a General Introduction section, addressing the main topics from the work-
plan of this thesis, including the study of naphthoquinones in the modulation of 
inflammation and allergy, as well as the study of ubiquinone analogues in the modulation 
of neurodegenerative disorders. This section includes only the essential information 
required to understand the experimental findings (results). Therefore, the first part of the 
General Introduction includes a brief approach to quinones and their chemical reactions, 
naphthoquinones and ubiquinone analogues. Moreover, it includes a focused description 
of the anti-inflammatory and anti-allergic properties of naphthoquinones (the two 
properties addressed in this thesis), and a more general review of the literature 
concerning naphthoquinones and their antitumoral and antimicrobial properties (the two 
properties more extensively studied in the literature). As the interest in ubiquinone 
analogues study in this thesis was due to the application of these drugs in mitochondrial 
dysfunction, only this topic was approached regarding ubiquinone analogues. The second 
part of the General Introduction comprises a brief description of inflammatory and allergic 
processes, as well as of neurodegenerative disorders, namely Parkinson’s disease, with 
special attention to mitochondrial function. This section ends with the objectives of this 
thesis. 
 
- CHAPTER II – EXPERIMENTAL SECTION 
The Experimental Section is divided in four items that correspond to the research 
papers originated from this thesis. Each paper includes a small introduction, material and 
methods section, results and discussion. 
 
- CHAPTER III – GENERAL DISCUSSION AND CONCLUSIONS 
This chapter discusses the key aspects of the different works and how they 
integrate with each other. Furthermore, the approached subjects are discussed according 
to recent bibliographic references. The thesis’ conclusions are enumerated at the end of 
this section. 
 
- CHAPTER IV – BIBLIOGRAPHIC REFERENCES 
This section comprises all the bibliographic references used in the writing of this 
thesis. 
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1. General Introduction 
 
Plants are living beings devoid of or with very limited motility, being susceptible to 
biotic and abiotic aggressions. Over the course of evolution, plants developed biosynthetic 
pathways to synthesize a wide variety of organic molecules, commonly named secondary 
metabolites (1, 2). These compounds can have several functions, such as structure 
stabilization, protection against ultraviolet (UV) radiation, insects and predators, as well as 
attractants, being responsible for colour and scents (1, 3). 
The study of secondary metabolites suffered a significant development in the last 
50 years (4), in which more than 200,000 compounds were described. However, it is 
expected that the number of compounds synthesized by all living organisms could be 
much higher (2, 5). The secondary metabolites are mainly classified according to their 
biosynthetic origin and/or structural features (1): alkaloids, flavonoids, terpenes and 
quinones are examples of some classes. This thesis will focus on the latter group. 
 
 
1.1. Quinones 
 
Quinones are ubiquitously present in nature, more than 1200 compounds being 
already described (6). Chemically, quinones are oxygen-containing compounds, in which 
a dione is conjugated with an aromatic nucleus. Three main groups are known: 
benzoquinones, naphthoquinones and anthraquinones (Figure 1.1).  
 
 
Figure 1.1. Basic chemical structure of the main groups of quinones.  
 
Despite several metabolic pathways being described for quinone biosynthesis, a 
limited number of precursors are known: precurors are derived from acetate or shikimate 
pathways (Figure 1.2). By the acetate pathway, a β-ketoester cyclization may originate 
anthraquinones and naphthoquinones (Figure 1.2A). The reaction of α-ketoglutaric acid 
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from acetate pathway with isochorismic acid from shikimate pathway forms 1,4-dihydroxy-
2-naphthoic acid, which is a direct precursor of naphthoquinones. Additionally, the 
addition of an isoprene unit to 1,4-dihydroxy-2-naphthoic acid may originate some 
anthraquinones (Figure 1.2B). 4-Hydroxybenzoic acid, which is formed from the shikimate 
pathway, is also a precursor of naphthoquinones and benzoquinones, such as 
ubiquinones (Figure 1.2C) (6). 
 
 
Figure 1.2. Main pathways for quinone biosynthesis. A, Acetate pathway. B, Acetate 
and shikimate pathway. C, 4-Hydroxybenzoic acid pathway. Adapted from Bruneton (6) 
and Babula and collaborators (7). 
 
 In this thesis, naphthoquinones and ubiquinones were the studied quinones. 
Regarding naphthoquinones, these compounds are generally more lipophilic than 
benzoquinones, whose majority has only one aromatic ring, and they are normally more 
reactive than anthraquinones, since naphthoquinones have in general higher redox 
potential than anthraquinones (8). Attending to naphthoquinones’ chemical characteristics 
and to the existence of little information about some dimeric naphthoquinones derived 
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from Diospyros species, naphthoquinones were chosen as object of study of this thesis. 
Additionally, ubiquinone analogues were also considered, because, in general, they have 
better lipophilic properties than non-prenylated benzoquinones and they are interesting 
compounds to modulate mitochondrial function (9). 
 
 
1.1.1. Chemical reactions  
 
Several quinones have important functions in cellular biochemistry, being essential 
for energy production or for defence, avoiding the proliferation of bacteria, parasites or 
fungi (8). The diversity of biological activities attributed to quinones is partially explained 
by their pro-oxidant character. Quinones, mainly benzoquinones and naphthoquinones, 
may undergo redox cycles, as well as addition and substitution reactions with nucleophiles, 
attending to the high electron density of the quinone moiety (8, 10, 11). The presence of 
substituents in the quinone skeleton, which can be electron-donating or electron-attracting 
groups, determines the quinones’ redox properties and, consequently, the tendency to 
react with nucleophiles or the semiquinone radical stability (12). 
Quinones may undergo one- or two-electron reduction, forming semiquinone 
radical or hydroquinone, respectively (Figure 1.3A) (10). These reactions can be 
catalyzed by flavoenzymes, which are oxidoreductases responsible by a large variety of 
different reactions (13). Flavoenzymes present in endoplasmic reticulum (β-nicotinamide 
adenine dinucleotide reduced form (NADH) cytochrome b5 reductase or β-nicotinamide 
adenine dinucleotide phosphate reduced form (NADPH) cytochrome c reductase) or in 
mitochondria (NADH dehydrogenase or lipoyl dehydrogenase) catalyze a single–electron 
reduction, transforming the quinone into a semiquinone radical. In the cytosol, the 
NAD(P)H quinone-oxidoreductase (NQO1), also known as DT-diaphorase, catalyzes two-
electron reduction, directly converting the quinone into hydroquinone (Figure 1.3A). Also 
in the cytosol, xanthine oxidase and xanthine dehydrogenase catalyse one- or two-
electron reductions (8). Despite the possibility of undergoing through autoxidation with a 
semiquinone radical formation, hydroquinones are, in general, less reactive than 
semiquinone radicals, being easily eliminated by conjugation with glucuronic acid or 
sulfate (Figure 1.3B, C) (10). Furthermore, hydroquinones autoxidation may be largely 
inhibited by glutathione, an endogenous antioxidant (8). In contrast, the majority of 
semiquinones are reoxidized under aerobic conditions, inducing the formation of 
superoxide anion radical (O2-) (Figure 1.3A) that may lead to the production of other 
reactive species, such as peroxynitrite (ONOO-), hydrogen peroxide (H2O2), hypochlorous 
acid (HOCl) or hydroxyl radical (HO) (Figure 1.3D) (8, 14). In addition to inducing a 
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depletion of cells’ antioxidant defences like the pool of reduced glutathione (GSH), 
reactive species induce damage in several macromolecules (proteins, nucleic acids and 
lipids), compromising their several functions (8). Thus, regarding the oxidative stress 
generated by semiquinones, NQO1 has been regarded as a cellular protector (8, 15). 
 
 
Figure 1.3. Quinones-induced oxidative stress and quinones’ metabolism phase 2 
reactions. A, Reduction of quinone into semiquinone and hydroquinone. Hydroquinone 
and semiquinone may undergo oxidation with superoxide anion (O2-) formation. NQO1 
[NAD(P)H quinone-oxidoreductase] catalyses the reduction of quinone directly into 
hydroquinone. B, Conjugation of hydroquinone with sulfate. PAPS, 3’-phosphoadenosine 
5’-phosphosulfate; PAP, 3’-phosphoadenosine 5’-phosphate. C, Conjugation of 
hydroquinone with glucuronic acid. UDPGA, uridine diphosphate glucuronic acid; UDP, 
uridine diphosphate. D, Oxidative stress generated from O2-. GSH, reduced glutathione; 
GSSG, oxidized glutathione. Adapted from Powis (10). 
 
Quinones are electrophilic Michael acceptors’, whereby they establish adducts 
with several macromolecules, compromising or modifying their functions as well. The 
reaction of quinones with nucleophiles, such as proteins or nucleic acids, may form a 
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hydroquinone adduct, which can be oxidized to a quinone adduct with reactive oxygen 
species (ROS) formation, or can react with a parent quinone forming the quinone adduct 
and hydroquinone (Figure 1.4) (10). Glutathione-quinone adduct formation may also 
occur, contributing to reduced glutathione depletion. 
 
         
Figure 1.4. Quinone-nucleophile (Nu) adduct formation. 
 
 
1.1.2. Naphthoquinones  
 
Naphthoquinones are widespread in nature, being produced by plants (7), 
actinomycetes (16, 17), fungi (18, 19), lichens (20, 21) and algae (22). Regarding plants, 
the main producing families are Avicenniaceae, Bignoniaceae, Boraginaceae, 
Droseraceae, Ebenaceae, Juglandaceae, Nepenthaceae and Plumbagnaceae (7). 
Chemically, naphthoquinones may be present as monomers, dimers or tetramers. The 
monomeric naphthoquinone is characterized by the presence of a naphthalene skeleton 
substituted in C1 and C4 (1,4-naphthoquinones) or in C1 and C2 (1,2-naphthoquinones) 
by two carbonyls (Figure 1.5) (7).  
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Figure 1.5. Basic chemical structure of naphthoquinones.  
 
 
1.1.2.1. Biological importance 
 
Naphthoquinones are produced by several organisms, possibly for their survival 
advantage. For example, naphthoquinones constitute a group of vitamins, influence the 
development of neighbouring living beings, and contribute to attracting pollinators since 
they are generally coloured (yellow, orange and brown), thus influencing the pigmentation 
of living beings (7).  
Naphthoquinones are also known as allelochemicals (23). Allelopathy is a 
biological phenomenon by which an organism influences the survival, growth and 
reproduction of neighbouring organisms through chemical substances. Juglone (5-
hydroxy-1,4-naphthoquinone) (Figure 1.6), which is a well-known example of 
allelochemical, may be released to the environment by black walnut (Juglans nigra L.), 
avoiding the development of other species (7, 24). The mechanisms linked to this activity 
include inhibition of plastoquinone biosynthesis, by inhibition of phenylpyruvate 
dioxygenase activity (25) and reduction of water reuptake by the roots (26).  
Naphthoquinones constitute an important group of vitamins: vitamin K. The vitamin 
K group is constituted by isoprenoid naphthoquinones, whose core skeleton is menadione 
(2-methyl-1,4-naphthoquinone) (Figure 1.6). Several organisms are able to synthesize 
vitamin K, such as plants, algae and bacteria, in contrast to mammals that need to obtain 
it from the diet or symbiotic bacteria living in their gut (7, 27). In mammals, vitamin K is 
important for coagulation, because it is an essential cofactor for γ-glutamyl carboxylase, 
an enzyme responsible for the activation of four procoagulant factors (II, VII, IX and X). 
Additionally, vitamin K is essential to bone tissue homeostasis, through regulation of 
mineralization and calcium homeostasis (28). Vitamin K’s function in the brain is related to 
sphingolipid metabolism modulation and the discovery of two vitamin K-dependent 
proteins closely associated with the nervous system [growth arrest-specific 6 (Gas6) and 
the protein S] (29). 
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1.1.2.2. Diospyros spp. naphthoquinones 
 
 Diospyros is an important genus of the Ebenaceae family, with more than 350 
species (trees and shrubs) distributed mainly by tropical zones. Diospyros is characterized 
by the synthesis of 1,4-naphthoquinones metabolites, from which non-monomeric 
naphthoquinones are mainly juglone derivatives	  (30). Naphthazarin derivatives, such as 2-
methylnaphthazarin, and plumbagin derivatives are also found in Diospyros species (7, 
30-32). Naphthoquinones may be present in several organs, especially in the bark, and 
they commonly occur in reduced and glycosidic form (7).  
Diospyros chamaethamnus Dinter ex Mildbr. is an African species from which little 
is known. Eight naphthoquinones were identified in its root barks, two of them being 
isolated in higher amounts: diospyrin and diosquinone (Figure 1.6) (31). 
 
 
Figure 1.6. Menadione and naphthoquinones that are commonly found in Diospyros 
spp. 
 
 
1.1.2.3. Pharmacological activities attributed to 
naphthoquinones 
 
Plants rich in naphthoquinones have been employed in folk medicine for the 
tentative treatment of several health problems: root extracts of the Chinese medicinal herb 
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Lithospermum erythrorhizon Siebold & Zucc., which is rich in shikonin/alkannin derivatives 
(Figure 1.7), is used in burns, haemorrhoids, external wounds and dermatitis (33); root 
extracts of Plumbago zeylanica L., rich in plumbagin, is used in Indian medicine as a 
putative antiatherogenic, cardiotonic, hepatoprotective and neuroprotective agent (34); 
Tabebuia impetiginosa (Mart. ex DC.) Standl extracts were used by native populations of 
South America in the context of several diseases like cancer, fever and infections (35). 
Different naphthoquinones’ pharmacological activities were already explored, 
these being mostly antitumoral and antimicrobial activities. Nevertheless, little is known 
about naphthoquinones’ anti-inflammatory and anti-allergic properties. In the following 
sections a brief description of the antitumoral and antimicrobial activity of 
naphthoquinones is presented, because these activities are the most explored concerning 
naphthoquinones. Additionally, a review of the literature concerning anti-inflammatory and 
anti-allergic activities of naphthoquinones is also presented, because these were the 
naphthoquinones’ activities studied in this thesis. 
 
           
Figure 1.7. Chemical structure of shikonin and alkannin. 
 
 
1.1.2.3.1. Antitumoral activity 
 
 Antitumoral activity of naphthoquinones has been studied in tumour cell lines from 
prostate (36), breast (37), ovary (38), colon (39), lungs (40), skin (39), pancreas (41), 
among others organs. Lapachol and β-lapachone (Figure 1.8), extracted from T. 
impetiginosa (also known as red lapacho), were extensively studied concerning 
antitumoral properties, showing activity against several tumour cell lines (42). Lapachol 
was even tested in phase I clinical trials, but showed a low oral bioavailability (43). 
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Figure 1.8. Chemical structures of lapachol and β-lapachone. 
 
The antitumoral activities of naphthoquinones may be explained by several 
mechanisms: a) intercalation into DNA base pairs through establishment of electrostatic 
bonds (44); b) inhibition of topoisomerases, which are regulatory enzymes of the DNA 
overwinding, and thus important to DNA replication (45); c) inhibition of nuclear factor 
(NF)-κB, which is a transcription factor involved in inflammation and proliferation (46); d) 
activation by cytochrome P450 reductase, which induces a one-electron reduction of 
naphthoquinones with the formation of highly reactive semiquinone radical (8); normally, 
the activity of cytochrome P450 reductase is increased in tumour cells in comparison to 
normal ones, conferring a selective toxicity of naphthoquinones to cancer cells (47). 
Naphthoquinones may also potentiate the anti-tumoral activity of other treatments: 
menadione derivatives and plumbagin induce sensitization to radiotherapy (48, 49); 
additionally, menadione showed synergic antitumoral effect with methotrexate and with 5-
fluorouracil (50, 51). 
 
 
1.1.2.3.2. Antimicrobial activity 
 
Antimicrobial activity is probably one of the best-studied naphthoquinones’ 
biological properties. Naphthoquinones are active against a wide variety of bacteria 
[Clostridium spp. (52), Mycobacterium spp. (53-55), Neisseria gonorrhoeae Zopf (55), 
Escherichia coli (Migula) Castellani and Charmers, Staphylococcus aureus Rosenbach 
(56) among others] and fungi [Candida spp. (57-59), Cryptococcus neoformans (San 
Felice) Vuill. (60), Aspergillus spp., Fusarium sp. and Trychophyton spp. (61)].  
Naphthoquinones are also effective against a wide spectrum of parasites with 
atovaquone (Figure 1.9) being a licensed antiparasitic drug. Atovaquone is a 
hydroxynaphthoquinone with activity against Plasmodium spp., Pneumocystis jirovecii 
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Frenkel (pneumonia) and Toxoplasma gondii (Nicolle & Manceaux) (toxoplasmosis). 
Atovaquone selectively inhibits ubiquinone (UQ) biosynthesis (62) and the mitochondrial 
complex III of the parasites, through the binding to the ubiquinol oxidation (Qo) site. Thus, 
atovaquone interrupts the parasites’ electron transport chain (ETC) and pyrimidine 
synthesis (63, 64), because complex III inhibition by atovaquone avoids regeneration of 
oxidized ubiquinone (required as electron acceptor of dihydroorotate dehydrogenase), an 
essential step of de novo pyrimidine biosynthesis (65). The inhibition of de novo 
pyrimidine biosynthesis is particularly toxic to malaria parasites, because salvage of 
pyrimidines in these organisms is minimal (65). Commercially, atovaquone is available 
alone or in combination with proguanil, an inhibitor of dihydrofolate reductase, which is an 
essential protein for pyrimidine biosynthesis (63).  
 
               
Figure 1.9. Chemical structure of atovaquone. 
 
Beyond Plasmodium spp., naphthoquinones have been studied against 
Schistosoma mansoni Sambon (64), Leishmania donovani Laveran et Mesnil (65, 66), 
Theileria parva Muguga (67) and Trypanosoma cruzi Chagas (68). Naphthoquinones’ 
action mechanisms against trypanosomatids (e.g. Trypanosoma spp. and Leishmania 
spp.) have been explored, being related with redox properties of naphthoquinones. 
Trypanosomatids have a NADPH-dependent flavoprotein disulphide, named 
trypanothione reductase, which is responsible for maintaining the trypanothione, a 
molecule similar to glutathione, in the thiol form. The absence of trypanothione reductase 
in mammalian hosts and the high susceptibility of these parasites to oxidative stress make 
this enzyme a potential target for new antiparasitic drugs (69, 70). According to 1,4-
naphthoquinones redox properties, these compounds constitute ”subversive” substrates 
for trypanothione reductase, avoiding the enzymatic reduction of the enzyme’s 
physiological substrate and subverting the physiological function of the enzyme, which 
becomes a prooxidant (69, 70).  
GENERAL INTRODUCTION 
15 
1.1.2.3.3. Anti-inflammatory activity  
 
β-Lapachone, shikonin and plumbagin are the most studied naphthoquinones as 
anti-inflammatory compounds and little is known about the other naphthoquinones, 
explaining the interest in exploring their anti-inflammatory potential. 
β-Lapachone induced a reduction in the expression of the inducible 
cyclooxygenase (COX)-2, decreasing prostaglandin (PG) E2 synthesis, but without 
significant changes in COX-1 levels (constitutive enzyme) in a cell system	   (71). The 
selective inhibition of inducible enzymes isoforms by β-lapachone was also confirmed for 
nitric oxide synthase (NOS): β-lapachone reduced inducible nitric oxide synthase (iNOS) 
expression after lipopolysaccharide (LPS) stimulation of rat alveolar macrophages and 
aortic rings, without affecting the constitutive isoforms of NOS (endothelial and neuronal) 
(72). In vivo, β-lapachone was efficient in LPS-induced mice lung oedema reduction. This 
effect was attributed to the inhibition of NF-κB expression, which consequently led to the 
inhibition iNOS expression (73).  NF-κB is a ubiquitous transcription factor involved in 
cellular proliferation and expression of immunoregulatory genes (74) that will be 
approached in more detail in section 1.2.1. β-Lapachone suppressed also the 
development of experimental autoimmune encephalomyelitis in a mouse model, 
decreasing the expression of interleukin (IL)-12 family cytokines (IL-12, IL-23 and IL-17) 
(75).  
Contrarily to β-lapachone, shikonin is reported to directly inhibit all NOS isoforms 
(inducible and constitutive) at the same range of concentrations (4-7 µM). Thus, in 
addition to reducing nitric oxide (NO) production in LPS-stimulated cells, shikonin alone 
induced a strong inhibition of the aorta relaxation response (76). However, these authors 
verified that shikonin decreased the NO production in stimulated cells to concentrations 
lower (< 1 µM) than the ones required to inhibit the enzymes in vitro, suggesting that 
shikonin reduced NO production through other mechanisms without direct enzyme 
inhibition (76). In fact, several research groups showed that shikonin suppresses 
extracellular signal-regulated kinase (ERK)1/2 phosphorylation and NF-κB expression (77-
79). NF-κB expression inhibition explains the COX-2 and NOS expression decrease (78) 
and the reduction of tumour necrosis factor (TNF)-α, IL-1β, IL-6 and myeloperoxidase 
activity in a mouse model of acute pancreatitis (80). Other mechanisms of action, beyond 
NF-κB inhibition, have been suggested. Shikonin supressed TNF-α transcription 
independently from inhibition of ERK1/2 phosphorylation or NF-κB activation and, 
therefore, the effects were attributed to the inhibition of transcription factor IID binding to 
TATA box, present in TNF-α promotor region (81). Inhibition of proteasome by shikonin 
was also suggested, given the observed accumulation of inhibitory factor κB (IκB) and 
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ubiquitinated proteins in a rat primary macrophage culture (82). Shikonin was also 
previously studied in animal models: shikonin reduced the 12-O-tetradecanoylphorbol-13-
acetate (TPA)-induced acute ear oedema in mice (78); it ameliorated the macroscopic 
lesions and cartilage destruction in a murine model of collagen-induced arthritis, with a 
decrease of pro-inflammatory mediators (TNF-α, IL-12 and IL-6) and an increase of anti-
inflammatory cytokines (IL-10 and IL-4) (83); additionally, it suppressed the allergic airway 
inflammation in a mouse model of asthma (84). 
Similarly to β-lapachone and shikonin, plumbagin also inhibits NF-κB activation, 
through the suppression of IκB kinase (IKK) activation and consequently IκB 
phosphorylation and degradation and through direct inhibition of p65 binding to DNA (34, 
85). The exact mechanism by which plumbagin inhibits IKK activation and the binding of 
p65 to DNA is not clear; however, some authors suggest that plumbagin interacts directly 
with critical serine residues of IKK and p65, given its redox properties (34). The 
interference with the NF-κB pathway is used to explain anti-inflammatory effects observed 
with plumbagin: plumbagin suppressed the paw oedema induced by carrageenan in rats 
with a decrease in pro-inflammatory mediators, such as IL-1β, IL-6, TNF-α, iNOS and 
COX-2 (86); it also inhibited cytokines production by phytohemagglutinin (PHA)-stimulated 
peripheral blood mononuclear cells (PBMC) (87). Immunossupressive properties of 
plumbagin have also been reported. Plumbagin inhibited activation, proliferation and the 
functions of T-cells, inhibiting the entry of concanavalin A-stimulated T cell in S phase of 
the cell cycle, reducing the expression of early (CD69) and late (CD25) activation markers, 
as well as reducing the cytokines release in activated T-cells (85). Plumbagin improved 
the clinical symptoms of experimental autoimmune encephalomyelitis in a mouse model, 
decreasing interferon (INF)-γ and IL-17 production, through the regulation of Janus kinase 
(JAK) / Signal transducer and activator of transcription (STAT) signalling pathway (88). 
Another work explained plumbagin’s anti-inflammatory effects with ROS generation, 
because the inhibition of cytokine production, the ERK mitogen-induced phosphorylation, 
as well as the inhibition of IκB proteins degradation, were abrogated by thiol antioxidants 
(89).  
Juglone and its 5-O-acyl derivatives (conjugation with acetic acid to C22:6 fatty 
acids) reduced the TPA-induced acute inflammation in mouse ears and decreased the 
TNF-α production using LPS-stimulated RAW 264.7 macrophages (90). 
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1.1.2.3.4. Anti-allergic activity 
 
Little information exists about the anti-allergic properties of naphthoquinones. 
Menadione avoided the antigen-stimulated RBL-2H3 cells (basophilic cell line) 
degranulation through inhibition of the cellular calcium influx. Furthermore, menadione 
inhibited 5-lipoxygenase (5-LO) translocation from the cytoplasm to the nuclear 
membrane [an important mechanism to leukotrienes (LT) production] and no effect was 
observed in phosphorylation of some important 5-LO regulators (mitogen-activated protein 
(MAP), ERK or p38). As the inhibition of LT production induced by menadione was 
reverted by antioxidants, ROS generated by menadione were considered to be important 
to its activity (91). Naphthoquinones extracted from Rhinacanthus nasutus Kuertz leaves 
(rhinacanthin-C, -D and –N) also reduced the degranulation and the release of TNF-α by 
IgE/antigen-stimulated RBL-2H3 cells (92). Chloro-1,4-naphthoquinones derivatives also 
decreased the degranulation of mast cells (93). 
Anti-allergic properties of juglone were related to its capacity to inhibit the peptidyl-
prolyl cis-trans isomerase NIMA-interacting 1 (PIN1), which regulates eosinophil 
differentiation (94). Juglone treatment of allergen-sensitized rats induced an improvement 
of allergic pathology, with reduction of eosinophilia and reduction of granulocyte-
macrophage colony-stimulating factor (GM-CSF) and IL-5 expression, without alterations 
in the other leukocytes and in the cytokines PIN1-independent (95). 
The known anti-inflammatory and anti-allergic properties of naphthoquinones 
studied in this thesis are resumed in Table 1.1. 
 
Table 1.1. Naphthoquinones studied in this thesis and known activities and targets 
concerning anti-inflammatory and anti-allergic properties. 
Naphthoquinones Target Activity References 
Juglone PIN1  Inflammatory mediators reduction; Eosinophilia reduction (95)   
Menadione 5-LO  Leukotrienes synthesis reduction (91)  
Plumbagin 
NF-κB 
JAK/STAT 
ERK1/2 
Inflammatory mediators reduction; COX-2 
and iNOS expression reduction 
(34, 85, 86, 
88, 89) 
  
 
 
1.1.3. Benzoquinones 
 
Benzoquinones are ubiquitous compounds that present a unique aromatic ring 
with two carbonyl groups. The most important are the prenylated benzoquinones, which 
vary in the length and in the saturation degree of the side chain, as well as in the 
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presence of additional groups (96). Examples of prenylated benzoquinones groups are 
plastoquinones, rhodoquinones and ubiquinones (Figure 1.10) (96). Due to their 
importance for energy production, ubiquinones (UQ) are approached in detail. 
  
 
Figure 1.10. Chemical structures of prenylated benzoquinones. 
 
 
1.1.3.1. Ubiquinones 
 
 UQ are prenylated benzoquinones (2,3-dimethoxy-5-methyl-6-polyprenyl-1,4-
benzoquinone) in which the number of isoprenoid units of the side chain may vary 
between 6 and 10 units long (96, 97). Some organisms have more than one type of UQ, 
despite one of them being the most abundant (96). UQ10 (Figure 1.10) is the most 
abundant UQ in humans, but UQ9 is also present. In contrast, in rodents there is a 
prevalence of UQ9 (96). Ubiquinones are found in prokaryotic and eukaryotic cells, being 
components of all membranes (98). The biosynthetic pathway of ubiquinones is highly 
conserved, being mainly constituted by three metabolic sequences (Figure 1.11). One is 
the synthesis of p-hydroxybenzoate, which can be formed by shikimate pathway or 
directly from tyrosine (and sometimes from phenylalanine) mainly in higher eukaryotes. 
Another is the synthesis of the polyprenyl side chain by the mevalonate pathway: from 
acetyl-coenzyme A (acetyl-CoA), a hydrophobic polyisoprenoid side chain with 6 to 10 
isoprene units is obtained; regarding UQ10, acetylCoA is transformed in farnesyl-
pyrophosphate (PP), which is also a precursor of cholesterol and of dolichol, and then in 
decaprenyl-PP. Afterwards, the condensation of p-hydroxybenzoate with the polyprenyl 
side chain, catalyzed by p-hydroxybenzoate prenyltransferases, occurs (98-100). 
Following condensation, the benzoquinone ring may undergo several modifications, such 
as C-hydroxylation, decarboxylation, O-methylation and C-methylation (98). The exact 
subcellular location of the several steps involved in UQ biosynthesis remains uncertain 
(101). Some authors suggest that it begins in the endoplasmic reticulum and ends in the 
Golgi apparatus, from where UQ is transported to other cellular compartments (99, 102, 
103). However, other authors consider that UQ biosynthesis localization may be more  
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Figure 1.11. Ubiquinone’s biosynthesis pathway. HMG-CoA, 3-hydroxy-3-
methylglutaryl-coenzyme A. 
 
complex and probably the same reaction may be performed in different cell compartments 
(104). For example, some enzymes are present in several cell compartments: farnesyl-PP 
synthase is present in cytoplasm, mitochondria and peroxisomes (105, 106), while trans-
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prenyltransferase was found in mitochondria, endoplasmic reticulum and peroxisomes 
(106-108). 
Among the most important UQ cellular functions are those related with energy 
production. The UQ functions are: a) electron carrier in several electron transport chains - 
mitochondrial respiratory chain, extramitochondrial electron transport (plasma membranes 
and lysosomes), photosynthetic and in chemosynthetic electron chain, where reduced 
inorganic compounds supply electrons (96, 104); b) stabilization of mitochondrial 
permeability transition pore (mPTP) in the closed conformation	   (109); c) activation of 
mitochondrial uncoupling proteins (110); d) regulation of physicochemical properties of the 
membranes (104); e) lipid-soluble antioxidant (111); f) regulation of NAD+/NADH ratio - 
the majority of plasma membranes contains a UQ-dependent NADH oxidase (112); g) 
anti-inflammatory - regulation of NF-κB expression (113); h) prevention of endothelial 
dysfunction - stimulation of NO release (114). 
 
 
1.1.3.2. Ubiquinone analogues 
 
Modifications of the alkyl chain of physiological UQ have been made in order to 
improve their biological effects and physicochemical properties (115). UQ analogues are 
thus mainly characterized by lower lipophilicity than endogenous UQ. In this section, the 
main groups of UQ analogues are described: the mitoQ group vs. the idebenone and 
decylubiquinone group. 
Quinones containing a UQ moiety and a lipophilic alkyl chain with variable length, 
terminating in a lipophilic cation (methyltriphenylphosphonium), constitute the mitoQ group 
(Figure 1.12). The lipophilic cation allows the accumulation of these UQ analogues in the 
mitochondria, due to the negatively charged environment characteristic of an established 
mitochondrial membrane potential (Δψm) (116). The mitoQ analogues series has been 
less explored than idebenone and decylubiquinone, probably because they cannot act as 
electron carriers in ETC, since they are not oxidized by complex III. However, mitoQ 
analogues are efficient antioxidants against lipid peroxidation, ONOO- and O2- (117). 
Both idebenone and decylubiquinone have an UQ head group linked to a ten-
carbon alkyl tail, differing only in the end of the tail: idebenone has a hydroxyl group, while 
decylubiquinone presents a methyl group (Figure 1.12) (117). Thus far, idebenone has 
been more extensively studied than decylubiquinone. 
Idebenone rescued the toxicity induced by digitonin, which consists on the 
solubilisation of mitochondrial membranes, impairing the mitochondrial ETC (118). 
Furthermore, despite the oxidized form of idebenone inhibiting complex I (119), idedebone 
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protected a rodent RGC cell line against complex I dysfunction (120). These effects of 
idebenone in mitochondrial activity increased the interest in idebenone as potential drug 
for mitochondrial disorders. In fact, idebenone was initially available on the Japanese 
market as a drug to ameliorate age-dependent brain functions impairment (101).  
  
 
Figure 1.12. Chemical structures of ubiquinone analogues. 
 
In contrast to UQ10, idebenone is rapidly absorbed by humans when taken orally 
(121). While there are studies suggesting that idebenone does not rescue UQ10 
deficiencies (122), there are also reports of its successfull use in the treatment of other 
pathologies. Several studies in animal models of Friedrich’s ataxia (FRDA) were made to 
test the therapeutic potential of idebenone in this pathology: idebenone revealed to be a 
promising drug, ameliorating the pathological condition (123, 124). FRDA is a hereditary 
disease caused by a deficiency in frataxin, a protein involved in mitochondrial iron content 
regulation, whereby in FRDA there is an increase of oxidative stress that compromises 
several mitochondrial proteins with iron-sulphur clusters, such as complexes I, II and III 
(125). Administration of idebenone during 4-9 months to FRDA patients ameliorated 
cardiomyopathy, with substantial decrease of myocardial hypertrophy (125). However, 
higher doses than needed to improve cardiac function were required to improve 
neurological function of FRDA patients (126). Several other clinical trials showed the 
beneficial effects of idebenone in FRDA (127, 128). Idebenone avoided stroke-like 
episodes and improved neurological symptoms in a patient with mitochondrial 
encephalomyopathy, lactic acidosis and stroke-like episodes (MELAS) (129), and also 
improved colour vision in patients with Leber’s hereditary optic neuropathy (LHON) (130). 
Idebenone was reported beneficial in several other diseases, such as Leigh syndrome, 
Duchenne muscular dystrophy, OPA-1 dominant optic atrophy, as well as in Alzheimer’s 
disease (AD) and Huntington’s disease	  (131-134).  
Regarding decylubiquinone, it was reported to improve mitochondrial function in 
synaptosomes, increasing complex I/II and complex II/III activities (135). Additionally, 
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decylubiquinone rescued respiration of isolated muscle mitochondria from a patient with 
UQ10 deficiency (136) and restored respiration in yeast mitochondria lacking UQ (117). 
Some authors attribute the effects of UQ analogues to their antioxidant properties 
(125), but the possibility of working as electron carriers has been studied (9, 119). A 
balance between hydrophilicity and lipophilicity is important so that UQ analogues rescue 
the adenosine-5’-triphosphate (ATP) levels, as well as for their antioxidant activity: 
hydrophilicity is essential to cytoplasmic reduction by NQO1, while lipophilicity determines 
membrane access (137). Thus, an advantage of idebenone and decylubiquinone is the 
ability to cross membranes that allows the UQ analogues to be either in the cytosol or in 
the mitochondria. Short-chain quinones can be reduced in the cytosol by NQO1 and their 
respective hydroquinones may be shuttled into mitochondria, transferring the electrons to 
complex III, passing any dysfunction of mitochondrial dehydrogenases (9). In contrast, 
UQ10 does not have polarity properties to go to cytosol and be reduced by NQO1, 
explaining the results obtained by Haefeli and collaborators that observed a rescue of 
ATP levels by idebenone (and not by UQ10), in a cell system, dependent on both NQO1 
and mitochondrial complex III after acute inhibition of complex I (9). Furthermore, both 
idebenone and decylubiquinone are good substrates of complex III (117, 119). Thus, the 
side chain of UQ analogues has an important role in determining the activity of the 
compound: decylubiquinone has better antioxidant, cytoprotective properties, and better 
ability to maintain Δψm than idebenone in CEM leukaemia cells (115); however, idebenone 
was more effective in increasing ATP levels in rotenone-treated cells than 
decylubiquinone (137). 
UQ analogues have other biological effects beyond antioxidant and respiratory 
chain improvement: idebenone inhibited COX enzymes, showing anti-inflammatory activity 
(138), and inhibited the respiration of Helicobacter pylori (Marshall et al.) Goodwin et al., 
having antibacterial activity (139). 
 
 
1.2. An overview of the immune system  
 
The main function of the immune system is to protect the organism against 
potential aggressors, normally a pathogenic infectious agent. Mammalian immune system 
is divided in innate and acquired immunity (140, 141). The innate immune response is the 
first line of host defence against an infectious agent, discriminating between self and 
foreign molecules (140). Pathogens are recognized by conserved molecular structures 
essential to microorganism survival, named pathogen-associated molecular patterns 
(PAMP), which include microbial structural components, proteins or nucleic acids that may 
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be shared by different classes of microorganisms (140, 142). PAMP are recognized by 
pattern-recognition receptors (PRR) that are constitutively expressed by the host (140). 
Depending on the PRR group, PRR binding may induce endocytosis, enhancing antigen-
presentation, induce opsonisation or even activate multiple signalling pathways, such as 
NF-κB, mitogen-activated protein kinases (MAPK) and interferon regulatory factors (IRF), 
controlling the expression of pro-inflammatory cytokines (142, 143). Thus, PRR initiate the 
innate immunity process: opsonisation, phagocytosis, complement and pro-inflammatory 
signalling pathways activation and apoptosis (141). Several classes of PRR are known, 
such as retinoic acid-inducible gene I-like receptors, nucleotide oligomerization domain-
like receptors and Toll-like receptors (TLR), the latter being the most explored (142). The 
innate immune response contributes to the initiation of adaptive immunity, characterized 
by immunological memory due to generation of pathogen antigen-specific B and T 
lymphocytes (141, 144). Adaptive immunity has two stages: a) antigen presentation and 
recognition specific T or B cells, leading to cell priming, activation and differentiation; this 
process normally occurs within lymphoid tissues; b) T cells leave the lymphoid tissue and 
move towards the disease site, while activated B cells release antibodies into blood and 
tissue fluids (143). Several pathological conditions are related with the immune system, 
more commonly exaggerated immunological responses, such as inflammation and allergy. 
 
 
1.2.1. Inflammation  
 
The inflammatory process is an essential response to tissue injury induced by 
invading pathogens (145). However, chronic inflammation is a persistent phenomenon 
that induces extensive tissue damage (146). Furthermore, inflammation is a 
pathophysiological condition associated with many other diseases, such as 
atherosclerosis (147) and cancer (145).  
During an inflammatory process, adhesion molecule activation and chemotactic 
cytokine release activate leukocyte migration from blood to damaged tissues	   (145). This 
process initiates with recognition of a PAMP such as LPS. LPS, the main outer membrane 
component of Gram-negative bacteria, is a glycolipid composed by a hydrophilic 
polysaccharide and a ‘lipid A’ hydrophobic domain (148). LPS binds TLR4 and activates 
NF-κB transcription and the MAPK cascade (Figure 1.13) (74, 149). MAPK are 
serine/threonine protein kinases regulating cell proliferation, differentiation and survival 
genes (150). ERK1/2, c-Jun N-terminal kinase (JNK) and p38 MAP kinase (151) are the 
major members of the MAPK family, representing three different signalling cascades that 
transduce a broad range of extracellular stimuli. All MAPK are activated through 
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phosphorylation by specific MAPK kinases (MKK or MEK) (150), inducing phosphorylation 
and activation of several other cytoplasmically- or nuclear-located transcription factors 
(149). 
 
 
Figure 1.13. Main signalling pathways involved in LPS inflammatory response. 
 
NF-κB is a family of seven structurally related transcription factor subunits, 
including proteins with a conserved amino-terminal region with dimerization, nuclease-
localization and DNA binding domains. The most frequent form of NF-κB comprises a p65 
subunit heterodimer associated with either a p50 or a p52 subunit (74, 152). NF-κB 
proteins interact with cytoplasmic anchoring-domain containing proteins, the IκB proteins 
(74, 153). IκB proteins retain NF-κB in the cytoplasm by masking the nuclear-localization 
signal (NLS), and with some IκB proteins containing a nuclear-export signal (NES) (74). 
NF-κB activation is most frequently triggered by IκB degradation (74). IKK-mediated 
phosphorylation of IκB proteins on specific serine residues induces their polyubiquitination 
and 26S proteasome-mediated degradation (74, 153). After IκB protein degradation, NF-
κB may translocate to the nucleus and activate κB-dependent gene transcription (74). NF-
κB activity may also be regulated by phosphorylation and acetylation of NF-κB proteins 
(74). NF-κB regulates the expression of more than 150 genes related with cell proliferation 
and inflammation (inducible cytokines, cell adhesion molecules, matrix metalloproteases, 
COX-2, iNOS and other vasoactive mediators), being important to innate and adaptive 
immune responses (74, 152, 153). COX-2 and iNOS are known inducible enzymes 
essential to inflammation and thus relevant therapeutic targets. While iNOS generates NO, 
COX are key enzymes for prostanoid (prostaglandins and tromboxans) synthesis from 
arachidonic acid (154). Prostanoids are essential for inflammation, platelet aggregation 
and vasoconstriction/relaxation (155). In addition to prostanoids synthesis during 
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inflammation, COX-2 is also constitutively expressed in the brain, kidney, pancreas, 
intestine and blood vessels (156).  
NF-κB is highly active in inflammatory disorders such as rheumatoid arthritis or 
asthma, and in tumour tissues (74, 157). Thus, several anti-inflammatory drugs act by NF-
κB inhibition, such as the glucocorticoid dexamethasone (158). Non-steroidal anti-
inflammatory drugs (NSAID) are the most widely-used anti-inflammatory drugs. Currently 
available NSAID, however, are associated with long-term gastrointestinal and renal side-
effects, stressing the need for new anti-inflammatory drugs with improved safety profile 
(154). 
 RAW 264.7 cells are murine macrophages frequently used to test anti-
inflammatory compounds. LPS is frequently used to induce an inflammatory response in 
these cells (159, 160), but other agents such as INF-γ are also useful for this purpose 
(161). In response to these stimuli, RAW 264.7 cells produce NO, TNF-α, interleukins, 
prostaglandins, and increase COX-2 and iNOS expression (77, 159, 162, 163). RAW 
264.7 cells have also been used to study TLR role in autophagy (164) and 
transmembrane transport of organic molecules (165). 
  
 
1.2.2. Alllergy  
 
Inflammation and allergy are increasingly recognized and interconnected 
pathologies, thus prompting the designation of “allergic inflammation” (166). Allergic 
responses are associated with exposure to otherwise innocuous substances present in 
the environment, named allergens. Thus, the therapeutic challenges are to induce 
immunological tolerance to allergens and to manipulate immune responses avoiding 
allergy development (166). However, these are mostly unmet challenges, with current 
anti-allergic therapies being focused on symptomatic management. 
Allergic disorders (allergic rhinitis, hay fever, eczema or asthma) affect about 25% 
of people in developed countries and its prevalence is increasing (167). The “hygiene 
hypothesis” associates the increasing number of allergic disorders with reduced 
microorganism exposure due to improved hygiene, vaccination and antibiotics. Contact 
with microorganisms promotes normal development of immune responses by T-helper 
(Th) 1 cells, associated to autoimmune diseases, bacterial and viral infections. In contrast, 
in the absence of microorganism contact the immune system responds inappropriately to 
innocuous substances, with Th2 cells prevalence associated to helminthic infections and 
allergic disorders (166-168). Thus, the “hygiene hypothesis” helps explain the lower 
prevalence of allergic diseases in developing countries and rural vs. urban areas of the 
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same country (167).  Furthermore, there is a genetic predisposition to allergic disorders: in 
contact with an allergen non-atopic adults produce allergen-specific IgG antibodies and 
tipically modest Th1 cell proliferation; atopic individuals, however, present exaggerated 
Th2 cell allergen-specific IgE response (169). 
Allergic responses may be IgE- or non-IgE-mediated, i.e., mediated by allergen-
specific lymphocytes or IgG antibodies. However, IgE-mediated reactions are the most 
prevalent (170). The first step in allergic reaction is the sensitization process, where the 
allergen may elicit a Th2 cell response, in which IL-4, IL-13 and the binding of CD40 on B 
cells induce IgE production, by promoting immunoglobulin class-switch recombination in B 
cells (166, 171) (Figure 1.14). Allergen binding to high-affinity IgE receptor (FcεRI) 
complex induces calcium influx, mast-cell degranulation, and synthesis of lipid mediators. 
Cytokines and chemokines released in this early phase initiate the late phase with 
recruitment and activation of inflammatory cells (172). 
 
 
Figure 1.14. IgE-mediated allergic response. MHCII, major histocompatibility complex 
class II; TCR, T-cell receptor. 
 
Mast cells are present in skin and mucosae, participating in inflammation and 
allergy, and being considered the major effectors of IgE-associated reactions (173, 174).  
Mast cells can partially or totally degranulate upon several factors: immune mechanisms 
(IgE-dependent or IgE-independent); endogenous mediators (tissues proteases or 
proteins derived from eosinophils and neutrophils); chemical substances (toxins and 
proteases) (173, 174). Mast cell granules contain several inflammatory mediators, such as 
chemotactic factors, histamine, proteoglycans (heparin), serotonin and proteases 
(tryptase, chymase, peroxidase, carboxidase or β-glucosidase) (171, 173, 174). 
Proteases are major mast cell products that degrade extracellular matrix proteins in 
defence against pathogens. For example, β-triptase is the major constituent of human 
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mast cell secretory granules (175). Histamine is a hallmark of allergic reaction that 
increases vascular permeability (176). Furthermore, mast cell activation increases calcium 
influx and induces synthesis of secondary mediators whose release pathophysiologically 
changes several organs: arachidonic acid metabolism derivatives (PG and LT) and other 
pro-inflammatory mediators [platelet activating factor (PAF), GM-CSF and TNF-α] (171, 
173, 174).  
Leukotrienes are synthesised from arachidonic acid released from the nuclear 
membrane by phospholipase A2 (PLA2) and converted in 5(S)-hydroperoxy-6-trans-
8,11,14-cis-eicosatetraenoic acid (5-HPETE) by 5-LO (177). 5-HPETE is not stable and 
may be reduced by peroxidases to 5-hydroxyeicosatetraenoic acid (5-HETE) or converted 
into leukotrienes. The first leukotriene, LTA4, has a labile epoxide intermediate, being 
metabolised into LTB4 or LTC4 (178, 179). LTB4 contrasts with other leukotrienes by 
lacking cysteine. LTC4 and LTD4 induce smooth muscle spasms, molecular adhesion, 
venopermeability and airway mucus secretion (178).  
Treatment of allergic disorders includes three main topics: environmental control 
and allergen avoidance, pharmacotherapy and immunotherapy. The pharmacotherapy 
approach includes corticosteroids, antihistamines, leukotrienes antagonists, β2-
adrenoreceptor agonists and α-adrenoreceptor agonists. Current pharmacotherapy, 
however, ameliorates symptoms only. The allergen-specific immunotherapy might be 
efficient to reduce the prevalence of allergic disorders by inducing immunological 
tolerance and decreasing allergen-specific IgE (180). 
RBL-2H3 cells are immortalized basophils used to model allergic inflammation. 
Basophils are granulocytes with some similarities to mast cells: FcεRI and Th2 cytokine 
expression, and mediator release (171). The calcium ionophore A23187 or IgE/antigen 
are known degranulation inducers in RBL-2H3 cells (181). 
 
 
1.3. Neurodegenerative disorders 
 
 
  1.3.1. Mitochondrial function – electron transport chain 
 
Mitochondria are fundamental organelles for calcium homeostasis (182), amino 
acid and steroids biosynthesis (183, 184), fatty acid β-oxidation (185), iron-sulphur cluster 
biogenesis (186), apoptotic signalling (187), but primarily known for its role in energy 
production in the form of ATP (184, 188). Distinguishing mitochondrial features are the 
double membrane and the mitochondrial DNA (mDNA). Human mDNA is maternally 
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inherited and has been completely sequenced (189): it has only 37 genes, encoding 13 
polypeptides of the ETC, 22 transfer RNAs (tRNA) and 2 ribossomal RNAs (rRNA) (12S 
and 16S) (189, 190). Mitochondria depend on nuclear DNA (nDNA) for its mDNA 
replication, repair, transcription and translation (191), and also for the synthesis of the 
overwhelming majority of mitochondrial components.  
The ETC is located in the inner mitochondrial membrane (IMM), being responsible 
for the majority of ATP production of most cells. The ETC includes both nDNA- and 
mDNA-encoded proteins (190). The main ETC components are four large protein 
complexes (complexes I, II, III and IV) with ubiquinone between complexes I/II and III and 
cytochrome c between complexes III and IV (Figure 1.15) (192). The supercomplex 
model considers that mitochondrial complexes organize into supramolecular complexes 
(193). In the ETC, electrons from donor compounds are transferred through several 
protein complexes towards a more positive oxidative potential, allowing proton pumping 
from the matrix to the inter membrane space (IMS), establishing a proton gradient and a 
negatively charged membrane potential towards the matrix side. The final electron 
acceptor is molecular oxygen (O2) (Figure 1.15) (192, 194). The proton gradient 
associated to electric potential across the IMM constitutes the proton-motive force, which 
is important to generate energy and to import proteins and calcium to the mitochondria 
(195, 196). The UQ moiety may accept two electrons and two protons, being reduced to 
ubiquinol (UQH2), transferring electrons from several dehydrogenases to the 
mitochondrial complex III (also known as ubiquinol-cytochrome c oxidoreductase or bc1 
complex). The most common electron donors are NADH and succinate formed during 
glycolysis, fatty acid oxidation and the Krebs cycle (192, 194). Complex I (also known as 
NADH:ubiquinone oxidoreductase or NADH dehydrogenase) constitutes the main route of 
electron entry in the ETC. It allows the transference of electrons from NADH to UQ and 
then to complex III. Complex I may be selectively inhibited by rotenone, which is highly 
lipophilic and crosses the blood brain barrier. Rotenone binds the ubiquinone-binding site, 
preventing electron flow from complex I to ubiquinone and thus to complex III (191). 
Complex II (also known as succinate:ubiquinone oxidoreductase or succinate 
dehydrogenase) participates in both Krebs cycle and the ETC, catalyzing succinate 
oxidation to fumarate and, consequently, ubiquinone reduction. NADH yields more ATP 
than succinate partly because complex II does not induce proton pumping (Figure 1.15) 
(192). Once reduced, UQ binds the outer UQ oxidation site (Qo; inhibited by myxothiazol) 
(197) and transfers one electron to the Rieske iron-sulphur (FeS) protein, and then to 
cytochrome c1 (C1) within complex III and posteriorly to cytochrome c (Cyt C). 
Consequently, UQ is transiently converted into semiubiquinone and then into oxidized UQ, 
due to loss of the second electron to the UQ reduction (Qi) site via two cytochrome b 
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hemes (bL and bH). Antimycin A, which is also a complex III inhibitor, binds to the inner Qi 
site, increasing O2- generation (192, 198). At the Qi site, an UQ is again reduced into 
ubiquinol, whereby one UQ reduction at the Qi site is linked with two ubiquinol oxidations 
at the Qo site (Figure 1.15). However, the two electrons from the ubiquinol at the Qo site 
can also be directly transferred to the cytochrome c instead of going to the Qi site, 
because in each Q-cycle two electrons are transferred from ubiquinol to two molecules of 
cytochrome c (192). Some authors have proposed that three UQ molecules bind to 
complex III: one binds at the Qi site, and two molecules bind at the Qo site (199). Lastly, 
complex IV, also known as cytochrome c oxidase, receives four electrons from four 
cytochrome c molecules and four protons, transfering them to one O2 molecule, 
generating two water molecules (Figure 1.15) (192).  
 
 
Figure 1.15. Mitochondrial respiratory chain. FAD, flavin adenine dinucleotide oxidized 
form; FADH2, flavin adenine dinucleotide reduced form;  
 
ATP synthase contains two domains: F1 with the catalytic site for ATP synthesis 
from adenosine-5’-diphosphate (ADP) and phosphate (Pi), being localized in the matrix 
side; and Fo with the proton channel across the IMM (Figure 1.15) (200). ATP is 
exchanged with cytosolic ADP by inner-membrane adenine nucleotide translocators (195). 
ATP synthase is inhibited by oligomycin that putatively binds to Fo 9 and 6 subunits (200). 
Mitochondria may reverse ATP synthase, consuming ATP to maintain the Δψm. Proton 
leak or mitochondrial uncoupling may be induced by protonophores [such as, carbonyl 
cyanide 4-(trifluoromethoxy)phenylhydrazone (FCCP)] or uncoupling proteins (194).  
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 In addition to complex I and II, several other dehydrogenases may supply the ETC 
with electrons through UQ reduction: glycerol-3-phospate dehydrogenase (enzyme of the 
IMM’s outer surface involved in lipid metabolism and glycolysis), electron transfer 
flavoprotein dehydrogenase (enzyme present in the IMM’s matrix surface, mainly involved 
in fatty acids oxidation) and dihydroorotate dehydrogenase (enzyme of the IMM’s outer 
surface, responsible for the dihydroorotate oxidation into orotate, a step of de novo 
pyrimidine biosynthesis). Other alternative dehydrogenases are located in both sides of 
IMM of plants, bacteria and fungi, catalyzing the NAD(P)H oxidation and the UQ reduction. 
The major differences of these complex I alternative dehydrogenases in relation to 
complex I are their rotenone insensitivity and lack of proton pumping capability (97). 
Similarly, other ubiquinol oxidases alternative to complex III are present in plants and 
fungi, however complex III appears to be the only ubiquinol-oxidase in mammals (201). 
Mitochondria are an important source of ROS and possess antioxidant defences 
such as superoxide dismutase, catalase and glutathione peroxidase (198, 202). Some 
authors suggest mitochondria as the major ROS source of the cell; however, Brown and 
Borutaite consider that this may not be true due to the existence of other ROS sources, 
such as lysosomes (203). In fact, under normal physiological conditions, ROS are formed 
at relatively low levels, being neutralized by mitochondrial antioxidants (204). Complexes I 
and III are the main sources of ROS in a mitochondrion (198). 
 
 
1.3.2. Mitochondrial disorders 
 
Mitochondrial dysfunction disorders may have as primary cause mutations in 
mDNA (MELAS or LHON) or nDNA (Charcot-Marie Tooth neuropathy type 2A or Leigh 
syndrome), but may also be acquired as a secondary event in disease pathogenesis (AD 
or PD) (205). mDNA is particularly susceptible to mutations, possibly due to less efficient 
DNA repair mechanisms and the absence of protective histones. Additionally, proximity to 
the ETC may favour mDNA damage by ROS (196). Regarding acquired mitochondrial 
dysfunction, the most important risk factor is ageing (206). With ageing, mitochondria tend 
to decrease in number, exhibiting cristae abnormalities, and decreased ETC activity (207). 
These alterations may result of accumulated mDNA mutations and oxidative damage. 
Ageing also down-regulates genes associated with synaptic plasticity, vesicular transport 
and mitochondrial function (206, 208).  
Mitochondrial dysfunction primarily impair organs with high-energy demand (195), 
such as brain, muscle and heart. These organs have a high density of mitochondria and 
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most energy is provided by oxidative phosphorylation (209, 210). Symptomatically, 
mitochondrial disorders may affect either single or, most frequently, several organs (205).  
No effective treatment exists for mitochondrial dysfunctions (205, 211, 212), but 
some metabolic approaches may provide modest improvement in patients’ life quality: 
UQ10 and its analogues, thiamine, uridine, dichloroacetate, L-arginine, antioxidants, mPTP 
modulators (cyclosporin A) and regulation of mitochondrial biogenesis and turnover 
[caloric restriction, Sirt1 agonists, activators of peroxisome proliferator-activated receptor 
(PPAR)/	   PPAR-γ coactivator 1α (PGC-1α), phosphoinositide 3-kinase antagonists and 
agonists] (195). 
 
1.3.2.1. Parkinson’s disease 
 
Parkinson’s disease (PD) is the most frequent movement disorder and the second 
most common neurodegenerative disorder (213). PD presents motor (bradykinesia, 
hypokinesia, resting tremor, gait difficult, postural instability and rigidity) and non-motor 
symptoms (cognitive impairment, depression and sleep disturbances) (196, 213). 
Biochemically, PD exhibits progressive loss of substantia nigra dopaminergic neurons, 
dopamine deficiency in the striatum, and cytoplasmic protein aggregates mainly 
composed by α-synuclein (α-syn), ubiquitin and molecular chaperones (Lewy bodies) 
(188, 196, 213).  
Sporadic PD likely combines genetic and environmental factors. Industrialization, 
rural environment, plant derived-toxins, pesticide exposure, bacterial and viral infection 
and ageing, have all been associated with sporadic PD (214). Ageing is the most 
important risk factor (196). 10% of PD cases have a genetic cause (196). Such familial 
variants are characterized by earlier onset of the symptoms, otherwise similar to sporadic 
PD (215).  
Mitochondrial dysfunction is associated with PD’s pathophysiology, being 
proposed to occur before the onset of the symptoms (204, 213, 216). Moreover, 
mitochondrial complex I is tipically impaired in PD patients. Deficient complex I activity 
was reported in dopaminergic neurons, in the frontal cortex, and in peripheral tissues (e.g. 
platelets and muscle), thus suggesting global complex I impairment in PD (217-221).  
Deficient complex III in lymphocytes and platelets was also reported in PD patients (217, 
222). Furthermore, mutations in several genes encoding mitochondrial proteins or proteins 
implicated in mitochondrial function have been linked with familial PD: e.g. α-syn (223), 
parkin (224), PTEN-induced putative kinase 1 (PINK1) (225) and leucine-rich repeat 
kinase 2 (LRRK2) (226). Parkin contains an ubiquitin E3 ligase domain and can have both 
cytosolic and mitochondrial localization. Parkin is proposed to have a crucial role in 
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mitochondrial turnover by mitophagy and biogenesis (224, 227, 228). The PINK1/Parkin 
pathway promotes mitochondrial fission (229) and controls motility (230). Dysfunctional 
PINK1/Parkin pathway associates with reduced proteasomal activity in PD substantia 
nigra (231), favoring accumulation and aggregation of potential cytotoxic proteins such as 
α-syn (232). α-Syn may directly bind the proteasome inhibiting its ubiquitin-dependent 
function (233). Significantly, proteosomal inhibitors (e.g. lactacystin) are known to induce 
neurodegeneration (234). 	  
α-Syn is expressed at high levels in the brain, localizing mainly at neuronal 
synaptic terminals (235). α-Syn inhibits mitochondrial fusion independently from the 
PINK1/Pakin pathway (236). Mutant α-syn accumulates on the IMM, being unclear 
whether as cause or consequence of complex I dysfunction and ROS (237). One 
hypothesis is that complex I inhibition and associated ROS induce α-syn aggregation, 
which subsequently impairs proteostasis thus causing dopaminergic neurodegeneration 
(238, 239). This hypothesis is supported by the report that mice lacking α-syn are 
resistant to the complex I inhibitor 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) 
(240). Alternative hypothesis suggest that Lewy bodies may be neuroprotective, 
sequestering potentially toxic proteins	   (241), this being supported by the observation of 
familiar forms of PD without Lewy bodies (242). 
Complex I impairment is associated with oxidative stress. PD patients present 
oxidative stress markers such as L-dopa and dopamine oxidation products (243, 244). 
Elevated iron in the substantia nigra of PD patients and decreased antioxidant enzymes is 
reported to favour oxidative stress (245). NQO1, an inducible flavoprotein involved in 
quinone detoxification (e.g. quinones derived from dopamine), is increased in PD brains, 
possibly in response to oxidative stress (244). Thus, ETC generated oxidative stress may 
have an important role in PD pathophysiology (204).  
Mitochondrial complex I inhibitors, like rotenone (246), paraquat (247) or MPTP 
(248) (Figure 1.16), have been used to induce PD. Rotenone is unselective for 
dopaminergic neurons, but can nevertheless induce preferential degeneration of 
dopaminergic neurons, suggesting that these are particularly sensitive to complex I 
inhibition (238). The pesticide paraquat, structurally related to MPTP’s active metabolite 
[1-methyl-4-phenylpyridinium (MPP+)] (Figure 1.16), also induces preferential 
dopaminergic neurodegeneration (249). Increased paraquat exposure is a PD risk factor 
(250). However, a Parkinsonism without complex I deficiency has also been reported, 
highlighting the limitations of the complex I impairment hypothesis in PD (242). 
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Figure 1.16. Mitochondrial complex I inhibitors used to induce Parkinsonism: 
Rotenone, paraquat, MPTP and MPTP’s active metabolite, MPP+. 
 
The main PD pharmacological approaches aim to rescue dopaminergic 
neurotransmission deficits, most frequently by combining the precursor L-dopa with a 
peripheral dopa decarboxylase inhibitor (e.g. carbidopa or benserazide) (251). 
Dopaminergic agonists (e.g. ropinirole) monoamine oxidase (MAO)-B inhibitors (e.g. 
selegiline), and amantadine have also been used in PD therapeutics (251, 252). These, 
however, are symptomatic therapies and no available treatment can rescue 
neurodegeneration or delay disease progression (252, 253). 
 
 
1.3.2.1.1. MPTP and MPP+ 
 
MPTP, a neurotoxin inducing severe Parkinsonism was identified as a byproduct 
of 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP), a meperidine analogue with heroin-
like properties (254, 255). MPTP crosses the blood brain barrier, being metabolised into 1-
methyl-4-phenyl-2,3-dihydropyridinium (MPDP+) by glial MAO-B. MPDP+ is then oxidized 
to the active metabolite MPP+, exits glia via the organic cation transporter (OCT)-3, and 
accumulates in dopaminergic neurons via their dopamine transporters (DAT) (Figure 
1.17) (256). Pre-treatment with MAO-B inhibitors (e.g. deprenyl) or with DAT inhibitors 
(e.g. nomifensine) can prevent MPTP toxicity (257-259). Intracellularly, MPP+ 
accumulates in mitochondria in a Δψm dependent manner, where it inhibits complex I (260, 
261). Δψm dependent accumulation of MPP+ is in accordance with higher MPP+ toxicity in 
intact mitochondria vs. submitochondrial particles (262, 263). While complex I is the main 
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MPP+ target, some studies suggest that MPP+ may also inhibits complexes III and IV (264).	  
Additionally, MPP+ may accumulate in synaptosomal vesicles through the vesicular 
monoamine transporter (VMAT)-2 (265) or interact with cytosolic proteins carrying 
negative charges (Figure 1.17) (266).  
         
 
Figure 1.17. Mechanism of action of MPTP and its active metabolite, MPP+. 
 
MPTP induced Parkinsonism has several similarities to sporadic PD. MPTP can 
induce Lewy bodies formation (267), impair mitochondrial ATP production, generate ROS, 
and activate pro-apoptotic pathways (268, 269); MPTP toxicity is selective to 
dopaminergic neurons (270); and L-dopa attenuates symptoms induced by MPTP (271). 
Thus, MPTP and MPP+ have been used to induce Parkinsonian phenotype in several 
animal models, such as monkeys (272, 273), tree shrews (274), mice (275, 276), and 
zebrafish (259), among others, despite variation of MPTP susceptibility among species 
(277). Specially in rodents, only specific strains of mice are sensitive to MPTP-induced 
toxic effects, which is perhaps related with metabolic differences, namely in MPP+ 
clearance	  (278). 
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1.4. Zebrafish as an experimental model 
 
Mammalian models, such as mice or rats, have been widely used to study human 
diseases, due to high homology between mammalian genomes and similarities in 
anatomy, physiology and cell biology. Mammalian models, however, are expensive, 
laborious, time- and drug-consuming, and there are increasing ethical and legislative 
pressures to limit their use in research (279, 280). Given the high conservation of basic 
cell biology between mammals and invertebrates, Drosophila melanogaster Meigen and 
Caenorhabditis elegans (Maupas) have been extensively used in biomedical research 
(281, 282). The major advantages of these models are their lower price and size, the 
possibility of high-throughput drug screening and the sequenced genome that allows easy 
genetic modifications. However, several structures and organs that are involved in human 
pathology are missing in invertebrates, limiting the use of these models (279). 
Zebrafish (Danio rerio Hamilton) (Figure 1.18) is a popular robust tropical pet that 
became a frequent biomedical model. Zebrafish allows the study of organogenesis, 
physiology and behaviour, associating genes to functions (280). Zebrafish has multiple 
advantages: less expensive than mammals, small size, high spawning rate (about 300 
eggs per female), external and optically transparent embryonic development, no feeding 
requirement for at least the first 7 days post fertilization (dpf), short generation time (3 
months), high-throughput drug screening potential, sequenced genome, easy genetic 
manipulation and high physiological and genetic homology to mammals (280, 283). 
Despite obvious differences between fish and humans, it is clear that zebrafish offers 
several advantages that make it a good complement to mammalian models. The majority 
of zebrafish experiments have been made in embryos or larvae; however, the use of adult 
zebrafish is critical for developmental/age dependent biological processes. Several 
regeneration and behaviour studies have been carried out in adults (284, 285). 
Additionally, several methodologies have been optimized/developed for zebrafish, such as 
in situ hybridization, antisense morpholino oligonucleotides and transgenic lines 
generation (286-288).  
Zebrafish allows high-throughput drug screening, where small molecules normally 
added to water are absorbed into the fish. Embryos/larvae can be assayed in multi-well 
plates without invasive or time-consuming injections (289). Zebrafish is also used as 
disease model for obesity and metabolic dysfunction (283), leukaemia (290), muscular 
dystrophies (291), cardiovascular, neurodegenerative, and multiple other human disorders. 
Zebrafish cardiac development begins very early with heartbeat starting at about 
24 h post fertilization (hpf) (292). Zebrafish needs no cardiac function to survive until 5 dpf, 
subsisting with simple oxygen diffusion, thus allowing the study of severe heart 
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abnormalities otherwise lethal to other key animal models (289, 293). Moreover, heart and 
blood vessels are easily visualised in transgenic zebrafish expressing fluorescent proteins 
driven by organ specific promotors (294). Zebrafish has thus been used to model dilated 
cardiomyopathy (295), long QT syndrome (296), aortic coarctation (297), and vascular 
lipid deposition (298) among other cardiovascular diseases.  
 
 
Figure 1.18. Zebrafish. Zebrafish at embryonic, larval and adult stage. (photos by Brígida 
R. Pinho). 
 
Zebrafish has been used to study the nervous system, under physiological and 
pathological conditions, and to search novel neuroactive molecules. The zebrafish brain 
has several common features with the mammalian brain: glial cells; a similar blood brain 
barrier (299, 300); similar central nervous system (CNS) organization, conventionally 
divided into spinal cord, hindbrain, midbrain and forebrain (292); and similar neuronal 
pathways, cellular homeostasis and pathology (300). Screening of neuroactive molecules 
can be easily made in zebrafish through photomotor- and embryonic touch-response 
(301). Mechanosensory stimuli evoke locomotor responses in larvae. Also, changes in 
ambient temperature, presence of chemical irritants, or olfactory stimuli may all promote 
locomotion as escape behaviour (302, 303). Zebrafish has been used to study neuronal 
circuits involved in learning and behaviour (303), and to model nervous system disorders 
such as such as Huntington’s disease (304), retinal degeneration (305), anxiety (306), 
Charcot-Marie Tooth disease (307), amyotrophic lateral sclerosis (ALS) (308), AD (309), 
PD (310). Zebrafish has also been used to model mitochondrial disorders such as multiple 
acyl-CoA dehydrogenase deficiency (MADD) (311). Some homologues genes associated 
with human neurodegenerative disorders were already identified in zebrafish. Zebrafish 
has a partial genome duplication, resulting in a subfunctionalization of some genes that 
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assists their study (300). One example is the presenilin-associated rhomboid-like (PARL) 
gene, recently associated to familial PD, that has two paralogs (parl-a and parl-b) in 
zebrafish	   (312). Examples of other neurodegeneration-linked genes in zebrafish are 
Parkin, PINK-1 (310, 313), LRRK2 (314), β-secretase, γ-secretase and presenilin-1 (315).  
The zebrafish dopaminergic system has been mostly explored in the context of PD. 
Dopaminergic neurons are first detected at 18 hpf (316) and at 3 dpf they form a cluster in 
the posterior tuberculum of the ventral diencephalon. At 3 dpf, the zebrafish has a well-
developed CNS with a spatial distribution of dopaminergic neurons equivalent to the 
nigrostriatal system observed in adults. In fact, as zebrafish mature into adults, their 
dopaminergic neurons in the posterior tuberculum ascend to the subpallium basal 
telencephalon, considered equivalent to the mammalian dopaminergic system (312, 316, 
317). Zebrafish dopaminergic neurons are also detected in the olfactory bulb, pretectum 
and retina (316). Similarly to mammals, zebrafish dopaminergic neurons also regulate 
locomotion and behaviour (318).  
Zebrafish allows the study of PD associated genes as well as PD phenotypes. 
Dopaminergic neurotoxins such as paraquat, rotenone, 6-hydroxydopamine, and 
MPTP/MPP+, have been used to induce PD phenotypes in zebrafish (319, 320). Zebrafish 
is equally susceptible to MPTP during all life stages, showing a locomotor activity deficit 
when exposed to this neurotoxin (257, 259). Selective MPTP concentrations induce a 
locomotor phenotype in zebrafish without morphological changes in treated larvae (319). 
Zebrafish, however, has a higher neurogenesis potential than mammals, which may 
influence its neurotoxin susceptibility 16 different neurogenesis regions were identified in 
zebrafish vs. 2 specially involved in mammalian neurogenesis (subventricular and 
subgranular zone of the telencephalon) (321), which may explain the higher zebrafish 
capacity for axonal and neuronal regeneration after local lesions (300).  
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2. Objectives 
 
This thesis had the following objectives: 
1. Evaluate naphthoquinones’ anti-inflammatory potential: 
a. Reduction of NO and pro-inflammatory cytokines release in LPS-treated 
cells; 
b. Contribution of naphthoquinone-generated oxidative stress to NO 
reduction. 
2. Evaluate naphthoquinones’ anti-allergic properties: 
a. Inhibition of basophils’ degranulation induced by IgE-antigen complex or 
calcium ionophore; 
b. Inhibition of allergy-related enzymes; 
c. Inhibition of leukotriene production induced by IgE-antigen complex. 
3. Characterize the consequences of mitochondrial dysfunction for zebrafish 
development and cardiovascular function, and test mitochondria-targeted 
quinones: 
a. Compare mitochondrial complex subunits between zebrafish and other 
species; 
b. Characterise mitochondrial inhibitors’ effects on zebrafish embryonic 
development and cardiovascular function; 
c. Characterise naphthoquinones and ubiquinone analogues’ effects on 
zebrafish embryonic development and cardiovascular function; 
d. Evaluate ubiquinone analogues’ potential for rescuing chronic and acute 
mitochondrial dysfunction in zebrafish. 
4. Evaluate ubiquinone analogues’ potential for rescuing the MPP+-induced PD 
model in zebrafish: 
a. Characterise locomotor profiles and sensorimotor reflexes under control 
conditions during the post-hatching period; 
b. Characterise MPP+-induced phenotypes in zebrafish larvae, including 
viability, effects on locomotion, reflexes, neuromast labelling and 
mitochondrial function; 
c. Characterise ubiquinone analogues’ effects on locomotion, reflexes and 
mitochondrial function in zebrafish larvae; 
d. Evaluate ubiquinone analogues’ potential for rescuing the MPP+-induced 
locomotor phenotype in zebrafish larvae. 
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3.1. Is nitric oxide decrease observed with naphthoquinones in LPS stimulated 
RAW 264.7 macrophages a beneficial property?  
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Is nitric oxide decrease observed with naphthoquinones in LPS Stimulated RAW 
264.7 macrophages a beneficial property? 
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Abstract 
 
The search of new anti-inflammatory drugs has been a current preoccupation, due to the need of effective 
drugs, with less adverse reactions than those used nowadays. Several naphthoquinones (plumbagin, 
naphthazarin, juglone, menadione, diosquinone and 1,4-naphthoquinone), plus p-hydroquinone and p-
benzoquinone were evaluated for their ability to cause a reduction of nitric oxide (NO) production, when RAW 
264.7 macrophages were stimulated with lipopolysaccharide (LPS). Dexamethasone was used as positive 
control. Among the tested compounds, diosquinone was the only one that caused a NO reduction with 
statistical importance and without cytotoxicity: an IC25 of 1.09 ± 0.24 µM was found, with 38.25 ± 6.50% (p < 
0.001) NO reduction at 1.5 µM. In order to elucidate if this NO decrease resulted from the interference of 
diosquinone with cellular defence mechanisms against LPS or to its conversion into peroxynitrite, by reaction 
with superoxide radical formed by naphthoquinones redox cycling, 3-nitrotyrosine and superoxide 
determination was also performed. None of these parameters showed significant changes relative to control. 
Furthermore, diosquinone caused a decrease in the pro-inflammatory cytokines: tumour necrosis factor-alpha 
(TNF-α) and interleukin 6 (IL-6). Therefore, according to the results obtained, diosquinone, studied for its anti-
inflammatory potential for the first time herein, has beneficial effects in inflammation control. This study 
enlightens the mechanisms of action of naphthoquinones in inflammatory models, by checking for the first 
time the contribution of oxidative stress generated by naphthoquinones to NO reduction. 
 
Keywords: Naphthoquinones; diosquinone; anti-inflammatory; nitric oxide; pro-inflammatory cytokines; 3-
nitrotyrosine; superoxide.  
 
Introduction 
Naphthoquinones are secondary metabolites 
widely distributed in nature. They are present 
mainly in several families of higher plants, as 
Diospyros spp., including the species producing the 
edible fruit persimmon, but also in fungi, lichens 
and in bacteria	   (7). Naphthoquinones present a 
diversity of structures, exhibiting several 
substituents and can group together forming 
dimers, trimers and more seldom tetramers (30). 
This chemical diversity probably explains the 
several activities described for them. 
Naphthoquinones exhibit very interesting 
pharmacological properties, being Diospyros 
extracts widely used in African, Chinese and Indian 
traditional medicine (7). In particular, Diospyros 
chamaethamnus is characterized by the presence 
of several 7-methyljuglone derivatives, including 
five dimers (diospyrin, isodiospyrin, diosquinone, 
mamegakinone and biramentaceone), a trimer 
(xylospyrin) and a tretramer (6-[2-(7-methyl- 
juglonyl)]-isoxylospyrin) (31). 
Antibacterial (53), antimalarial (322), antipyretic 
(323) and antitumor (324) activities are some of the 
properties attributed to naphthoquinones. Although 
naphthoquinones have also a toxicological 
potential, mainly due to their ability to induce 
oxidative stress (8), they can be good lead 
compounds for new anti-inflammatory drugs, as 
several previous studies evidence. 
Bisnaphthoquinones inhibit platelet aggregation 
(325), plumbagin inhibits cytokines release (85), 
shikonin derivatives inhibit cyclooxygenase-2 
expression (326), mast cell degranulation (327) 
and iNOS (an inducible calcium-independent 
isoform of nitric oxide (NO) synthases) (77), 
interfering with NO production (328). However 
more studies are needed to confirm a really 
beneficial property. 
During inflammation highly reactive species, 
such as superoxide radical, peroxynitrite, hydrogen 
peroxide, hypochlorous acid and NO are produced. 
NO is a small diffusible molecule with important 
biological functions, including vasodilatation, 
neurotransmission and inflammation. NO 
generated by iNOS in activated macrophages is 
important for host defences. NO modulates the 
synthesis of prostaglandins, tromboxans and other 
inflammatory molecules (329). 
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Macrophages are important producers of pro-
inflammatory cytokines, such as tumour necrosis 
factor-alpha (TNF-α), interleukin 1β (IL-1β) and 
interleukin 6 (IL-6), when they are stimulated by an 
aggression, like lipopolysaccharide (LPS) exposure 
(330). These pro-inflammatory cytokines allow an 
increase in blood flow and permeability into 
capillaries, leading to infiltration of immune cells. 
TNF-α has a central role in the inflammatory and 
destructive processes found in several human 
autoimmune and chronic inflammatory diseases 
(331). IL-1β is important for the initiation and 
enhancement of inflammatory response to 
proliferation of some microorganisms (332) and IL-
6 is regarded as an endogenous mediator of LPS-
induced fever (333). Furthermore, there is some 
evidence of the involvement of these cytokines in 
carcinogenicity (334). 
Although inflammatory mediators like cytokines 
are necessary for successful defence against 
foreign invaders, their production also results in 
collateral damage to host tissue components, 
including proteins, lipids/membranes and DNA. A 
delicate balance between formation and 
detoxification of reactive species produced in 
inflammation process allows directing signalling 
pathways to physiological or pathological 
conditions. Therefore, inflammation plays a pivotal 
role in the pathogenesis and development of some 
diseases, like certain cancers, neurodegenerative 
lesions and chemical toxicity (335). 
For the management of inflammation a broad 
range of immunosuppressive drugs, as calcineurin 
inhibitors, steroids and anti-inflammatory non-
steroids have been used. Nevertheless, these 
drugs have undesirable side effects like metabolic 
derangements, development of infections, cancers 
and gastric toxicity	  (85). 
In the present work, the ability to induce a 
decrease of NO in LPS-stimulated RAW 264.7 
macrophages of several naphthoquinones 
(plumbagin, naphthazarin, juglone, menadione, 
diosquinone and 1,4-naphthoquinone), p-
hydroquinone and p-benzoquinone (Figure 3.1.1) 
was evaluated. This chemical mediator was chosen 
due to its importance in inflammatory processes 
and for inflammatory damage, besides being easily 
quantified. Regarding the anti-inflammatory 
potential of the involved naphthoquinones, 
naphthazarin and 1,4-naphthoquinone were 
already studied for their ability to decrease NO in 
LPS-stimulated RAW 264.7 macrophages (77). 
Nevertheless, naphthoquinones are also known to 
undergo redox cycling, causing oxidative stress in 
cells (8). As far as we know, there are no reports 
assessing whether the decrease of NO in this 
model is due to a reduction of its production or to 
the reaction of NO with superoxide generated 
during redox cycling of naphthoquinones. If the 
second hypothesis is true, the generation of 
peroxynitrite can lead to protein nitration, impairing 
cellular functioning, and no beneficial effect can be 
attributed to naphthoquinones. Thus, this work 
intended to: extend the knowledge on the ability to 
cause a NO decrease in the LPS – RAW 264.7 
macrophages model to other naphthoquinones 
(juglone, menadione, plumbagin and diosquinone) 
and related compounds (p-hydroquinone and p-
benzoquinone); establish possible structure-activity 
relationships; determine if NO decrease induced by 
naphthoquinones is due to its consumption in 
peroxynitrite formation. Pro-inflammatory cytokines 
(TNF-α, IL-1β and IL-6), superoxide radical and 
protein nitration levels were determined for the 
most promising compound. 
As far as we know, the contribution of oxidative 
stress induced by naphthoquinones to NO 
reduction has not been studied yet. Furthermore, 
diosquinone, an epoxide dimeric naphthoquinone 
found in several Diospyros species (31, 336), was 
evaluated for its anti-inflammatory potential for the 
first time herein. 
 
Materials and Methods 
 
Materials 
DPBS (Dulbecco’s Phosphate Buffered Saline), 
DMEM (Dulbecco’s Modified Eagle 
Medium)+GlutaMAXTM-I, heat inactivated foetal 
bovine serum and penicillin + streptomycin (Pen 
Strep) were obtained from Gibco, InvitrogenTM 
(Grand Island, NY, USA). Plumbagin, naphthazarin, 
juglone, 1,4-naphthoquinone, p- hydroquinone, p-
benzoquinone, menadione, sulphanilamide, 
potassium nitrite, β-nicotinamide adenine 
dinucleotide reduced disodium salt hydrate (NADH), 
sodium pyruvate, 3-(4,5-di- methylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT), methanol, 
triton, tris-HCl, ethylene glycol-bis(2-
aminoethylether)-N,N,N’,N’-tetraacetic acid (EGTA), 
brilliant blue G, dimethyl sulfoxide (DMSO), DL-
dithiothreitol (DTT), phenylmethanesulfonyl fluoride 
(PMSF), nitrotetrazolium blue chloride (NBT), 
bovine serum albumin, lipopolysaccharide from 
Salmonella enteric serotype Typhimurium, 
monoclonal anti-3-nitrotyrosine antibody produced 
in mouse and GBX fixer and developer of Kodak 
processing chemicals for autoradiography films 
were purchased from Sigma-Aldrich (St. Louis, MO, 
USA). N-(1)-Naphthylethylenediamine, glycerol and 
ethylenediaminetetraacetic acid (EDTA) were 
obtained from Merck (Darmstadt, Germany). 
Sodium chloride and potassium hydroxide (KOH) 
were purchased from Vaz Pereira (Lisbon, 
Portugal) and ortho-phosphoric acid 85% was 
obtained from Panreac (Barcelona, Spain). Goat 
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Figure 3.1.1. Chemical structures of the tested compounds. A, p-hydroquinone; B, p-benzoquinone; C, 1,4-
naphthoquinone; D, menadione; E, plumbagin; F, juglone; G, naphthazarin; H, diosquinone. 
 
 
antibody to mouse IgG (horseradish peroxidase) 
(0.8 mg/mL), TNF-α, IL-1β and IL-6 mouse ELISA 
kits were purchased from Abcam (Cambridge, 
United Kingdom). Hybond – ECL, HyperfilmTM ECL 
and the enhanced chemiluminescence (ECL)-Plus 
reagent Kit were obtained from AmershamTM (GE 
Healthcare, Piscataway, NJ, USA). Diosquinone 
was isolated from root barks of D. chamaethamnus 
(31) and its purity was checked by HPLC-DAD. 
 
Diosquinone HPLC-DAD analysis 
Chloroform solution of diosquinone was analysed 
in a HPLC system (Gilson), using a Spherisorb 
OSD2 column (Waters, Milford, USA) (250 x 4.6 
mm, i. d., 5 µm). The solvent used was a mixture of 
acetic acid 5% in water (A) and methanol (B) and 
the gradient was as follows: 0 min - 75% B, 10 min 
- 75% B, 25 min - 85% B, 35 min - 100% B and 60 
min - 100% B. The HPLC system was equipped 
with a Gilson diode array detector (DAD). 
Spectroscopic data of the peak was accumulated in 
the range of 200–400 nm, and chromatogram was 
recorded at 255 nm. The data was processed on 
Unipoint system software (Gilson Medical 
Electronics, Villiers le Bel, France). 
 
Cell culture and treatments 
The mouse macrophage-like cell line RAW 264.7 
was kindly provided by Prof. Maria S. J. 
Nascimento (Laboratório de Microbiologia, 
Departamento de Ciências Biológicas, Faculdade 
de Farmácia, Universidade do Porto). Cells were 
grown in DMEM+GlutaMAXTM – I supplemented 
with 10% heat inactivated foetal bovine serum, 100 
U/mL penicillin and 100 µg/mL streptomycin, under 
5% CO2 at 37ºC, in humidified air. Cells were 
plated at 1.5x105 cells/mL in a plate with 48 wells 
(1 mL/well). The tested compounds were dissolved 
in DMSO, at 10 mM, and stored, as small aliquots, 
at -20ºC. The compounds were diluted with 
supplemented DMEM as needed, before cell 
exposure. When cells reach confluence, the 
compounds were added, 1 h before exposure to 
LPS (1 µg/mL). After addition of LPS, the cells 
were maintained in culture for 18 h. 
Dexamethasone at a concentration of 50 µM was 
used as positive control. The effect of all tested 
compounds in the absence of LPS was also 
evaluated, in order to observe if they induced 
changes in NO basal levels. In negative controls, 
no LPS was added. The final concentration of 
DMSO was 0.5% (v/v) and all control groups 
received the same amount of DMSO. 
 
Lactate dehydrogenase (LDH) leakage assay 
The release of the cytosolic enzyme LDH into 
culture medium was evaluated as follows: an 
aliquot of culture medium was taken and mixed 
with a NADH buffered solution and pyruvate 
solution (337). LDH activity was measured 
spectrophotometrically by following the conversion 
of NADH to NAD+, at 340 nm. Results are 
expressed as a percentage of the respective 
control (with or without LPS). 
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MTT reduction assay 
Cellular viability was also assessed by the 
mitochondria dependent reduction of MTT to 
formazan, according to Sousa and collaborators 
(338) with some modifications. After described 
incubation with tested compounds, culture 
medium removal and cells washing with DPBS, 
cells in 48-wells plates were incubated with 1 
mL/well of MTT (0.5 mg/mL), during 30 min at 
37ºC. In the end, supernatant was rejected and 
formazan was solubilized in DMSO (1 mL). The 
extent of reduction of MTT to formazan within 
cells was quantified by measurement of optical 
density at 550 nm, using a microplate reader 
(Multiskan ASCENT Thermo®). Results are 
expressed as a percentage of the respective 
control (with or without LPS). 
 
NO determination 
In culture, the NO released by the macrophages 
into the medium is converted to several nitrogen 
derivatives, from which only nitrite is stable, being 
easily measured by Griess reagent (1.0% 
sulphanilamide and 0.1% N-(1)-naphthylethylenedi- 
amine in 2% phosphoric acid) (77). After incubation, 
100 µL of culture medium supernatant was mixed 
with the same volume of Griess reagent, during 10 
min, at room temperature. The nitrite produced was 
determined by measuring the optical density at 550 
nm, in a microplate reader (Multiskan ASCENT 
Thermo®). Nitrite was quantified by external 
standard, using potassium nitrite to generate a 
standard curve. Results are expressed as a 
percentage of the control with LPS. 
 
Measurement of superoxide radical 
Superoxide radical was measured by the NBT 
reduction assay (338). Each well of a 12-wells plate 
was seeded with 2 mL of RAW 264.7 macrophages 
suspension containing 1.5x105 cells/mL. The 
treatment of cells proceeded as described 
previously: pre-exposure to tested compounds for 1 
h, followed by addition of 1 mg/mL or vehicle and 
further incubation for 18 h. After incubation, 40 µL 
of a NBT solution at 1 µg/mL was added to the 
medium and incubated at 37ºC, for 1 h. Then, the 
incubation medium was removed and cells were 
lysed with DMSO: 4 mM KOH (1:1). The 
absorbance of reduced NBT, formazan, was 
measured at 630 nm, in a microplate reader 
(Multiskan ASCENT Thermo®). Results are 
expressed as a percentage of the control without 
LPS. 
 
Protein quantification 
Protein quantification was performed by addition of 
200 µL of Bradford dye reagent (brilliant blue G, 0.1 
mg/mL; ethanol, 5% (v/v); phosphoric acid, 10% 
(v/v) and water) to 40 µL of samples, pre-diluted 
100 times. The photometrical measure was 
performed at 595 nm. Bovine serum albumin was 
used to generate a standard curve. 
 
Slot-immunoblotting analysis of 3-nitrotyrosine 
RAW 264.7 macrophages were plated with 4 
mL/well at a density of 1.5x105 cells/mL, in a plate 
with 6 wells. After treatment with dexamethasone 
(50 µM), diosquinone (1.5 µM) and LPS (1 µg/mL), 
as described above, the cells were washed and 
subjected to 200 µL triton lysis buffer (1% triton, 20 
mM tris HCl, 150 mM NaCl, 5 mM EGTA, 10 mM 
EDTA and 10% glycerol) with 1 mM DTT and 0.5 
mM PMSF, as proteases inhibitors, during 60 min. 
Samples were centrifuged at 12 000 rpm, for 10 
min, at 4ºC, and respective supernatants were 
collected. Samples solutions were diluted to 
contain the same protein concentration (0.5 
mg/mL) and 100 µL of these solutions were applied 
in a nitrocellulose membrane, pre-washed with 
10% of methanol and pre-hydrated during 5 min. 
Negative pressure was applied after application of 
all samples (in duplicate). The membrane was then 
disassembled from the apparatus and incubated in 
a TBS-T blocking solution with 5% milk for 5 h, at 
room temperature. A mouse polyclonal anti-3-
nitrotyrosine antibody was used at a dilution of 
1:1000 in TBS-T blocking solution with 5% milk. 
The membrane and the antibody were incubated 
overnight, at 4ºC, and further incubated at room 
temperature for 2 h. After washing the membrane 
with TBS-T, during 5 min, three times, a goat anti-
mouse secondary antibody conjugated with 
horseradish peroxidase (1:2000) was applied to the 
membrane for 2 h, at room temperature. All 
incubations were made with mixing. Finally, the 
membrane was washed three times with TBS-T 
buffer and one time with TBS. Blots were revealed 
using the ECL system kit and 3-nitrotyrosine were 
visualized on high performance chemiluminescen- 
ce film, after 15 min of exposure of film to 
membrane. Three assays were performed. This 
method is in accordance to Moreira-Gonçalves and 
collaborators with some modifications (339). Three-
dimensional surface plot analyses were generated 
with the ‘‘Surface Plot’’ function of Image J 1.44 
(http://rsbweb.nih.gov/ij/download. html). 
 
Enzyme linked immunosorbent assay (ELISA) 
RAW 264.7 macrophages were plated with 4 
mL/well at a density of 1.5x105 cells/mL, in a 6 
wells plate. Supernatants from dexamethasone (50 
µM), diosquinone (1.5 µM) exposed macrophages, 
either without or with LPS (1 µg/mL) stimulation, 
were collected at 18 h and centrifuged at 4000 rpm 
for 3 min, to remove any cells. Cell free culture 
media were stored at -70ºC until use. TNF-α, IL-1β 
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and IL-6 secreted cytokines were measured in 
duplicate, using purified biotinylated antibodies in 
ELISA sets according to the protocol provided by 
the supplier (Abcam, Cambridge, United Kingdom). 
The ELISA plates were read using a microplate 
reader (Multiskan ASCENT Thermo®). 
 
Statistical analysis 
OneWay ANOVA and Dunnett test, as post-hoc 
test, were used to determine the statistical 
significance in comparison to control. Data are 
expressed as the mean ± standard error of the 
mean (SEM) of at least four independent 
experiments, performed in duplicate or triplicate, as 
described above. P values of 0.05 or less were 
considered statistically significant. Statistical 
analysis was made using: PAWS Statistic 18 
Software (Chicago, IL, USA) and Graphpad Prism 
5 Software (San Diego, CA, USA). 
 
Results 
 
Cellular viability 
The exposure to LPS (1 µg/mL) for 18 h induced a 
decrease in cellular viability (14.22 ± 2.50 % 
relative to control, in MTT assay), with statistical 
importance (P < 0.001) (Figure 3.1.2). 
Dexamethasone (1–50 µM) was used as positive 
control. At 50 µM, dexamethasone alone caused 
22.98 ± 4.11 % (P < 0.001) of cell death, as 
evaluated by MTT assay. However, for the same 
concentration of dexamethasone and in the 
presence of LPS, cell viability of RAW 264.7 
macrophages was higher than 100% relative to 
control (P < 0.01). These differences in cell viability 
were not verified in the LDH assay (Figure 3.1.2.). 
Therefore, as MTT assay allowed detecting more 
alterations on cells’ survival than the measure of 
LDH leakage (Figures 3.1.2 and 3.1.3), the results 
presented herein for cell viability after treatments 
with naphthoquinones were obtained by the first 
assay. 
Naphthazarin was the most toxic compound 
(LC25 = 0.73 ± 0.07 µM), followed by plumbagin 
(LC25 = 1.26 ± 0.28 µM) (Figure 3.1.4). For 
plumbagin, at 5 µM, there was 70.50 ± 7.12 % (P < 
0.001) of cell death, by MTT assay, while in the 
LDH assay cell viability was higher than 100% (P < 
0.01) (Figure 3.1.5). In order to explore this result, 
a study of cell viability over time, with 5 µM of 
plumbagin was performed (data not shown). In the 
MTT assay, it was verified that cell death began to 
occur 2 h after treatment, rapidly increasing until 5 
h and reaching 70% at the end of the treatment (19 
h). Cell death measured by LDH assay showed the 
same profile during the first 8 h. After this period, 
the LDH quantified in the culture medium began to 
decrease. Cell death overtime was confirmed by 
microscopic evaluation. 
1,4-Naphthoquinone (P < 0.001) and 
diosquinone (P < 0.01) showed some toxicity at 
concentrations of 5 µM and 2.5 µM, respectively 
(about 35% of cell death relative to control). 
Juglone caused nearly 20% of cell death at 10 µM 
(P < 0.001). Menadione (0.5 – 10 µM), p-
hydroquinone and p-benzoquinone (0.5 – 5 µM) 
revealed no cytotoxicity under the concentration 
range used (Figure 3.1.4).  
 
 
Figure 3.1.2. Influence of LPS in cell viability. RAW 
264.7 macrophages were exposed to 1 µg/mL of LPS, 
during 18 h and cell viability were assessed by LDH and 
MTT assays. Results are expressed in percentage of 
control (mean ± SEM of five independent experiments, 
performed in duplicate). *P < 0.05, ***P < 0.001. 
 
NO production 
None of the tested compounds induced changes in 
NO basal levels, when incubated without LPS (data 
not shown). 
Dexamethasone caused a decreased of NO for 
all tested concentrations, having an IC25 of 1.72 ± 
0.54 µM. With 50 µM of dexamethasone, the 
amount of NO was similar to basal levels (Figure 
3.1.6). 
Diosquinone decreased NO to 38.25 ± 6.50 % 
(P < 0.001) relative to control at 1.5 µM, with an 
IC25 of 1.09 ± 0.24 µM (Figure 3.1.7). The IC25 
found for 1,4-naphthoquinone was 0.72 ± 0.09 µM. 
However, at 1.5 µM, NO reduction by 1,4-
naphthoquinone was 27.36 ± 0.28% (P > 0.05). 
Menadione did not induce NO reduction with 
statistical significance. Juglone, naphthazarin and 
plumbagin did not cause a decrease of NO at non-
cytotoxic concentrations (Figures 3.1.4, 3.1.5 and 
3.1.7). 
p-Benzoquinone and p-hydroquinone exhibited 
an IC25 of 1.82 ± 0.57 µM and 1.14 ± 0.28 µM, 
respectively, being the last more active than p-
benzoquinone: p-hydroquinone caused a reduction 
of 50% of NO, at 3.74 ± 0.18 µM (Figure 3.1.7). 
As diosquinone caused higher NO reduction 
than the other tested naphthoquinones to lower 
concentrations, it was chosen to study the effect on 
superoxide and pro-inflammatory cytokines 
production and protein nitration. 
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Figure 3.1.3. Influence of dexamethasone with and 
without LPS in cell viability. RAW 264.7 macrophages 
were pre-exposed for 1 h to dexamethasone followed by 
18 h co-exposure with 1 µg/mL of LPS (A) or vehicle (B). 
The cell viability was assessed by MTT and LDH assays. 
All results are percentage of control (mean ± SEM of five 
independent experiments, performed in duplicate). *P < 
0.05, **P < 0.01, ***P < 0.001. 
 
Superoxide generation 
The different treatments (without tested 
compounds, with 1.5 µM of diosquinone and 50 µM 
of dexamethasone, in the presence and in the 
absence of LPS) did not reveal significant 
differences (Figure 3.1.8). However, LPS seemed 
to increase superoxide generation, especially in 
control cells. 
 
Protein nitration 
Diosquinone (1.5 µM) alone did not increase 
protein nitration, relative to control. On the other 
hand, dexamethasone (50 µM) by itself led to 
protein nitration, which was potentiated by LPS 
(Figure 3.1.9). 
 
Pro-inflammatory cytokines 
Diosquinone (1.5 µM) was able to reduce TNF-α by 
51.38 ± 9.72 % and IL-6 by 39.42 ± 19.79 % 
relative to LPS exposed cells only. With respect to 
IL-1β, macrophages stimulation with LPS did not 
cause a measurable increase of this cytokine under 
the assay conditions. So no reduction in this 
interleukin could be observed in cells exposed to 
diosquinone and LPS. 
 
Discussion 
 
Several compounds, the majority of them being 
naphthoquinones (Figure 3.1.1), were screened for 
their ability to alter NO production by LPS 
stimulated RAW 264.7 macrophages. In a second 
part of this work, assays were made to confirm the 
beneficial effect of diosquinone, the most promising 
one. Diosquinone, previously isolated from D. 
chamaethamnus (31), was pure, as ascertained by 
HPLC-DAD analysis (data not shown). 
Macrophages, which express high levels of 
inducible NO synthase, play a central role in host’s 
defence against bacterial infection, being the major 
cellular targets for LPS action (340). 
Among inflammatory modulators produced in 
response to LPS, NO is an important cytotoxic 
mediator (341). The first precaution when studying 
the direct interference of a given compound on NO 
production is to guarantee that it does not cause 
cell death, decreasing the number of NO producing 
cells. Thus, the effect on cell viability should be 
assessed. 
The results obtained after incubation with 
dexamethasone in MTT assay depended on the 
presence of LPS (Figure 3.1.3): when cells were 
treated with both LPS and dexamethasone the 
cellular viability was higher than 100% (P < 0.01), 
while the treatment only with dexamethasone gave 
the opposite result. This could be explained by the 
mechanism of action of dexamethasone, which 
inhibits NF-κB transcription factor (342). NF-κB is 
central to a series of cellular processes, like 
inflammation, cell proliferation and apoptosis (343). 
As constitutive expression of NF-κB is frequently 
found in tumour cells (34), the NF-κB inhibitory 
action of dexamethasone can be responsible for 
the decrease in RAW 264.7 macrophages viability. 
As LPS activates NF-κB (334) and dexamethasone 
has an opposite activity, the dexamethasone effect 
in cell survival is counterbalanced by the presence 
of LPS. 
In this work, LDH and MTT assays revealed 
different effects on cellular viability. The decrease 
in cell survival, in the presence of 50 µM of 
dexamethasone, was not detected by LDH assay 
(Figure 3.1.3). Analogous observations had also 
been reported by other authors (337, 344). LDH 
assesses cell death due to cell membrane damage 
which leads to the release of LDH into culture 
medium (337). MTT assay provides information on 
mitochondrial function, as MTT reduction mainly 
occurs in this organelle through the action of  succi- 
	   EXPERIMENTAL SECTION 3.1 
51 
 
Figure 3.1.4. Influence of tested compounds in cell viability. Viability of LPS stimulated RAW 264.7 macrophages, after 
19 h of exposure to the tested compounds, by MTT assay. All results are expressed in percentage of control with LPS 
(mean ± SEM of four independent experiments, performed in duplicate). *P < 0.05, **P < 0.01, ***P < 0.001.
 
 
 
nate dehydrogenase (337). The MTT assay is also 
a preferential method when cell death occurs long 
before cellular viability determination, as we 
observed for plumbagin treatment at 5 µM. With 
this naphthoquinone, cell viability after 19 h 
exposure assessed by the MTT assay was too low, 
while it reached a mean of 151.90 ± 41.39% (P < 
0.01) in the LDH assay (Figure 3.1.5). Therefore, 
the influence of exposure time on cell viability was 
studied. It was observed that cell death occurred 
mainly in the beginning of the exposure period 
(data not shown). Thus the majority of the LDH 
leaked to the medium was degraded at 19 h. In 
this study, MTT assay appeared to be more 
sensitive in detecting toxicity compared to the 
LDH leakage assay. For these reasons, the MTT 
assay was chosen to assess the effect on cell 
viability. 
Another important factor was the choice of the 
LPS concentration to be used in the assays. The 
LPS concentration must be such that not causes 
cell death, but allows a measurable NO amount. 
In this work, 1 µg/mL of LPS was used, which is a 
concentration currently applied by other authors 
(77, 345). However, the exposure of RAW 264.7 
macrophages to 1 µg/mL of LPS for 18 h lead to 
14.22 ± 2.50% (P < 0.001) of cell death relative to 
control (Figure 3.1.2). This result can be 
explained by excessive reactive oxygen species 
production (about 15% increase in superoxide 
relative to control), as it can be seen in Figure 
3.1.8.  
 
 
Figure 3.1.5. Influence of plumbagin in cell viability 
and in NO production. After pre-exposure with 
plumbagin and stimulation with LPS, RAW 264.7 
macrophages viability was assessed by LDH and MTT 
assays and NO production was quantified. Results are 
expressed as percentage of control (mean ± SEM of four 
independent experiments, performed in duplicate).**P < 
0.01, ***P < 0.001. 
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Figure 3.1.6. Dexamethasone effects on NO 
production. Quantification of NO produced by RAW 
264.7 macrophages exposed to dexamethasone, in the 
presence and in the absence of 1 µg/mL of LPS (18 h). 
All results are expressed in percentage of control with 
LPS (mean ± SEM of four independent experiments, 
performed in duplicate). ***P < 0.001.  
 
As so, the results of cell viability in the presence of 
LPS for the tested compounds are expressed in 
percentage of control with LPS. In addition, LPS 
(1 µg/mL) induced NO production in amounts easy 
to quantify (19.21 ± 0.274 µM) and we considered 
that NO produced by LPS exposed RAW 264.7 
cells was 100%. 
Concerning the cytotoxicity of tested 
compounds, naphthazarin and plumbagin were 
the most toxic ones (Figure 3.1.4). In general, 
tumour cells, as RAW 264.7 macrophages, are 
sensitive to the deleterious effects of 
naphthoquinones in low µM range. In studies 
involving other tumour and non-tumour cells (34, 
85), the authors used plumbagin concentrations 
similar to those used in our work, but no 
significant cell death was noticed. This difference 
may be explained by distinct sensitivity of the cells 
to naphthoquinones. 
The cytotoxicity of diosquinone was lower 
compared to most of the other tested hydroxy-
naphthoquinones (Figure 3.1.4). Quinones
 
Figure 3.1.7. Influence of tested compounds in NO production. Quantification of NO produced by LPS stimulated RAW 
264.7 macrophages after pre-exposure to tested compounds. Results are expressed in percentage of control (0.5% DMSO 
+ 1 µg/mL LPS) (mean ± SEM of four independent experiments, performed in duplicate). *P < 0.05, **P < 0.01, ***P < 0.001.
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Figure 3.1.8. Superoxide radical quantification. 
Superoxide radical produced by RAW 264.7 
macrophages, after pre-treatment (1 h) with diosquinone 
(1.5 µM) and dexamethasone (50 µM), in the presence 
and in the absence of 1 µg/mL of LPS (18 h). Results are 
expressed in percentage of control (mean ± SEM of four 
independent experiments, performed in duplicate). 
 
cytotoxicity is related with their pro-oxidant 
properties and interaction with nucleophilic 
biomolecules	   (12, 346). It is known that 
nucleophilic attack to thiol groups involves 
positions 2 and 3 of naphthoquinones (347). As 
diosquinone has an epoxy group at positions 2 and 
3 of one monomer and the C2 of the other 
monomer is involved in the linkage between the 
two monomers, probably diosquinone causes less 
oxidative stress and glutathione depletion than the 
other naphthoquinones. For the other compounds, 
the presence of a hydroxyl group in the benzene 
ring seems to be important for the exhibited toxicity, 
as the introduction of electron-donating hydroxyl 
groups increases the pro-oxidant potential of 
naphthoquinones (12, 346). This may explain the 
higher toxicity of naphthazarin and plumbagin and 
why juglone is more toxic than menadione. 
However, juglone is less toxic than the 
corresponding non-hydroxylated 1,4- 
naphtoquinone, which is in accordance with a 
previous work by Klaus and colleagues (346). In 
addition,	   hydroxyl groups at positions 5 and 8 of 
naphthazarin confer a high redox potential, 
explaining its higher toxicity relative to other 
naphthoquinones (8). 
In what concerns to NO decrease (Figure 
3.1.7), it seemed to follow the effect on cell viability 
(Figure 3.1.4). However, the decrease of NO was, 
in general, more pronounced. Furthermore, we only 
concluded about NO reduction if no cell death with 
statistical meaning occurred. Diosquinone, the only 
tested dimer, was the most interesting compound. 
Diosquinone caused 38.25 ± 6.50% (P < 0.001) of 
NO reduction relative to control at 1.5 µM (Figure 
3.1.7). Although p-hydroquinone caused 75.92 ± 
5.53% (P < 0.001) of NO reduction at 5 µM, NO 
reduction for 3.20 ± 0.16 µM corresponded to 40%. 
Thus, diosquinone was more active at lower 
concentrations than p-hydroquinone. Diosquinone 
had an IC25 of 1.09 ± 0.24 µM, lower than that of 
dexamethasone (1.72 ± 0.54 µM). However, 
dexamethasone caused a decrease in NO for all 
used concentrations, reaching basal levels at 50 
µM (Figure 3.1.6). The greater activity of 
diosquinone in relation to the other 
naphthoquinones could be explained by its higher 
lipophilicity. Lipophilicity favours both the entrance 
of the compound in the cell and the establishment 
of hydrophobic bonds with a potential active site 
(348). The importance of lipophilicity may also be 
observed when comparing the activities of 1,4-
naphthoquinone and p-benzoquinone: 1,4-
naphthoquinone was more cytotoxic and leads to a 
higher NO decrease than p-benzoquinone 
(Figures 3.1.4 and 3.1.7). 
 
 
Figure 3.1.9. Semi-quantitative analysis of 3-
nitrotyrosine. Image of slot-blot film, where 3-
nitrotyrosine was detected by immunoblotting and 
respective surface plot analysis (Y axis represents 
intensity of bands). This assay was performed after RAW 
264.7 macrophages pre-treatment (1 h) with diosquinone 
(1.5 µM) and dexamethasone (50 µM) in presence and in 
absence of 1 µg/mL of LPS (18 h). Control cells were 
exposed to vehicle (0.5% DMSO). 
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Although naphthoquinones may suppress NF-
κB activation and, consequently, inhibit iNOS 
induction (34, 77), the observed NO reduction can 
also result from direct reaction of NO with 
superoxide radical, which is generated during 
quinone oxidation (349). The product of this 
reaction is peroxynitrite, which may react with thiol 
groups or nitrate hydroxylate phenolic amino acids, 
most importantly tyrosine residues, forming 3-
nitrotyrosine. The increase of 3-nitrotyrosine has 
toxicological consequences, because it alters 
phosphorylation of tyrosine (350). Therefore, to 
clarify the effect of diosquinone we proceeded to 
the determination of superoxide radical and 3-
nitrotyrosine. 
It was observed that diosquinone (at 1.5 µM) 
did not induce more nitration than control (Figure 
3.1.9), indicating that the decrease of NO is 
beneficial to cells, precluding LPS action and 
reducing inflammation. Some authors defend that 
nitration of tyrosine may not occur, having nitration 
of dityrosine (351, 352). However, that seemed to 
be not the case, as the used method allowed to 
detect high levels of 3-nitrotyrosine with 
dexamethasone and LPS treatment. With respect 
to superoxide radical, no significant differences 
were noticed, although cells treated with LPS 
tended to exhibit higher levels of this reactive 
species (Figure 3.1.8). 
The potential of diosquinone to reduce LPS 
induced inflammation was confirmed by its ability to 
reduce the pro-inflammatory cytokines TNF-α and 
IL-6, which have a central role in inflammation. The 
decrease in TNF-α was the most expressive and 
since this cytokine has a fundamental role in the 
activation of macrophages themselves, being the 
first mediator in the inflammatory cascade (335), 
diosquinone may have interest to be explored as 
candidate to a new anti-inflammatory drug. 
In conclusion, among the several compounds 
screened for anti-inflammatory activity, diosquinone, 
the only dimeric naphthoquinone, was the most 
promising naphthoquinone, causing a reduction of 
NO, without cytotoxicity. The NO decrease induced 
by this compound was probably due to its 
interference with the mechanism of action of LPS 
and not to NO consumption in the reaction with 
superoxide. This hypothesis was confirmed by the 
reduction of the inflammatory mediators TNF-α and 
IL-6 in macrophages stimulated with LPS. Thus, 
according to these results, diosquinone brings 
beneficial effects to cells by inhibiting the 
inflammatory response. This study contributes to 
the knowledge of naphthoquinones properties, 
mainly anti-inflammatory activity, and, as far as we 
are aware, constitutes the first work concerning 
diosquinone anti-inflammatory potential. 
Furthermore, it is the first study assessing whether 
the oxidative stress induced by naphthoquinones 
contributes to NO reduction, in this model. 
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Abstract 
 
Allergic disorders are characterized by an abnormal immune response towards non-infectious substances, 
being associated with life quality reduction and potential life-threatening reactions. The increasing prevalence 
of allergic disorders demands for new and effective anti-allergic treatments. Here we test the anti-allergic 
potential of monomeric (juglone, menadione, naphthazarin, plumbagin) and dimeric (diospyrin and 
diosquinone) naphthoquinones. Inhibition of RBL-2H3 rat basophils’ degranulation by naphthoquinones was 
assessed using two complementary stimuli: IgE/antigen and calcium ionophore A23187. Additionally, we 
tested for the inhibition of leukotrienes production in IgE/antigen-stimulated cells, and studied hyaluronidase 
and lipoxidase inhibition by naphthoquinones in cell-free assays. Naphthazarin (0.1 µM) decreased 
degranulation induced by IgE/antigen but not A23187, suggesting a mechanism upstream of the calcium 
increase, unlike diospyrin (10 µM) that reduced degranulation in A23187-stimulated cells. Naphthoquinones 
were weak hyaluronidase inhibitors, but all inhibited soybean lipoxidase with the most lipophilic diospyrin, 
diosquinone and menadione being the most potent, thus suggesting a mechanism of competition with natural 
lipophilic substrates. Menadione was the only naphthoquinone reducing leukotriene C4 production, with a 
maximal effect at 5 µM. This work expands the current knowledge on the biological properties of 
naphthoquinones, highlighting naphthazarin, diospyrin and menadione as potential lead compounds for 
structural modification in the process of improving and developing novel anti-allergic drugs. 
 
Keywords: Allergy; Histamine and β-hexosaminidase; Hyaluronidase; Lipoxidase; Naphthoquinones. 
 
 
Introduction 
 
Allergy is an abnormal immune response against 
non-infectious environmental substances, named 
allergens (166). Allergy comprises chronic 
disorders associated with reduced quality of life, 
such as eczema or allergic rhinitis, and potential 
life-threatening reactions, including anaphylaxis 
and severe asthma episodes (353). The 
prevalence of allergic disorders has been 
increasing globally, affecting roughly 25% of 
people in developed countries. This increased 
prevalence has been associated to environmental 
changes, such as air pollution and ambient 
temperature increment, which may induce early 
springs with increased airborne pollen (166). On 
the other hand, the “hygiene hypothesis” suggests 
that reduced exposure to microorganisms in early 
life contributes to an immune system more 
susceptible to allergic and autoimmune diseases 
(168). In the allergic process, immune cells, such 
as mastocytes, eosinophils, basophils and 
macrophages, release several mediators (including 
histamine and leukotrienes) that are responsible for 
allergic symptoms (354). Additionally, these 
mediators may promote the development of 
different diseases, by inducing pathophysiological 
changes in the affected organs (173). A classic 
example is the role of leukotrienes in the 
pathogenesis of asthma and allergic rhinitis, by 
inducing bronchoconstriction and increased 
vascular permeability (179). Thus, the increased 
allergy prevalence, together with the deleterious 
consequences of repetitive exposure to allergens, 
stresses the need for new strategies to induce 
immunological tolerance to allergens as well as 
new anti-allergic drugs (166).  
Nature continues to be a rich source of novel 
bioactive molecules, and several plant extracts 
have been probed for anti-allergic properties. 
Namely, the grape seed extract of Vitis vinifera L. 
(355), the rhizomes extract of Dioscorea 
membranacea Pierre ex Prain & Burkill, in which 
the main active compound was a quinone 
(dioscoreanone) (356), or the leaf extract of 
Rhinacanthus nasutus Kuntze, which is rich in 
naphthoquinones (92). In fact, R. nasutus contains 
three 1,4-naphthoquinones capable of inhibiting 
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RBL-2H3 basophils’ degranulation in the 
micromolar range, and decreasing tumour necrosis 
factor (TNF)-α and interleukin production (92). 
Further studies, with synthetic naphthoquinones, 
support their anti-allergic properties: 2-
alkyl/arylcarboxamido derivatives of 3-chloro-1,4-
naphthoquinone inhibited the degranulation on 
mastocytes stimulated with compound 48/80 (93). 
On the other hand, allergic reactions are common 
after temporary tattoos with henna (derived from 
Lawsonia inermis L.), where lawsone (2-hydroxy-
1,4-naphthoquinone) is the main compound 
responsible for dye properties. Still, allergic 
reactions to henna have been attributed only to the 
occasional additive p-phenylenediamine (357) 
(358). 
In this work we studied the anti-allergic 
properties of naphthoquinones commonly 
produced by Diospyros species: diospyrin (DPR), 
diosquinone (DQN), juglone (JGL), menadione 
(MND), naphthazarin (NTZ) and plumbagin (PLB) 
(Figure 3.2.1). Several biological activities have 
been attributed to these compounds, namely, anti-
inflammatory (359), antitumor (360) and 
antimicrobial (59), but anti-allergic properties were 
only identified for menadione (91) and plumbagin 
(87). To our knowledge, no anti-allergic data exists 
for the other Diospyros’ naphthoquinones. For the 
initial screening, two different stimuli were used to 
induce RBL-2H3 basophils’ degranulation 
(IgE/antigen or the calcium ionophore A23187) and 
the released β-hexosaminidase and histamine 
were quantified. Additionally, hyaluronidase and 
lipoxidase inhibition by naphthoquinones were 
evaluated, as well as the inhibition of leukotrienes 
production in IgE/antigen-exposed RBL-2H3 cells. 
 
Materials and Methods 
 
Test compounds 
Plumbagin (PLB), naphthazarin (NTZ), menadione 
(MND) and juglone (JGL) were obtained from 
Sigma-Aldrich (St. Louis, MO, USA). Diospyrin 
(DPR) and diosquinone (DQN) (Figure 3.2.1) were 
isolated from the root barks of Diospyros 
chamaethamnus Dinter ex. Mildbr. (31) and their 
purity was evaluated by HPLC-DAD as b efore 
(359). 
 
Chemicals and reagents 
Medium, buffers and supplements for cell culture, 
including Earle’s Balanced Salt Solution (EBSS) 
were from Gibco, InvitrogenTM (Grand Island, NY, 
USA) and bovine albumin fraction V solution 7.5% 
(BSA) was from Sigma-Aldrich (St. Louis, MO, 
USA). 
Hyaluronic acid sodium salt from Streptococcus 
equi, hyaluronidase from bovine tests (type IV-S; 
EC 3.2.1.35), lipoxidase from Glicine max (L.) Merr. 
(type V-S; EC 1.13.11.12), as well as degranulation 
stimuli, monoclonal anti-dinitrophenyl (DNP) 
antibody produced in mouse, dinitrophenyl albumin 
(DNP-BSA) and calcium ionophore A23187 were 
from Sigma-Aldrich (St. Louis, MO, USA). 
Fluorescein-isothiocyanate (FITC)-conjugated 
recombinant annexin-V was from Immuno Tools 
(Friesoythe, Germany) and leukotriene C4 EIA kit 
was from Abcam (Cambridge, United Kingdom). All 
other chemicals were from Sigma-Aldrich (St. 
Louis, MO, USA), with the exception of 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromi- 
de (MTT), which was from Duchefa Biochemie 
(Haarlem, The Netherlands). 
 
Cell assays 
Rat basophilic leukaemia cell line, RBL-2H3, was 
from the American Type Culture Collection 
(ATCC®) (LGC Standards S.L.U., Barcelona, 
Spain). Cells were cultured in DMEM (Dulbecco’s 
Modified Eagle’s Medium) + GlutaMAXTM- I 
supplemented with 15% heat inactivated foetal 
bovine serum, 100 U/ml penicillin and 100 µg/ml 
streptomycin. Cells were maintained under 5% CO2, 
at 37 ºC, in humidified air. 
 
Cell treatment 
 
Solvent, stimuli and drugs. RBL-2H3 cells were 
seeded at 3.0×105 cells/ml in 24-wells plate (1 
ml/well), and assayed after 24 h at near-confluent 
stage (~90%). Two different degranulation stimuli 
were used: calcium ionophore A23187 500 ng/mL 
(1 µM) and an immunologic stimulus (100 ng/mL 
IgE anti-DNP followed by 100 ng/mL DNP-BSA) 
that we refer to as IgE/antigen (Figure 3.2.2A and 
3.2.3A). Both stimuli induced degranulation, which 
was quantified by β-hexosaminidase and histamine 
release. With IgE/antigen, β-hexosaminidase 
release (p-nitrophenolate absorbance) increased 
by 65.4 ± 6.8 % above basal (n = 16; P < 0.001), 
whereas histamine increased from the basal value 
of 0.156 ± 0.151 µM towards 0.521 ± 0.186 µM (n 
= 10; P < 0.05). With A23187, β-hexosaminidase 
release increased by 187 ± 18.9 % above basal (n 
= 12; P < 0.001), whereas histamine increased 
towards 2.43 ± 0.330 µM (n = 12; P < 0.001). Thus, 
the ability of naphthoquinones to reduce β-
hexosaminidase release was quantified for both 
stimuli, whereas effects upon histamine were only 
quantified with the A23187 stimulus, given the low 
histamine release and poor signal to noise 
achieved with IgE/antigen. 
Quercetin was used as positive anti-
degranulation control (361) and the anti-
degranulation effects of diospyrin, diosquinone, 
juglone, menadione, naphathazarin and plumbagin 
EXPERIMENTAL SECTION 3.2 
59 
(Figure 3.2.1), were studied at non-toxic 
concentrations as inferred by the MTT assay. The 
concentrations of the tested compounds in the 
degranulation assays with different stimuli were 
kept constant [0.1 µM (NTZ), 1 µM (DQN and PLB), 
5 µM (MND) and 10 µM (JGL)], except for diospyrin 
and quercetin, where a 10 fold higher 
concentration was also tested in the A23187 assay. 
A23187, quercetin and naphthoquinones stocks 
were dissolved in dimethyl sulfoxide (DMSO), 
aliquoted and stored at -20 ºC. We determined the 
maximal non-interfering solvent concentrations 
(Figure 3.2.2B and 3.2.3B; 0.1% and 0.5% DMSO 
for IgE/antigen and A23187 assays, respectively), 
as this was a limiting factor for testing higher 
naphthoquinone concentrations. 
 
IgE/antigen assay. When the IgE/antigen was used 
as stimulus, cells were incubated during 16 h with 
100 ng/mL IgE anti-DNP and with individual 
naphthoquinones diluted in culture medium. After 
washing twice with Dulbecco’s phosphate buffered 
saline (DPBS), cells were treated for 1 h, at 37 ºC, 
with 100 ng/mL DNP-BSA and with individual 
naphthoquinones diluted in EBSS supplemented 
with 0.1% BSA (Figure 3.2.2A) (362). After 
treatments, supernatants were collected in order to 
quantify released β-hexosaminidase and released 
histamine, while cell viability assay was performed 
on adherent cells. 
 
A23187 assay. Before treatment with A23187, cells 
were incubated with individual naphthoquinones 
during 15 min, at 37ºC. After that, A23187 1 µM 
was added and cells incubated for 30 min, at 37 ºC 
(Figure 3.2.3A). Compounds were freshly diluted 
prior to cell exposure using EBSS supplemented 
with 0.1% BSA (362). β-hexosaminidase and 
histamine release was quantified in supernatants, 
whereas the MTT cell viability assay was 
performed on adherent cells. 
 
Cell viability 
Cell viability was assessed by the cellular 
dehydrogenases’ dependent reduction of MTT to 
formazan, which was quantified by the 
measurement of optical density at 550 nm using a 
microplate reader (Multiskan ASCENT Thermo®), 
as described before (359). 
 
Released β-hexosaminidase quantification 
The release of β-hexosaminidase from stimulated-
RBL-2H3 cells was measured as previously 
described (362). In a 96-wells plate, 50 µL of 
substrate solution [p-nitrophenyl N-acetyl-D-
glucosamine 1.3 mg/mL in citrate buffer (pH 4.5)] 
were added to 30 µL of supernatant. The plate was 
incubated at 37ºC, during 1 h. The reaction was 
stopped by the addition of 80 µL of NaOH 0.5 M 
and the reaction product, p-nitrophenolate, was 
measured spectrophotometrically at 405 nm, in a 
microplate reader (Multiskan ASCENT Thermo®).  
 
 
 
 
 
Figure 3.2.1. Chemical structures of monomeric and dimeric naphthoquinones. 
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Figure 3.2.2. Effect of naphthoquinones pre-exposure in IgE/antigen-stimulated RBL-2H3 cells. A, Protocol; B, effect 
of the solvent (DMSO) on cell viability (i) and β-hexosaminidase release (ii) with/without IgE/antigen, n=3-4. *P<0.05, One 
way ANOVA with Bonferroni post-hoc (vs. control); C, effect on cell viability and β-hexosaminidase release in IgE/antigen-
stimulated cells treated with quercetin (QCT) and naphthoquinones [diospyrin (DPR), diosquinone (DQN), juglone (JGL), 
menadione (MND), naphthazarin (NTZ) and plumbagin (PLB)], n=3-4. *P<0.05, paired t test to respective control (100 
ng/mL IgE/DNP + 0.1% DMSO).  
 
 
β-hexosaminidase inhibitory activity 
Beyond avoiding β-hexosaminidase release, 
individual naphthoquinones may directly inhibit β-
hexosaminidase enzymatic activity. For this, the 
inhibition of β-hexosaminidase enzymatic activity 
by naphthoquinones and quercetin was evaluated 
in an assay similar to the one described above: 
individual naphthoquinones (5 µL) were incubated 
with supernatant of degranulated cells where β-
hexosaminidase is present (25 µL of supernatant of 
cells treated with A23187), in presence of 50 µL of 
substrate solution, during 1 h, at 37ºC. The 
determination was made at 405 nm, in a microplate 
reader (Multiskan ASCENT Thermo®) (363). 
 
Released histamine quantification 
100 µL of NaOH 1 M and 25 µL of o-
phthalaldehyde (OPA) 1% (w/v) were added to 500 
µL of supernatant to convert histamine into 
fluorescent histamine-OPA-products. After 4 min 
incubation at room temperature, the reaction was 
stopped with of 50 µL of HCl 3 M. Precipitated 
proteins were removed by centrifugation at 14,000 
rpm, during 3 min. The fluorescent histamine-OPA-
products were quantified in the supernatant using 
360 nm excitation and 450 nm emission in a 
microplate reader (Biotek Synergy HT®) (362). 
Changes in histamine release are expressed as 
the difference between maximal and basal release, 
in percentage of control. 
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FITC-Annexin-V labelling 
After promoting degranulation with IgE/antigen 
treatment, cells were washed and exposed to 
FITC-conjugated annexin-V (5 µL/well with a final 
volume of 75 µL), according to the supplier’s 
instructions (Immuno Tools, Friesoythe, Germany). 
After 15 min in the dark, cells were washed and 
visualized at 40x magnification in a system 
composed by an inverted microscope (Eclipse 
TE300, Nikon, Tokyo, Japan), a CCD camera 
(C6790; Hamamatsu Photonics, Japan) and a 
computer with an Aquacosmos software (version 
2.5; Hamamatsu Photonics). FITC was excited at 
488 nm with an exposure time of 727 ms and 
emission at 520 nm. 5 Random fields/well (2 wells 
per condition) were photographed 
 
Leukotriene C4 quantification 
Leukotriene C4 quantification was performed in the 
supernatant of IgE/antigen stimulated cells using a 
competitive enzyme immunoassay kit, according to 
the supplier’s protocol (Abcam, Cambridge, United 
Kingdom) in a microplate reader (Multiskan 
ASCENT Thermo®) at 405 nm. 
 
Assays of enzymatic inhibition in cell-free 
systems 
  
Hyaluronidase. The enzymatic reaction mixture 
was composed by 50 µL hyaluronic acid (5 mg/mL 
in water), 100 µL buffer pH 3.68 (HCOONa 0.2 M, 
NaCl 0.1 M and BSA 0.2 mg/mL), 200 µL water, 50 
µL individual naphthoquinones solution and 50 µL 
hyaluronidase 600 U. The enzymatic reaction 
occurred during 1 h, at 37ºC. The reaction product, 
N-acetyl-sugar, was quantified according Morgan-
Elson colour reaction with minor modifications. The 
Morgan-Elson reaction was started by addition of 
25 µL disodium tetraborate 0.8 M and subsequent 
heating in a boiling water bath during 3 min. After 
cooling, 750 µL p-dimethylaminobenzaldehyde 
(DMAB) was added and the reaction mixture was 
incubated at 37ºC for 20 min. DMAB stock solution 
was prepared by dissolving 2 g DMAB in glacial 
acetic acid with 12.5% of HCl 10 N. This solution 
was further diluted in glacial acetic acid (1:2) 
immediately before use. The measurement was 
made spectrophotometrically, at 560 nm, in a 
microplate reader (Multiskan ASCENT Thermo®) 
(364). Sodium cromoglycate was used as a 
positive control for inhibition (365). DMSO was kept 
constant at 1%, without inducing enzyme inhibition. 
 
Lipoxidase. Lipoxidase catalyses the oxidation of 
linoleic acid to the conjugated diene, 13-
hydroperoxy linoleic acid, which was measured 
spectrophotometrically at 234 nm on a UV/visible 
spectrophotometer (UNICAM Helios α) (366). The 
blank was measured in a reaction mixture with 20 
µL of individual naphthoquinones solution, 1 mL of 
phosphate buffer (pH 9) and 20 µL of soybean 
lipoxidase 500 U. After 5 min pre-incubation at 
room temperature, the reaction was started by 
addition of 50 µL of substrate (linoleic acid) at 2 
mM in ethanol. The reaction time was 3 min. 
DMSO was kept constant at 1.8%, without inducing 
enzyme inhibition. Quercetin was used as positive 
control (367). 
 
Statistical analysis 
Values are presented as mean ± standard error of 
mean (SEM) of at least three independent 
experiments (n), performed at least in duplicate. 
Results concerning cell viability, released 
histamine and released β-hexosaminidase are 
expressed in percentage of the respective control. 
The normality of the values was evaluated by 
Shapiro-Wilk test, which was performed using 
Statistical Package for the Social Sciences version 
20.0 (SPSS Inc., Chicago, IL, USA). Paired t-test or 
One-Way ANOVA with Bonferroni as post-hoc test 
were used, respectively, to compare two or more 
groups (GraphPad Prism version 5.0, San Diego, 
CA, USA). P values under 0.05 were considered 
statistically significant.  
 
Results 
 
Naphthazarin and diospyrin decreased  
RBL-2H3 degranulation 
To test the anti-allergic properties of 
naphthoquinones, we evaluated their ability to 
inhibit RBL-2H3 basophils’ degranulation evoked 
by two different stimuli: IgE/antigen (100 ng/mL, 
16h exposure) or the calcium ionophore A23187 (1 
µM, 30 min exposure); Schematic protocols in 
Figure 3.2.2A and 3.2.3A. DMSO was used as a 
solvent, and we started by determining the 
maximal DMSO concentrations that could be used 
without interfering with the assays, and 
consequently the maximal concentrations that 
could be tested for the dissolved naphthoquinones 
(Figure 3.2.2B and 3.2.3B). DMSO at 0.5% 
decreased β-hexosaminidase release by 52.1 ± 
11.9% when IgE/antigen was used (P < 0.05) 
(Figure 3.2.2B), but it had no detectable effect on 
the release of β-hexosaminidase and histamine in 
A23187 stimulated cells (Figure 3.2.3B), likely due 
to the shorter exposure time. Thus, the DMSO 
amount used in the IgE/antigen assay was 0.1%, 
while in the A23187 assay it was 0.5%, thus 
allowing for higher naphthoquinone concentration 
testing. None of the naphthoquinone 
concentrations used significantly affected cell 
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viability, as assessed by the MTT reduction assay 
(Figure 3.2.2C and 3.2.3C; black bars). 
In the IgE/antigen assay, naphthazarin (NTZ; 
0.1 µM) was the only naphthoquinone able to 
significantly reduce degranulation, decreasing β-
hexosaminidase release by 30.8 ± 3.3% (n = 4; P < 
0.05) (Figure 3.2.2C). Naphthazarin (0.1 µM) and 
the positive control quercetin (1 µM) also 
decreased FITC-annexin-V labelling, consistent 
with a mechanism of degranulation inhibition 
(Figure 3.2.4). Juglone (JGL; 10 µM) also 
displayed a tendency to reduce the degranulation 
induced by IgE/antigen, since it induced a 
decrease of 39.2 ± 13.3% of released β-
hexosaminidase (Figure 3.2.2C). 
In the A23187 assay, the positive control 
quercetin required a 10-fold higher concentration 
(100 µM) to reduce β-hexosaminidase release, 
when compared with the IgE/antigen assay. 
Diospirin (DPR) at the higher 10 µM concentration 
allowed by this assay, significantly decreased both 
β-hexosaminidase (56.8 ± 14.6%) and histamine 
(51.4 ± 12.8%) release, an amplitude of effect 
approaching that achieved with quercetin, and 
standing out amongst the other dimeric and 
monomeric naphthoquinones, none of which 
significantly affected degranulation at the maximal 
tested concentrations (Figure 3.2.3C). None of the 
tested naphthoquinone concentrations induced 
degranulation in the absence of stimuli 
(IgE/Antigen or A23187) nor directly inhibited the β-
hexosaminidase enzymatic activity (data not 
shown).  
 
 
 
Figure 3.2.3. Effect of naphthoquinones pre-exposure in calcium ionophore (1 µM A23187) stimulated RBL-2H3 
cells. A, Protocol; B, effect of solvent (DMSO 0.01-0.5%) on cell viability (i), released histamine (ii) and released β-
hexosaminidase (iii) in cells with/without A23187 stimuli, n=3-4; C, Cell viability (black), histamine release (grey) and β-
hexosaminidase release (white) in A23187-stimulated cells treated with quercetin (QCT) or individual naphthoquinones 
[diospyrin (DPR), diosquinone (DQN), juglone (JGL), menadione (MND), naphthazarin (NTZ) and plumbagin (PLB)], n=5-10. 
*P<0.05, paired t test to respective control (1µM A23187 + 0.5% DMSO).  
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Figure 3.2.4. Degranulation quantification by FITC-annexin-V labelling. Images with (right) and without 
(left) IgE/antigen stimuli in RBL-2H3 cells treated with naphthazarin (NTZ, 0.1 µM) and quercetin (QCT, 10 
µM) after exposure to FITC-annexin-V (40x magnification). Values are the percentage of annexin-V-labelled 
cells in relation to total number of the cells (mean ± SEM, n=3).  
 
 
 
Naphthoquinones are weak hyaluronidase 
inhibitors 
Sodium cromoglycate was used as a positive control 
for hyaluronidase inhibition (365). Complete 
hyaluronidase inhibition required 10 mM sodium 
cromoglycate (Figure 3.2.5). Solubility precluded the 
testing of naphthoquinone concentrations above 100 
µM. Only menadione and naphthazarin significantly 
inhibited hyaluronidase. While their level of inhibition 
(about 20%) at 100 µM surpasses that achieved with 
the same sodium cromoglycate concentration (Figure 
3.2.5), insolubility at higher concentrations, argues 
against these naphthoquinones as promising 
hyaluronidase inhibitors. 
 
Naphthoquinones effects on soybean lipoxidase 
and in leukotriene levels 
All tested naphthoquinones concentration-
dependently inhibited soybean lipoxidase (Figure 
3.2.6A). Dimeric naphthoquinones, diospyrin and 
diosquinone, were the most potent with respective 
IC50 values of 28.9 and 83.8 µM, whereas all 
monomeric naphthoquinones displayed IC50 values 
above 100 µM, with the most potent being menadione 
with an IC50 of 128 µM (Table 3.2.1). These three 
most potent naphthoquinones were selected for an 
exploratory assay on leukotriene levels in IgE/antigen-
stimulated RBL-2H3 cells. IgE/antigen treatment 
induced a robust increase in the levels of leukotriene 
(LT) C4 in the supernatant of RBL-2H3 cells, which 
was unaffected by either diospyrin (1 µM) or 
diosquinone (1 µM), but completely abrogated by 
menadione (5 µM). We thus performed a 
concentration response curve for menadione on LTC4 
levels (Figure 3.2.6C). Results showed that the 
lowest menadione concentration tested (5 nM) 
strongly decreased LTC4 levels evoked by 
IgE/antigen, suggesting interference with LTC4 
synthesis mechanisms. Increasing menadione 
concentration-dependently decreased LTC4 levels 
until full inhibition of the IgE/antigen evoked release, 
with an IC50 of 0.34 ± 0.018 µM (Figure 3.2.6C). 
 
 
Figure 3.2.5. Concentration-dependent hyaluronidase 
inhibition by sodium cromoglycate (black circles) 
menadione (grey circles) and naphthazarin (white 
circles). n=3-4. 
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Figure 3.2.6. Lipoxidase inhibition and leukotriene C4 production. Soybean lipoxidase inhibition by individual 
naphthoquinones (A) and by quercetin (B) in a cell-free assay and inhibition of leukotriene C4 production in IgE/antigen-
stimulated RBL-2H3 by menadione (C). Grey box represents LTC4 production of stimulated (upper) and non-stimulated 
(lower) control cells. n=3-5.  
  
Table 3.2.1. IC50 values (mean ± SEM) for soybean 
lipoxidase inhibition by naphthoquinones and 
quercetin, using a cell-free assay.  
 
Discussion 
 
In this work we investigated the anti-allergic 
potential of monomeric and dimeric 
naphthoquinones (Figure 3.2.1) by testing for 
inhibition of RBL-2H3 cells’ degranulation. RBL-
2H3 cells are a rat basophilic leukaemia cell line, 
expressing high affinity IgE receptors (FcεRI), 
being a model to study allergy and inflammation 
(181, 368). Potent inflammatory mediators 
(histamine, proteases, cytokines, arachidonic acid 
metabolites and chemotactic factors) are released 
from immune cells after an allergic stimulus that 
can be IgE-dependent or IgE-independent (174). 
To induce degranulation we used two previously 
described effective degranulation stimuli for RBL-
2H3 (362): IgE/antigen (simulation of IgE-
dependent allergic response) and calcium 
ionophore (A23187; simulation of events that 
Compound IC50 (µM) 
Quercetin 10.6 ± 5.82 
Dimeric naphthoquinones 
Diospyrin 28.9 ± 2.53 
Diosquinone 83.8 ± 9.33 
Monomeric Naphthoquinones 
Juglone >184 
Menadione 128 ± 9.38 
Naphthazarin 142 ± 27.1 
Plumbagin >184 
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Figure 3.2.7. Simplified scheme of RBL-2H3 cells’ degranulation pathways. The DNP antigen activates multiple signal 
transduction pathways via the IgE anti-DNP/FcεRI receptor complex. DNP receptor binding activates the immunoreceptor 
tyrosine activation motifs (ITAM)-Spleen tyrosine kinase (SyK) pathway that can be inhibited by shikonin (369) and probably 
by naphthazarin. Activated Syk catalyses protein phosphorylation of several proteins, leading indirectly to the activation of 
protein kinase C (PKC) that induces degranulation and the activation of phospholipase A2 (PLA2). PLA2 increases 
arachidonic acid (AA) bioavailability that can be converted in leukotrienes (LT) by 5-lipoxygenase (5-LO; inhibited by 
menadione), or in oxidized lipids by means of ROS production. 5-LO converts AA into 5-hydroperoxyeicosatetraenoic acid 
(5-HPETE), which is metabolised to an unstable epoxide, LTA4, and finally in LTC4, in RBL-2H3 cells. The increase in 
intracellular calcium by SyK pathway, as well as by A23187 promotes degranulation.  
 
 
 
 
immediately precede degranulation: increase of 
intracellular calcium) (Figure 3.2.7). These 
complementary stimuli assist characterization of 
the mechanisms by which the studied compounds 
reduce degranulation. In the present study, the 
release of immune cell degranulation markers – β-
hexosaminidase and histamine	   (355) – was higher 
with ionophore than with IgE/antigen treatment, 
consistently with previous studies (370).  
Naphthazarin (0.1 µM) decreased IgE/antigen-
induced degranulation (Figure 3.2.2C) and the 
labelling with FITC-annexin-V (Figure 3.2.4), 
reported to bind specifically to phosphatidylserine 
near sites of granule fusion (371). However, the 
same naphthazarin concentration failed to reduce 
ionophore-induced degranulation (Figure 3.2.3C), 
suggesting that naphthazarin’s mechanism of 
degranulation inhibition is upstream of intracellular 
calcium increase. While this is the first report for 
naphthazarin, a similar mechanism was previously 
described for another naphthoquinone, namely, 
shikonin	   (372). Shikonin reportedly inhibits the 
spleen tyrosine kinase (SyK), downstream from 
FcεRI activation, possibly explaining its anti-allergic 
properties (372). Meaningfully, naphthazarin 
displays the highest structural similarities to 
shikonin, among the naphthoquinones in the 
present study. In fact, both compounds share a 
5,8-dihydroxy-1,4-naphthoquinone core (Figure 
3.2.1). Thus, we propose that naphthazarin and 
shikonin act through a similar mechanism and that 
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both C5 and C8 hydroxyls modulate direct enzyme 
interaction via hydrogen bonds (373).  
Diospyrin (10 µM) reduced degranulation in 
calcium ionophore-stimulated cells (Figure 3.2.3C). 
Another naphthoquinone, acetylshikonin, was 
reported to attenuate ionophore-mediated 
intracellular calcium elevation in rat neutrophils 
(369). While, attenuation of calcium elevation might 
partly explain the effects of both diospyrin and 
acetylshikonin, their spectrum of activity does not 
necessarily overlap, since acetylshikonin is 
reported to decrease leukotriene B4 and 
tromboxane A2 (369), whereas in the present study 
diospyrin was unable to reduce leukotrien C4, albeit 
in different cell models and stimuli. 
Plumbagin was previously reported to exhibit 
anti-allergic properties, namely, at 5 µM plumbagin 
inhibited cytokines production by phytohema- 
gglutinin-stimulated peripheral blood mononuclear 
cells (PBMC) (87). In the present study, the 
maximum non-toxic concentration of plumbagin 
that could be tested in RBL-2H3 cells was 1 µM, 
and at that concentration plumbagin did not 
prevent degranulation evoked by either IgE/antigen 
or A23187. 
Following degranulation studies, we addressed 
the inhibition of enzymes involved in allergic 
responses: hyaluronidase and lipoxygenase. 
Hyaluronidase increases vascular permeability in 
inflammation, by cleavage of internal β-N-acetyl-D-
glucosaminidic linkages of hyaluronic acid (374), 
thus being a possible target for anti-allergic drugs. 
Our data shows that the tested monomeric and 
dimeric naphthoquinones are poor hyaluronidase 
inhibitors, with only menadione and naphthazarin 
displaying modest inhibitory activity (Figure 3.2.5). 
5-Lipoxygenase is a rate-limiting enzyme for 
leukotriene synthesis, converting arachidonic acid 
into 5-hydroperoxyeicosatetraenoic acid (5-
HPETE). 5-HPETE is metabolised to an unstable 
epoxide LTA4, which is transformed to LTB4 or 
LTC4 according with the cell type and the enzymes 
present (Figure 3.2.7) (375). In RBL-2H3 cells, 
LTC4 is the major leukotriene released, while LTD4 
and LTE4 are not produced (376). Soybean 
lipoxidase is often used to model human 5-, 12- 
and 15-lipoxygenases, given the high catalytic 
domain similarity between plant and mammalian 
lipoxygenases (377). All tested naphthoquinones 
exhibited lipoxidase inhibiting activity (Figure 
3.2.6A). Dimeric naphthoquinones (diospyrin and 
diosquinone), and the monomeric menadione were 
the most potent, showing the lowest IC50 values 
(Table 3.2.1). Considering that these three 
naphthoquinones are the most lipophilic of the 
studied compounds, our results raise the 
hypothesis that naphthoquinones inhibit lipoxidase 
by competing with natural lipophilic substrates. 
Considering the results obtained with soybean 
lipoxidase, we tested the inhibition of leukotriene 
production by diospyrin, diosquinone and 
menadione. Menadione was the only 
naphthoquinone able to reduce leukotriene 
production, achieving full inhibition at 5 µM (Figure 
3.2.6C). Higher menadione concentrations (50-200 
µM) were previously reported to reduce leukotriene 
production by inhibiting 5-lipoxygenase 
translocation to the nuclear membrane (91). Given 
that menadione is a known oxidative stress 
generator (378), and that reactive oxygen species 
(ROS) may react with arachidonic acid forming 
oxidized lipids (Figure 3.2.7) (379), decreased 
LTC4 with our lower menadione concentrations 
may stem from decreased arachidonic acid 
availability. Consitently with our concentration 
range, menadione was reported to inhibit 
prostaglandin H2 synthase via ROS production with 
an IC50 of 5 µM (380). 
Concluding, we evaluated the anti-allergic 
properties of monomeric and dimeric 
naphthoquinones by studying the inhibition of RBL-
2H3 basophils’ degranulation and LTC4 production 
induced by allergic stimuli, as well as by the 
evaluation of inhibition of enzymes involved in 
allergic responses. To our knowledge, this is the 
first study addressing the anti-allergic potential of 
diospyrin, diosquinone, naphthazarin and juglone. 
Naphthazarin and diospyrin reduced degranulation 
by different mechanisms of action. Naphthazarin 
and diospyrin acted, respectively, upstream and 
downstream of the intracellular calcium increase. In 
spite of being poor inhibitors of hyaluronidase, 
naphthoquinones inhibited lipoxidase and 
menadione reduced leukotriene production. Thus, 
this work expands the current knowledge on the 
biological properties of naphthoquinones, 
highlighting naphthazarin, diospyrin and 
menadione as potential lead compounds for 
structural modification in the process of improving 
and developing novel anti-allergic drugs. 
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Abstract 
 
BACKGROUND AND PURPOSE 
Mitochondria are a drug target in mitochondrial dysfunction diseases and in antiparasitic chemotherapy. While 
zebrafish is increasingly used as a biomedical model, its potential for mitochondrial research remains 
relatively unexplored. Here, we perform the first systematic analysis of how mitochondrial respiratory chain 
inhibitors affect zebrafish development and cardiovascular function, and assess multiple quinones, including 
ubiquinone mimetics idebenone and decylubiquinone, and the antimalarial atovaquone. 
 
EXPERIMENTAL APPROACH 
Zebrafish (Danio rerio) embryos were chronically and acutely exposed to mitochondrial inhibitors and quinone 
analogues. Concentration-response curves, developmental and cardiovascular phenotyping were performed 
together with sequence analysis of inhibitor-binding mitochondrial subunits in zebrafish versus mouse, human 
and parasites. Phenotype rescuing was assessed in co-exposure assays. 
 
KEY RESULTS 
Complex I and II inhibitors induced developmental abnormalities, but their submaximal toxicity was not 
additive, suggesting active alternative pathways for complex III feeding. Complex III inhibitors evoked a direct 
normal-to-dead transition. ATP synthase inhibition arrested gastrulation. Menadione induced hypochromic 
anaemia when transiently present following primitive erythropoiesis. Atovaquone was over 1000-fold less 
lethal in zebrafish than reported for Plasmodium falciparum, and its toxicity partly rescued by the ubiquinone 
precursor 4-hydroxybenzoate. Idebenone and decylubiquinone delayed rotenone- but not myxothiazol- or 
antimycin-evoked cardiac dysfunction. 
 
CONCLUSION AND IMPLICATIONS 
This study characterizes pharmacologically induced mitochondrial dysfunction phenotypes in zebrafish, laying 
the foundation for comparison with future studies addressing mitochondrial dysfunction in this model 
organism. It has relevant implications for interpreting zebrafish disease models linked to complex I/II inhibition. 
Further, it evidences zebrafish’s potential for in vivo efficacy or toxicity screening of ubiquinone analogues or 
antiparasitic mitochondria-targeted drugs. 
 
Keywords: Mitochondria; zebrafish; Danio rerio; idebenone; decylubiquinone; atovaquone; menadione.
 
Introduction 
 
Mitochondrial dysfunction is a common feature in 
multiple human diseases. Mitochondrial diseases 
present diverse clinical symptoms with the most 
common being neurological and cardiological 
manifestations, including cardiomyopathies and heart 
conduction defects (190, 210). Mutations in 
mitochondrial DNA (mDNA) may affect respiratory 
chain elements or ribosomal and transfer RNAs 
required for mitochondrial gene expression, causing 
diseases such as Leber’s hereditary optic neuropathy 
or mitochondrial myopathy, encephalopathy, lactic 
acidosis and stroke syndrome (190). Also, mutations 
in nuclear encoded mitochondrial proteins are 
associated with human diseases (e.g. optic atrophy 
or Charcot-Marie-Tooth 2A). Furthermore, key 
neurodegenerative disorders such as Alzheimer, 
Parkinson and Huntington diseases, among others, 
have been associated with mitochondrial dysfunction 
(381). Current treatment options for mitochondrial 
dysfunction disorders are scarce and mostly 
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symptomatic (205). Further treatment development is 
partly hindered by limited in vivo models of 
mitochondrial disease. Notably, strong purifying 
selection in the mammalian female germ line 
imposes difficulties in establishing mouse models of 
mDNA mutations (382). 
 Zebrafish (Danio rerio) is increasingly used for 
modelling human diseases (383). Its mitochondrial 
genome is sequenced (384) and zebrafish is 
emerging as a model for studying mitochondria-
linked disorders. Indeed, silencing mitofusin-2 in 
zebrafish generated an in vivo model of Charcot-
Marie-Tooth 2A neuropathy (385). Similarly, 
depletion of cytochrome c oxidase, optic atrophy 3 
protein and electron transfer flavoprotein 
dehydrogenase (ETFDH) were respectively used to 
model cytochrome c oxidase deficiency (386), 
Costeff syndrome (387) and multiple acyl-CoA 
dehydrogenase deficiency in zebrafish (388). 
Moreover, zebrafish was reported sensitive to 
mitochondrial toxins linked to Parkinson’s disease 
(319), and parkin knockdown in embryos led to 
mitochondrial complex I deficiency (389). Currently, 
few studies addressed normal zebrafish 
mitochondrial physiology and bioenergetics. These 
include analysis of mDNA metabolism (390), oxygen 
consumption (391), calcium buffering and 
mitochondrial permeability transition (392) in 
zebrafish embryos. Still, further studies are required 
to validate zebrafish as a model to study 
mitochondrial dysfunction and its experimental 
treatment, including the identification of similarities 
and specific limitations when extrapolating towards 
mammalian physiology. 
 Here, we model mitochondrial dysfunction in 
zebrafish and use it to test mitochondria-targeted 
drugs. We characterize the effects of mitochondrial 
inhibitors and quinone analogues on zebrafish 
embryonic development and cardiovascular function, 
identifying morphological and functional phenotypes 
associated with impaired respiratory complexes and 
ubiquinone deficiency. Among several quinone 
analogues, we test the ubiquinone mimetics 
idebenone and decylubiquinone. Also, we test the 
antimalarial atovaquone, appraising zebrafish’s 
potential for differential toxicity screening of the 
growing class of mitochondria-targeted antiparasitic 
drugs (393). 
 
Methods 
 
Drugs, solvents and solutions 
Mitochondrial inhibitors [rotenone, 3-nitropropionic 
acid (3NP), myxothiazol, antimycin and oligomycin] 
and all other drugs/chemicals were from Sigma-
Aldrich (St. Louis, MO, USA), unless otherwise 
stated. Quinones analogues were: natural 
monomeric naphthoquinones [menadione (MND), 
juglone (JGL), naphthazarin (NTZ), plumbagin (PLB), 
lapachol (LPC) and β-lapachone (βLPC)]; natural 
dimeric naphthoquinones [diospyrin (DPR) and 
diosquinone (DQN)]; synthetic naphthoquinone 
[atovaquone (ATV)]; and synthetic benzoquinones 
[idebenone (IDB) and decylubiquinone (DCB)]. Other 
drugs include the ubiquinone synthesis precursor [4-
hydroxybenzoic acid (4HB)] and respective inhibitor 
[4-nitrobenzoic acid (4NB)]; the NAD(P)H:quinone 
oxidore- ductase (NQO1) inhibitor [dicoumarol 
(DCM)]; and the control abnormality inducer [valproic 
acid (VPA)]. DPR and DQN were isolated from root 
barks of Diospyros chamaethamnus Dinter ex Mildbr 
(31). 4HB was from Extrasynthese (Genay Cedex, 
France). For all drugs, chemical structures are in 
Supporting Information Figure 3.3.S1, summarized 
data in Table 3.3.2 and Figure 3.3.5C, and their 
mechanism/ sites of action depicted in Figure 3.3.8. 
Stock drug solutions were prepared in water, DMSO 
or methanol, according to their solubility. Prior to 
assays, stocks were diluted in dechlorinated 
autoclaved water (egg water). Non-water drug 
solvents, DMSO or methanol, were kept constant at 
all drug dilutions and always below 0.5 or 0.05% 
respectively. These solvent concentrations induced 
no significant effects (Figure 3.3.1B). 
 
Egg production 
Adult wild-type zebrafish (D. rerio), were maintained 
at 28 ± 1°C on a 14 h:10 h light:dark cycle, and 
handled for egg production as we previously detailed 
(394). Briefly, adults (14:7 male:female) were placed 
in a 30 L breeding tank on the day before egg 
collection. Ninety minutes after starting the light 
period, eggs were collected and cleaned. This time 
point was recorded as 0 h post fertilization (hours 
post fertilization, hpf; Figure 3.3.1A). 
 
Chronic drug exposure assays 
 
Embryo maintenance and drug treatment. Embryos 
were randomly distributed in 12-well plates (10 
embryos/well; 2 mL egg water/well) and kept at 28 ± 
1°C on a 14 h:10 h light:dark cycle throughout the 
assay. Embryos were continuously exposed to drugs 
from 4 to 80 hpf. VPA, a known teratogen in 
zebrafish, was used as positive control for 
developmental abnormalities and also cardiovascular 
abnormalities such as bradycardia (395). Dead 
embryos were removed during the readings (Figure 
3.3.1A) and two out of three of each well content was 
renewed with freshly prepared drug solution at 32 
and 56 hpf. All drug concentrations were assayed in 
duplicate wells (10 + 10 eggs), in at least three 
independent experiments (≥60 eggs). 
 
Monitoring of zebrafish development and cardiac 
function. At regular time points (8, 32, 56 and 80 hpf: 
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Figure 3.3.1A) embryos were scored as normal, 
abnormal or dead; hached/ unhatched; using a 
stereomicroscope (Stemi DV4, Zeiss, Göttinger, 
Germany) or an inverted microscope (Eclipse TS 
100, Nikon, Tokyo, Japan) with colour camera (Nikon 
8400; Tokyo, Japan) for digital recording. Normal 
development was as previously described (292). 
Abnormalities were organized as: pigmentation, 
cardiac and structural – for subdivisions description 
and photographs see Table 3.3.1 and Figure 3.3.2A. 
Heart rates (Figure 3.3.5A) were measured in two 
embryos per phenotype per well, during 20 s, at 80 
hpf. Weighted averages (Figure 3.3.5Ai) consider 
the embryos with/ without cardiac oedema among 
the live population per well. For detailed heartbeat 
analyses (Figure 3.3.5B), videos were recorded at 
20x magnification in an inverted microscope (Eclipse 
TE300, Nikon), with CCD camera (C6790; Hama- 
matsu Photonics, Hamamatsu, Japan) and 
Aquacosmos software (version 2.5; Hamamatsu 
Photonics). Videos were captured at 28 Hz during 10 
s and processed with ImageJ (NIH) for assessing 
atrioventricular coordination. 
 
Parameters and abnormality indexes. NC50, AC25 
and LC50 signify concentrations required for, 
respectively, 50% decrease in normal embryos, 25% 
of embryos with abnormalities and 50% lethality. LS 
and NS are slopes from concentration-response 
curves depicting dead and normal embryos 
respectively. Abnormality indexes were expressed by 
LC50/NC50 and LS/-NS ratios. Both are ~1 when 
increasing drug concentrations convert normal 
embryos directly into dead embryos. When abnormal 
embryos survive, the LC50/ NC50 ratio is >1. The LS/-
NS can still be ~1, but otherwise is inversely 
proportional to the resilience of abnormal embryos to 
increasing drug concentrations. Indeed, an LS 
steeper or shallower than -NS signifies a more or 
less abrupt abnormal-to-dead conversion respec- 
tively. 
 
Acute drug exposure assays 
Hatched embryos at 56 hpf were randomly 
distributed in 12-well plates (10 embryos in 2 mL egg 
water/well). Following acute exposure to isolated or 
combined drugs, embryos were scored for 
presence/absence of circulation and heartbeat at 10  
 
 
 
Figure 3.3.1. Mitochondrial inhibitors and zebrafish development. A, Protocol and images of normal development. B–G, 
Changes in normal (white circles), abnormal (grey triangles), dead (black circles) and hatched (white diamonds) embryos (% 
total) across time and drug concentrations. B, Controls – egg water (i), with 0.5% DMSO (ii) and 0.05% methanol (iii, MeOH). 
C–G, Mitochondrial inhibitors. Data are mean ± SEM of n independent experiments: control: n = 34, 4 and 4, for egg water, 
DMSO and MeOH, respectively; rotenone, n = 4–14; 3NP, n = 3–9; myxothiazol, n = 4–12; antimycin, n = 5–6; oligomycin, n = 
3–5. C-Giii, Arrows – peak abnormalities at 80 hpf. 
EXPERIMENTAL SECTION 3.3 	  
72 
10 min intervals. For each treatment, 40–60 embryos, 
from two to three independent clutches, were 
assayed in two to three independent experiments, 
before data aggregation for Kaplan–Meier analysis. 
Data sources and comparison of protein 
sequences  
Protein sequence data of NADH dehydrogenase 
subunit 1 (ND1, complex I), succinate dehydroge- 
nase complex subunit A (complex II), cytochrome b 
(complex III) and ATPase subunit 6 and 9 (complex 
V) were obtained from NCBI (http:// ncbi.nlm.nih.gov/ 
protein). Percentages of identity were calculated 
using BLAST (http://blast.ncbi.nlm.nih.gov/Blast. cgi). 
COBALT (http://www.ncbi.nlm.nih.gov/tools/cobalt) 
was used to align cytochrome b sequences (Figure 
3.3.3). 
 
Statistics 
Values are mean ± SEM from n independent 
experiment, unless otherwise stated. Conventional ‘E 
notation’ is used when appropriate. For normally 
distributed data, t-test or ANOVA were used, 
respectively, to compare two or more groups. The 
Mann–Whitney test and Kruskal– Wallis ANOVA 
were used for non-normally distributed data. 
Changes in proportion of embryos with/without 
circulation or heartbeat were analysed via Kaplan–
Meier. Cluster analysis was performed by k-means 
clustering, preceded by exploratory hierarchical 
clustering. Linear regressions (for computing NC50, 
AC25, LC50, and slopes – NS, LS) and non-
parametric tests were performed with GraphPad 
Prism version 5.0 (San Diego, CA, USA). All other 
statistical analyses were performed with SPSS 20.0 
(SPSS Inc., Chicago, IL, USA). Differences from 
control were considered statistically significant when 
P < 0.05. Simultaneous biological relevance was 
assumed only for differences larger than 10% (Δ > 
10%). 
 
 
 
Results 
 
Mitochondrial inhibitors induce different 
abnormalities in zebrafish 
To assess how mitochondrial dysfunction affects 
zebrafish development, fertilized eggs were 
chronically exposed to different mitochondrial 
inhibitors. Protocol and concentration- response 
curves are in Figure 3.3.1 and representative 
abnormalities (Figure 3.3.2A) described in Table 
3.3.1. 
 Complex I and II inhibitors (rotenone and 3NP, 
respectively) induced more abnormalities in surviving 
embryos than complex III inhibitors (myxothiazol and 
antimycin), which primarily induced a direct transition 
from normal to dead. The ATP synthase inhibitor 
(oligomycin) arrested surviving embryos at the 
gastrula stage, followed by a time-dependent death 
(Figure 3.3.1C-G and Figure 3.3.2B-G). The order 
of potency for lethality was antimycin > myxothiazol > 
rotenone > oligomycin > 3NP (LC50 in Table 3.3.2). 
Comparing LC50/ NC50 and LS/-NS ratios at 80 hpf 
(Table 3.3.2) highlights 3NP as the most frequent 
inducer of abnormalities among the mitochondrial 
inhibitors (highest LC50/NC50 and lowest LS/-NS; 
AC25 = 3.4E3 ± 1.7E2 µM, n = 4), followed by 
rotenone, myxothiazol, antimycin and oligomycin. At 
56 hpf, oligomycin stands out as an abnormality 
inducer, but the corresponding embryos do not 
survive until 80 hpf (Table 3.3.2, Figure 3.3.2G). 
 Types and frequency of abnormalities varied 
across mitochondrial inhibitors (Figure 3.3.2B-G). 
Rotenone and 3NP significantly decreased 
pigmentation (melanin) at 56 hpf suggesting 
developmental delay, and induced cardiovascular 
abnormalities (oedema and asystole); 3NP also 
caused necrotic lesions and head abnormalities 
(abnormal otoliths); Figure 3.3.2C, D. Oligomycin-
induced abnormalities were primarily arrests at the 
gastrula stage, lethal at 80 hpf (Figure 3.3.2G). My- 
 
 
 
Table 3.3.1. Description of zebrafish abnormalities. Criteria for scoring zebrafish as abnormal or dead, and respective 
reading times. 
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xothiazol and antimycin evoked no statistically 
significant abnormalities (Figure 3.3.2E, F), 
consistent with direct transition from normal to dead 
(Figure 3.3.1E, F). 
 Heart rate analysis showed that bradycardia and 
cardiac oedema were strongly associated (Figure 
3.3.5Aii vs. Aiii; with few exceptions). Control heart 
rate was 179 ± 3 beats per minute (bpm) and 163 ± 5 
bpm, for embryos without and with spontaneous 
oedema respectively (Figure 3.3.5Aiii). Embryos 
with oedema caused by rotenone, 3NP, myxothiazol 
or oligomycin, all displayed concentration-dependent 
bradycardia, more pronounced than that caused by 
spontaneous oedema in controls (Figure 3.35Aiii). In 
weighted average, however, only 3NP caused 
relevant bradycardia among the mitochondrial 
inhibitors (Figure 3.3.5Ai), consistent with its higher 
proportion of oedema (Figure 3.3.2Diii). Also, cluster 
analysis and scaling across three domains (cardiac, 
structural and pigmentation) clearly separated 3NP 
from all other mitochondrial inhibitors (Cluster 5; 
Figure 3.3.5C). 
 
Comparison of mitochondrial complex subunits 
between zebrafish, human, mouse and 
parasites targetable with quinone analogues 
To appraise zebrafish for mitochondrial dysfunction 
modelling and drug testing, we compared inhibitor-
binding subunits for rotenone (396), 3NP (397), 
myxothiazol, antimycin, atovaquone (393) and 
oligomycin (200)  – (Figure 3.3.3A, B).  
Pneumocystis jiroveci (398) and Plasmodium 
falciparum (399) are included because of relevant 
cytochrome b differences allowing selective targeting 
with atovaquone (393, 399). Zebrafish identity with 
human subunits is only 9–13% lower than mouse 
versus human, except for ATPase subunit 6 (Figure 
3.3.3A). Our LC50 for mitochondrial inhibitors in 
zebrafish were lower than LC50 or concentrations 
fully inhibiting mammalian mitochondrial complexes, 
except 3NP where only its AC25 approximated the 
LC50 reported for mammalian cells (Table 3.3.2). The  
 
 
Figure 3.3.2. Mitochondrial inhibitors and abnormalities in zebrafish. A, Representative abnormalities in comparison 
with post- and pre-hatched control embryos (top and bottom left, respectively) at 80 hpf. B, Spontaneous abnormalities 
under control conditions; C–G, Mitochondrial inhibitor induced abnormalities at the indicated concentrations (arrows in 
Figure 1C-Giii); Boxplots (specific abnormalities, % total embryos) show median, mean (+), interquartile distances, 
maximum and minimum; Symbols (normal, white circles; abnormal, grey triangles; and dead; black circles) show mean ± 
SEM (% total, embryos). Data are from n independent experiments: control: n = 34; rotenone (RTN), n = 14; 3-nitropropionic 
acid (3NP), n = 9; myxothiazol (MYX), n = 12; antimycin (ANT), n = 5; oligomycin (OLG), n = 5. *P < 0.05 in boxplots, 
Kruskal–Wallis ANOVA with Dunn’s post hoc (vs. control). *P < 0.05 in grey triangles (mean abnormalities), One-way 
ANOVA with Bonferroni post hoc (vs. control). 
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Figure 3.3.3. Amino acid sequence comparison of mitochondrial inhibitor-binding subunits. A, Percentage of identity 
among inhibitor-binding subunits of mitochondrial complexes I, II, III and V (NADH dehydrogenase subunit 1, ND1; succinate 
dehydrogenase subunit A, cytochrome b, and ATPase subunits 6 and 9), from human, mouse, zebrafish and parasites 
targetable with quinone analogues (P. jiroveci and P. falciparum; ‘n.a.’, not applicable – no homologue subunit in this species). 
B, Comparison of Qo and Qi sites (grey highlight). Xn summarises non-Qo/Qi amino acids. 
 
genetic and functional correlation is evidenced by 
ND1 and complex V subunit 6 absence in Pl. 
falciparum versus zebrafish/ mammals, and the 
associated 10-fold higher concentrations required for 
rotenone or oligomycin to kill Pl. falciparum versus 
zebrafish embryos in this study (Table 3.3.2). 
Differences in cytochrome b Qo (binds myxothiazol/ 
atovaquone) and Qi (binds antimycin) (Figure 
3.3.3B) are functionally relevant since antimycin 
displays >1000-fold lower LC50 towards zebrafish/ 
mammals versus parasites. Therapeutically more 
relevant, atovaquone displays much higher toxicity 
towards Pl. falciparum versus zebrafish/ mammals 
(Table 3.3.2) 
 
Quinone analogues and other ubiquinone-
related compounds induce different 
abnormalities in zebrafish 
Aiming to validate zebrafish as in vivo model for 
exploring the therapeutic potential of quinone 
analogues, we tested their effects in chronically (4–
80 hpf) exposed embryos, along with other drugs for 
mechanistic studies (Supporting Information Figure 
3.3.S1). All 11 quinone analogues were lethal within 
the tested range of concentrations (Table 3.3.2). The 
LC50 interval 0.5–1 µM includes PLB, DQN and JGL; 
1–10 µM includes ATV, βLPC, DPR, MND, NTZ, IDB 
and LPC. The least lethal of all quinone analogues 
was decylubiquinone (DCB; LC50 at 80 hpf = 20.10 ± 
0.74 µM, n = 3). Other drugs exhibited an LC50 
comprised between 21 µM and 4 mM (DCM, VPA 
and 4NB); The LC50 for 4HB was > 5 mM, its AC25 at 
80 hpf was 1.3 ± 0.66 mM, n = 5. Relatively few 
(4:11) quinone analogues induced a significant 
proportion of structural/functional abnormalities (ATV, 
LPC, MND and DCB; Table 3.3.2, LC50/ NC50 > 1; 
Figure 3.3.4). Among the ‘other drugs’, 4NB, DCM 
and VPA exhibited an LC50/NC50 > 1 at either 56 or 
80 hpf (Table 3.3.2 and Figure 3.3.4). 
 Atovaquone induced abnormalities were primarily 
cardiac oedema and focal lesions (e.g. 
bleedings/clots), most noticeable at 1 mM and 56 hpf 
(some lethal at 80 hpf; Figure 3.3.4A). Meaningfully, 
although atovaquone shares complex III inhibition 
with myxothiazol and antimycin (Figure 3.3.8A), it 
induces different abnormalities (Figure 3.3.2E, F vs. 
Figure 3.3.4A), which may be better explained by 
atovaquone’s inhibition of ubiquinone synthesis 
(Figure 8D). Consistently, the ubiquinone synthesis 
inhibitor 4NB replicated distinguishing atovaquone 
features, such as focal lesions and pronounced 
cardiac oedema without relevant bradycardia (Figure 
3.3.4A vs. Figure 3.3.4D; Figure 3.3.5Aiii). 
 Decylubiquinone’s lethality was strikingly time-
dependent increasing about 90% from 56 to 80 hpf 
(Figure 3.3.4B). Decylubiquinone caused a tail fin 
anomaly (Figure 3.3.2A; ~50% embryos at 10 µM; 
Figure 4Eiv, 80 hpf), also observed within 90 min of 
exposure in hatched embryos (experiments in Figure 
3.3.7A), suggesting altered neuromuscular tonus and 
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not necessarily developmental defects. Interestingly, 
the structurally related idebenone (terminal –OH in 
decylubiquinone’s aliphatic chain; Supporting 
Information Figure 3.3.1) displayed higher lethality 
(~3x lower LC50; Table 3.3.2) and no significant 
abnormalities other than delayed pigmentation 
(melanin; Figure 3.3.4C). 
 Lapachol (10 mM) induced a diverse abnormality 
profile afflicting ~80% embryos at 56 hpf, precluding 
hatching and leading to >50% death at 80 hpf 
(Figure 3.3.4Fi,iii). Lapachol caused decreased 
pigmentation (melanin), head defects (abnormal 
eyes, otoliths and craniofacial defects), gastrula 
arrest, oedema and asystole (Figure 3.3.4 Fii,I v). 
Asystole was typically preceded by cardiac oedema 
and concentration-dependent bradycardia (Figure 
3.3.5A; with signs of atrioventricular block Figure 
3.3.5Biii). In contrast, dicoumarol (50 µM) 
abnormalities were merely decreased melanin 
(Figure 3.3.4G). 
 Menadione (1 µM) was the single most powerful 
inducer of hypochromic anaemia among 20 
compounds, affecting the majority of embryos at 80 
hpf (Figure 3.3.4H). We thus investigated hypochro- 
 
Table 3.3.2. Comparative toxicity of mitochondrial inhibitors, quinone analogues and other drugs in 
zebrafish vs. other species. 
[1]-[45] are literature references for drug effects, provided as supporting information Appendix S1. 
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Figure 3.3.4. Influence of quinone analogues and ubiquinone related compounds on zebrafish development. A-I, i, 
iii, Mean ± SEM of changes in normal, abnormal, dead and hatched embryos (% total) for the indicated times (56 and 80 
hpf) and drug concentrations; ii, iv, Boxplots (specific abnormalities, % total embryos) show median, mean (+), interquartile 
distances, maximum and minimum, for the indicated concentrations (arrow; peak abnormalities at 80 hpf). Data are from n 
independent experiments with: A, atovaquone, n = 3–12; B, decylubiquinone, n = 4–8 C, idebenone, n = 3–8; D, 4NB, n = 
3–11; E, 4HB, n = 4–16; F, lapachol, n = 3–5; G, dicoumarol, n = 3–8; H, menadione, n = 3–15; and I, β-lapachone, n = 3–
10. *P < 0.05, Mann–Whitney (vs. control) if difference in medians >10%. J, Effect of dicoumarol [DCM; NQO1 inhibitor, 
(Preusch et al., 1991)] upon abnormalities induced by menadione (MND) or β-lapachone (βLPC) at 80 hpf. P > 0.05 for 
differences between MND/βLPC alone versus combined with 50 or 500 nM DCM, one-way ANOVA with Bonferroni post hoc, 
n = 5–6. K, Periods of menadione (1 µM) exposure and resulting mean ± SEM of embryos with hypochromic anaemia (% 
live, 80 hpf). *P < 0.05 versus 48–80hpf exposure, ANOVA with Bonferroni post hoc, n = 3–4 independent experiments. The 
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periods of primitive, transient and definitive haematopoiesis were derived from Chen and Zon (400). 
mic anaemia, modulating the duration and 
developmental stage of menadione exposure. 
Strikingly, a short exposure from 24 to 32 hpf sufficed 
to evoke over 50% hypochromic anaemia at 80 hpf, 
whereas longer exposures at earlier (8–24 hpf) or 
later (48-80 hpf) stages resulted in normally coloured 
erythrocytes at 80 hpf (Figure 3.3.4K). 
 
Rescue experiments with ubiquinone analogues 
or precursor during chronic mitochondrial 
inhibition 
 
Idebenone and decylubiquinone fail to rescue 
chronic mitochondrial inhibition. Following individual 
drug titration, we tested whether ubiquinone 
analogues rescued the effects of chronic 
mitochondrial inhibition in zebrafish. Embryos were 
chronically exposed to concentrations inducing the 
highest percentage of abnormalities at 80 hpf for 
rotenone (0.1 µM), 3NP (10 mM), myxothiazol (0.03 
µM) and atovaquone (1 µM), in the presence or 
absence of the highest concentration of ubiquinone 
analogues without detectable chronic toxicity (1 µM 
idebenone; 3 µM decylubiquinone). Neither 
idebenone nor decylubiquinone rescued changes in 
number of normal embryos, hatching, heart rate or 
oedema induced by chronic mitochondrial inhibition 
(Figure 3.3.6A). 
 
Zebrafish has active alternative ubiquinone reduction 
pathways. Lack of rescuing from chronic complex I or 
II inhibition with ubiquinone analogues prompted us 
to test whether combined rotenone and 3NP 
displayed additive toxicity. Results showed that the 
combination of rotenone (0.1 µM) with 3NP (10 mM) 
does not exceed the toxicity of 3NP alone (Figure 
3.3.6C). Together with development beyond the 
gastrula stage requiring mitochondrial ATP synthesis 
(oligomycin effect; Figure 3.3.2G), these results 
suggest that alternative ubiquinone reduction 
pathways actively feed complex III (Figure 3.3.8C), 
supporting mitochondrial ATP synthesis. 
 Given the possible contribution of NQO1 in the 
reduction of idebenone to idebenol and feeding of 
complex III [(9); Figure 3.3.8D], we appraised the 
contribution of this enzyme by testing how its inhibitor 
dicoumarol modulated toxicity of its substrates – 
menadione and β-lapachone. Results showed that 
dicoumarol (50 or 500 nM; concentrations devoid of 
lethality, Figure 3.3.4G) did not significantly increase 
the toxicity of 1 µM menadione [predicted to be 
detoxified by NQO1; (401)] and did not decrease the 
toxicity of 3 µM β-lapachone [predicted to be 
bioactivated by NQO1; (402) (Figure 3.3.4J, Figure 
3.3.8D). 
 
The ubiquinone precursor 4HB rescues atovaquone 
but not myxothiazol or antimycin toxicity. Given the 
central role of ubiquinone and complex III in 
energizing the mitochondrial respiratory chain, we 
tested whether the ubiquinone precursor 4HB (5 µM) 
could rescue the toxicity of complex III inhibitors 
(Figure 3.3.6B). Although failing to rescue embryos 
from myxothiazol or antimycin toxicity, 4HB 
significantly rescued atovaquone toxicity, increasing 
the proportion of normal embryos (Figure 3.3.36Bi; 
P < 0.05, Δ > 10%) and displaying a trend towards 
decreased oedema (Figure 3.3.6Biii; ATV vs. ATV + 
4HB). 4HB failed to rescue the effects of the 
ubiquinone synthesis inhibitor 4NB (Figure 3.3.6B). 
The 2000-fold difference in concentrations required 
for 4NB toxicity (10mM; Figure 3.3.4D) vs. 4HB 
efficacy (5 µM; Figure 3.3.6B), and the toxicity 
displayed by ≥ 5 mM 4HB (Figure 3.3.4E) precluded 
equimolar competition in rescue assays with 4HB 
and 4NB. 
 
Rescue experiments with ubiquinone analogues 
upon acute mitochondrial inhibition 
 
Acute complex I inhibition with rotenone induces 
cardiac insufficiency and asystole via ATP depletion. 
Following literature data supporting in vitro rescuing 
by ubiquinone analogues of decreased mitochondrial 
oxygen consumption or ATP levels in synaptosomes 
(135), cell lines (9) or isolated mitochondria (117), we 
aimed to establish an in vivo testing paradigm for 
ubiquinone analogues in zebrafish. Thus, we 
monitored circulation and heartbeat in 56 hpf 
embryos acutely challenged with mitochondrial 
inhibitors with or without ubiquinone analogues 
(idebenone or decylubiquinone; Figure 3.3.7). 
Circulatory arrest upon acute mitochondrial inhibition 
was associated with bradycardia and atrioventricular 
block (e.g. Figure 3.3.5Biii) or supraventricular 
arrhythmia (e.g. Figure 3.3.5Biv), and followed by 
asystole. Mitochondrial ATPase inhibition 
(oligomycin) evoked circulatory arrest. When 
combined, oligomycin did not modify rotenone’s 
circulatory arrest (Figure 3.3.7Aii), but delayed 
rotenone induced asystole by 18% (Figure 3.3.7Aiv, 
P < 0.05). The latter can be explained by preventing 
ATP consumption upon rotenone induced ATPase 
reversal.  
 
Idebenone and decylubiquinone delay the onset of 
cardiac dysfunction evoked by rotenone but not by 
myxothiazol or antimycin. Idebenone (3 µM) and 
decylubiquinone (30 µM) delayed rotenone induced 
cardiac insufficiency, respectively, by 61 and 79% 
(Figure 3.3.7Ai, P < 0.05), and also delayed asystole 
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Figure 3.3.5. Detailed heartbeat analysis and multiple-abnormalities profiling. A, Concentration-dependent changes in 
heart rate at 80 hpf, showing total weighted average (i, see Methods), and separating embryos without (ii) from those with (iii) 
cardiac oedema; embryos in asystole were excluded from calculations. Horizontal rectangles are the 95% confidence interval 
(CI) for control means without (light grey) and with (dark grey, iii) spontaneous cardiac oedema, n = 33 experiments. Data for 
drugs are mean ± SEM from n = 3–14 experiments. B, Detailed heartbeat analysis at 56 hpf showing examples of normal 
atrioventricular coordination and frequency (i), bradicardia (ii), atrioventricular block (iii) and supraventricular arrhythmia (iv). C, 
Multi-dimensional scaling and clustering of abnormality profiles at 80 hpf. Axes are the sum of mean abnormalities for the 
respective subdomains (Table 3.3.1). Clusters: 1 (3NP); 2 (DCB); 3 (MND and 4HB); 4 (VPA, LPC and 4NB); 5 (all other drugs); 
k-means clustering. 
respectively by 52 and 104% (Figure 3.3.7Aiii, P < 
0.05). In contrast, both ubiquinone analogues failed 
to protect from cardiac dysfunction induced by either 
myxothiazol (1 µM; Figure 3.3.7Bi, iii) or antimycin 
(100 nM, Figure 3.3.7Bii, iv). 
 
Discussion and conclusions 
 
Modelling mitochondrial dysfunction in zebrafish 
 
Mitochondrial respiratory chain and inhibitors. Here, 
we show that zebrafish and mammalian mitochondria 
display high genetic and functional homology, and 
characterize the developmental and cardiovascular 
consequences of mitochondrial dysfunction evoked 
by respiratory chain inhibitors. Chronic complex I or II 
inhibition induced developmental abnormalities, 
whereas complex III inhibition directly converted 
normal into dead embryos, plausibly by lack of 
downstream alternatives to sustain mitochondrial 
ATP synthesis. Interestingly, when combining 
effective concentrations of rotenone and 3NP, lack of 
additive effects suggests a negligible residual 
complex I activity during complex II inhibition and 
vice versa. Yet, albeit abnormal, embryos undergo 
organogenesis and survive past 80 hpf. Because this 
cannot happen without mitochondrial ATP synthesis 
(oligomycin arrests gastrulation), data suggests 
alternative mitochondrial dehydrogenases [ETFDH, 
glycerol-3-phosphate dehydrogenase or 
dihydroorotate dehydrogenase (DHODH); Figure 
3.3.8] actively reduce endogenous ubiquinone to 
support mitochondrial ATP production. This is 
important for interpreting zebrafish models of 
complex I or II deficiencies, for example in primary 
mitochondrial disease or in neurodegenerative 
disorders which have been associated with deficits in 
complexes I or II, such as Parkinson and 
Huntington’s diseases respectively. Specifically, 
alternative feeding of complex III may explain why 
parkin knockout zebrafish presented 45% reduction 
of complex I activity without significant changes in 
swimming behaviour (403). 
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 While the concentrations we have used for 
mitochondrial inhibitors are within the range 
commonly used in the literature, it is conceivable that 
in zebrafish, as with other models, there may be 
some contribution of off-target effects, such as 
microtubule depolymerization by rotenone (404), and 
fumarase inhibition by 3NP (405). 
 
 
 
Figure 3.3.6. Effect of ubiquinone analogues and precursor upon chronic mitochondrial inhibition. A,B, Normal 
embryos (i), hatching (ii), and average heart rate (iii; asystole included) in % of control, as well as oedema in surviving 
embryos (% live; iii); Readings at 80 hpf, following chronic exposure to the indicated concentrations of drugs isolated vs. 
combined with idebenone (IDB, 1 µM, A) or decylubiquinone (DCB, 3 µM, A), or with 4-hydroxybenzoate (4HB, 5 µM, B). Data 
are mean ± SEM on n independent experiments with rotenone (RTN, 0.1 µM, n = 4), 3-nitropropionic acid (3NP, 10 mM, n = 
3), myxothiazol (MYX, 0.03 µM, n = 5; 0.1 µM, n = 6), atovaquone (ATV, 1 µM; n = 6), antimycin (ANT, 3 nM, n = 3), and 4-
nitrobenzoate (4NB, 10 mM, n = 4). *P < 0.05 for combined vs. isolated drug, unpaired t-test. C, Normal, abnormal and dead 
embryos upon chronic exposure to 3NP (10 mM), alone or combined with RTN (0.1 µM). Data are mean ± SEM for n = 3 
independent experiments, with readings at 32 (i), 56 (ii) and 80 hpf (iii). Note that 3NP toxicity (judged from abnormal and 
dead embryos vs. normal) does not increase upon combination with rotenone. 
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Figure 3.3.7. Effect of ubiquinone analogues upon acute mitochondrial inhibition. A,B, Time-dependent changes in 
proportion of 56 hpf zebrafish with active circulation (i,ii) and heartbeat (iii,iv) following acute exposure to mitochondrial 
inhibitors (at time = 0 min). Ai,iii, Rotenone (RTN, 1 µM) with/without idebenone (IDB, 3 µM) or decylubiquinone (DCB, 30 
µM); Aii,iv, RTN (1 µM) and oligomycin (OLG, 3 µM), alone and combined. Bi-iv, Myxothiazol (MYX, 1 µM) or antimycin (ANT, 
0.1 µM), with/without IDB (3 µM) or DCB (30 µM). *P < 0.05 and % delay in circulatory arrest or assystole; Kaplan-Meier with 
Log Rank. Data are from 40–60 embryos per treatment, from 2–3 independent clutches. IDB or DCB (IDB/DCB) alone 
maintained 100% circulation or heartbeat throughout the experiment. 
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Cytosolic dehydrogenase: NQO1. In contrast with 
mitochondrial dehydrogenases, cytosolic NQO1, unlikely 
feeds complex III physiologically, since ubiquinone 
hydrophobicity precludes significant cytosolic-
mitochondria shuttling. Pharmacologically, however, 
NQO1 may be quite relevant in reducing exogenous 
ubiquinone analogues (9, 134). Indeed, exogenous 
idebenone or decylubiquinone must travel the 
cytosol, where they may be reduced by NQO1, 
before feeding electrons to mitochondrial complex III. 
NQO1 inhibition was reported to decrease 
melanogenesis in zebrafish and melanoma cell lines 
(406). Here, we tested the NQO1 inhibitors 
dicoumarol and lapachol and both caused melanin 
defects in zebrafish embryos. Interestingly, lapachol 
was more potent than dicoumarol for melanin defects 
and presented a wider spectrum of abnormalities. 
Considering the higher NQO1 inhibiting potency of 
dicoumarol versus lapachol [IC50 = 10nM vs. 150nM, 
respectively; (407, 408)], we argue that effects may 
instead be mediated by DHODH inhibition, where 
lapachol was shown more potent than dicoumarol 
[IC50 = 61nM vs. 5 µM, respectively; (409, 410)]. 
Together, these findings suggest that the overall 
level of NQO1 activity during early zebrafish 
development is low, in contrast with that of DHODH. 
Consistently, dicoumarol failed to modulate chronic 
toxicity of menadione or β-lapachone suggesting 
they are not being significantly detoxified or 
bioactivated by NQO1. Still, specific organs like the 
heart may exhibit higher NQO1 activity, as 
addressed below. 
 
Cardiovascular abnormalities and ubiquinone. 
Mitochondrial respiratory chain dysfunction and 
ubiquinone deficiency disorders are frequently 
associated with cardiovascular manifestations (210). 
Consistently, we show that mitochondrial inhibitors 
induce cardiac oedema associated with bradycardia 
and arrhythmia in zebrafish. Interestingly, we 
identified an unusual cardiovascular phenotype for 
4NB and atovaquone, consisting in focal bleeding 
and necrosis, with pronounced cardiac oedema but 
normal heart rate. Meaningfully, 4NB inhibits 
ubiquinone biosynthesis (411), atovaquone was 
suggested to cause feedback inhibition of ubiquinone 
biosynthesis (62), and the ubiquinone precursor 4HB 
reduces atovaquone but not myxothiazol or antimycin 
toxicity. Therefore, data suggests that this unusual 
cardiovascular phenotype reflects ubiquinone 
deficiency, and may thus assist future study of 
related disorders in zebrafish. 
 
In vivo testing of quinone analogues 
 
Quinone analogues as research tools and 
chemotherapeutics. Quinone analogues are 
widespread in nature, playing key roles in electron 
transport chains and in interspecies chemical 
warfare. Their ability to interfere with biological 
processes stems from redox properties, and has 
promoted their use as research tools and as putative 
anticancer or antiparasitic drugs (8). 
 Menadione is a research tool for inducing 
oxidative stress, increasing mitochondria superoxide 
by redox cycling (412). While sometimes used as 
precursor for vitamin K, menadione may induce 
haemolysis in patients lacking glucose-6-phosphate 
dehydrogenase (413). Here, we report that 
menadione causes hypochromic anaemia in 
zebrafish when present between 24 and 32 hpf, 
following primitive erythropoiesis (400), but not when 
present for longer subsequent periods. Hence, 
instead of acute haemolysis, data suggests that 
menadione impairs zebrafish haematopoiesis, 
possibly by depolarizing mitochondria via redox-
cycling or complex I inhibition (414) and disturbing 
membrane potential-dependent biosynthesis of the 
iron-sulfur cluster haem (Figure 3.3.8D) (415). Thus, 
we suggest that menadione may be a useful 
research tool for studying erythropoiesis and its 
mitochondrial dependence in zebrafish. 
 Lapachol and β-lapachone are putative 
anticancer lead compounds, with their presence in 
plant extracts (e.g. Tabebuia impetiginosa) being 
associated with cytotoxicity against multiple cell lines 
(35). Similar reasoning applies to diospyrin, 
diosquinone, juglone and plumbagin. Here, we show 
that the LC50 of these quinone analogues in 
developing zebrafish is similar or even smaller than 
reported for cancer cells. Considering the similarities 
between cellular divisions in a developing embryo 
and in cancer cells, results suggest caution in 
interpreting data from zebrafish embryos whilst 
testing for selective anticancer toxicity. 
 Atovaquone is used therapeutically against Pl. 
falciparum malaria and Pn. jiroveci pneumonia. 
Selective toxicity for parasites versus humans is 
achieved by structural differences in atovaquone’s 
target – the cytochrome b Qo site in complex III 
(416). Here, we report a high amino acid homology of 
zebrafish, mice and humans at the Qo and Qi sites, 
confirming predicted functional differences by 
comparing LC50 of atovaquone, myxothiazol and 
antimycin with that reported for parasites. Together, 
data supports using in vivo zebrafish assays for 
comparative toxicity of mitochondria-targeted 
quinone analogues, namely in anti-malaric drug 
research. 
 
Ubiquinone analogues and treatment of 
mitochondrial dysfunction. Ubiquinone analogues are 
among the few specific therapeutic options for 
mitochondrial diseases (129). Idebenone improved 
cardiac function in Friedrich ataxia (125), with higher 
doses required for improving neurological function 
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Figure 3.3.8. Mitochondrial and cytosolic biochemical pathways with sites of drug action. A, Mitochondrial respiratory 
chain, depicting electron flow (dashed-line arrows) from substrates to oxygen, and proton (H+) pumping across the inner 
mitochondrial membrane (IMM). Drugs (blue text) and inhibitory sites (grey arrows). Note that antimycin (ANT) binds Qi, 
downstream of a potential electron exit site promoting superoxide (O2–) formation, whereas both myxothiazol (MYX) and 
atovaquone (ATV) bind the upstream Qo in complex III. B, Mitochondrial and cytosolic dehydrogenases, capable of reducing 
ubiquinone (UQ) or its analogues idebenone (IDB) and decylubiquinone (DCB). Complex I, NADH dehydrogenase; Complex 
II, succinate dehydrogenase; ETFDH, electron transfer flavoprotein (ETF) dehydrogenase; GPDHm, glycerol-3-phosphate 
dehydrogenase (mitochondrial); DHODH, dihydroorotate dehydrogenase; NQO1, NAD(P)H: quinone oxidoreductase. C, 
Lipid metabolism and other metabolic pathways feeding dehydrogenases (ETFDH, GPDHm and DHDOH) that can reduce 
ubiquinone, thus being alternatives to Complex I and II. D, Ubiquinone, melanin and haemoglobin biosynthesis. Note that: 4-
hidroxibenzoate (4HB) is a precursor for UQ synthesis, inhibited by ATV and 4-nitrobenzoate (4NB); NQO1 promotes (white 
arrows) melanin synthesis, increases and decreases β-lapachone (βLPC) and menadione (MND) toxicity, respectively. 
Dicoumarol (DCM) and lapachol (LPC) inhibit NQO1; Haem synthesis is critically dependent on mitochondria and its 
membrane potential (Δψm). 
(126). Idebenone effects have been ascribed to 
antioxidant properties (101). Further, idebenone can 
mimic ubiquinone, transferring to complex III the 
electrons received from mitochondrial 
dehydrogenases, thus promoting mitochondrial ATP 
production (418). Although ubiquinone analogues 
have failed to rescue ubiquinone deficient cells (122), 
there are also evidences that idebenone’s ability to 
rescue ATP levels correlates with NQO1 activity (9), 
promoting idebenone reduction and subsequent 
complex III feeding. Current support for this 
hypothesis stems from in vitro evidence, using cells 
or isolated mitochondria and predictive parameters 
such as ATP levels and oxygen consumption. Here, 
we explore this hypothesis in vivo, using zebrafish 
and cardiovascular parameters, testing the ability of 
ubiquinone analogues to prevent/delay cardiac 
insufficiency following induced mitochondrial 
dysfunction.  
 Idebenone and decylubiquinone significantly 
delayed cardiac insufficiency and asystole evoked by 
acute rotenone exposure. However, both drugs were 
ineffective against chronic rotenone exposure, as 
ubiquinone analogues clearly cannot sustainably 
protect from chronic multi-organ toxicity. The 
mechanisms of cardioprotection by idebenone and 
decylubiquinone in our zebrafish model are more 
likely related to increased ATP production efficiency 
than to antioxidant or reactive oxygen species (ROS) 
scavenging properties. Indeed, these ubiquinone 
analogues were without effect against both acute and 
chronic complex III inhibition, particularly with 
antimycin that is also an inducer of mitochondrial 
ROS production (419). Thus, transient cardiac 
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protection from acute rotenone exposure in zebrafish 
might be explained by higher NQO1 activity in the 
heart [as in mammals: (420, 421), allowing enhanced 
local ubiquinone analogue reduction (9, 134), and 
consequently more feeding of complex III and ATP 
production in the heart. 
 In future studies of mitochondrial dysfunction in 
zebrafish, it would be valuable to further explore 
ATP/ADP ratios as well as ROS production in this 
model organism. Significantly, Mendelsohn et al. 
(422) have monitored AMP/ ATP by HPLC and total 
ATP by luciferase assays in zebrafish. Also, 
Niethammer et al. (423) have successfully used a 
genetically encoded H2O2 sensor in zebrafish. 
 
Concluding remarks 
In summary, the present work supports zebrafish for 
studying mitochondrial dysfunction and testing 
mitochondria-targeted treatments. Our reported 
developmental and cardiovascular phenotypes 
should assist further research on mitochondrial 
diseases in this model organism. The present data, 
on mitochondrial sequence analysis and atovaquone 
effects, highlights zebrafish’s potential for the in vivo 
differential toxicity screening of mitochondria-
targeted antiparasitic drugs. Further, our in vivo 
assay identifying a delay of cardiac failure by 
idebenone and decylubiquinone may assist 
comparisons of other ubiquinone analogues, 
currently being developed as mitochondria-targeted 
drugs. Data on other quinone analogues (especially 
menadione) should assist their use as research tools. 
Lastly, our data showing a relatively low dependence 
of young zebrafish on mitochondrial complex I/II for 
ATP production should help interpret phenotypes of 
disease models linked to complex I/II inhibition. 
 
Acknowledgements. This work was supported by 
“Fundação para a Ciência e a Tecnologia” (FCT), 
Strategic Project: PEst-C/EQB/LA006/ 2011, and by 
Research Grants (PI: J. M. A. O.) PTDC/NEU- 
NMC/0237/2012 (FCT), FCOMP-01-0124-FEDER-
029649 (COMPETE), and PPII_CARDIAC and 
PPII_ZEBRA (Universidade do Porto and Santander-
Totta). B. P. is grateful to FCT for her PhD grant 
(SFRH/BD/63852/2009). 
 
EXPERIMENTAL SECTION 3.3 	  
84 
 
Figure 3.3.S1. Drug categories and structures. 
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Abstract 
 
BACKGROUND AND PURPOSE 
No current treatment avoids the progression of Parkinson’s disease. Further understanding of Parkinson’s 
disease pathophysiology and development of disease modifying drugs requires characterization of 
Parkinsonian animal models and validation of new drug targets. In this work, we further characterize the 
zebrafish Parkinson model induced by MPP+ (a dopaminergic toxin) and tested lysine deacetylase inhibitors 
(KDACi) and ubiquinone (UQ) analogues in this model.  
 
EXPERIMENTAL APPROACH 
Zebrafish larvae were chronically exposed to MPP+, UQ analogues (idebenone and decylubiquinone) and 
KDACi (tubastatin A and MS-275) from 3-6 days post fertilization (dpf) with sensorimotor reflexes, locomotor 
profile and mitochondrial complexes analysed at 6 dpf. KDAC’s (HDAC1 and HDAC6) expression was 
evaluated by qPCR and KDAC inhibition confirmed by western blotting acetylated KDAC targets. 
 
KEY RESULTS 
HDAC1 and HDAC6 were expressed during zebrafish embryonic development and their deacetylase activity 
was inhibited by MS-275 and tubastatin A, respectively. Zebrafish HDAC1 displays high functional and 
structural homology with the human enzyme. Zebrafish HDAC6, however, displays substantially lower 
structural homology with the human enzyme but, nevertheless, exhibits tubulin deacetylase activity. MPP+ 
inhibits zebrafish complex I, inducing intermittent and disorganized locomotion, and impairing head reflex. 
These phenotypes were not rescued by coexposure to UQ analogues or KDACi.  
 
CONCLUSION AND IMPLICATIONS 
This study further characterizes zebrafish MPP+-induced Parkinsonian behavioural phenotypes, thus assisting 
further studies with this model. The characterization of KDAC transcription and active deacetylation profiles, 
validates KDACs as targetable enzymes in zebrafish, highlighting the value of this in vivo model for epigenetic 
drug testing.  
 
Keywords: Parkinson’s disease, Danio rerio, idebenone, decylubiquinone, HDAC1, HDAC6, mitochondria. 
 
 
Introduction 
 
Neurodegeneration is characterized by progressive 
and selective loss of specific groups of neurons. 
The causes of neurodegeneration remain 
uncertain, but mitochondrial function has been 
largely associated to neurodegenerative disorders, 
such as Alzheimer’s (AD), Huntington’s (HD) or 
Parkinson’s diseases (PD) (424). The increasing 
prevalence of neurodegenerative diseases 
demands for currently unavailable disease 
modifying drugs. Lysine deacetylase (KDAC) 
inhibitors (KDACi) and ubiquinone analogues are 
emerging experimental therapeutics for 
neurodegeneration, whose cellular effects include 
the modulation of mitochondrial function (9, 135, 
425).  
Ubiquinone (UQ) analogues are drugs 
structurally similar to endogenous ubiquinone 
(coenzyme Q10), but generally with lower 
lipophilicity and better pharmacokinetics than 
ubiquinone. UQ analogues have antioxidant 
properties, decreasing oxidative stress generated 
by mitochondrial dysfunction, and can act as 
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electron carriers, improving electron transport in 
the mitochondrial respiratory chain (9). UQ 
analogues, particularly idebenone, have been 
tested as treatment for several neurodegenerative 
disorders. Despite no rescue of primary ubiquinone 
deficiencies in in vitro experiments (426), 
idebenone reduced cardiomyopathy and improved 
neurological function of Friedreich’s ataxia patients 
(125, 126). Additionally, idebenone improved vision 
in patients with Leber’s hereditary optic neuropathy 
(130) and OPA-1 dominant optic atrophy (131). In 
AD, idebenone was reported to improve cognitive 
function and daily living activities of 50% treated 
patients (427). Idebenone also enhanced lifespan 
and motor function of mice with mitochondrial 
dysfunction induced by HtrA2 knockout, a 
mitochondrial protease associated with HD and PD 
(428). 
KDACs catalyse the deacetylation of lysine 
residues in histone and non-histone proteins. 
Decrease histone acetylation promotes chromatin 
condensation, repressing gene transcription, the 
opposite occurring with increased histone 
acetylation (425). KDAC function is closely related 
to mitochondrial dynamics, regulating mitochondrial 
biogenesis, trafficking, fission-fusion and 
mitophagy (425). Valproic acid (VPA) and 
trichostatin A (TSA) are two pan-KDAC inhibitors 
largely used to study KDAC function: both drugs 
promoted neurogenesis and neurite outgrowth in 
rat primary cortical neurons subjected to ischemic 
conditions (429). VPA also decreased retinal 
neuronal death induced by optic nerve crush (430) 
and TSA improved the pathological conditions and 
increased the survival of a mouse model of 
amyotrophic lateral sclerosis (431). Furthermore, 
KDACi have also neuroprotective properties in 
several other neurodegenerative diseases models: 
sodium butyrate, a pan-KDAC inhibitor, restored 
normal locomotion in a Drosophila PD model (432); 
4b, a HDAC1 and HDAC3 selective inhibitor, 
improved motor and cognitive parameters and 
prevented huntingtin aggregation formation in HD 
mice brain (433); in a mouse model of AD, HDAC6 
knockout restored learning and memory, 
associated with mitochondrial trafficking 
improvement mediated by α-tubulin acetylation 
(434). 
Zebrafish became a popular biomedical due to 
several advantageous features, such as embryonic 
and larval transparency, rapid embryonic 
development, and high physiological and genetic 
homology to mammals (280). The neuronal 
pathways involved in physiology and disease are 
similar between zebrafish and mammals (300), 
thus allowing the use of zebrafish to model several 
human diseases, including neurodegenerative 
disorders such as HD (304), AD (309), amyotrophic 
lateral sclerosis (308) and PD. PD may be induced 
in zebrafish by genetic manipulation or by drug 
treatment. Gene silencing has been used to study 
PD-related genes, such as presenilin-associated 
rhomboid-like (PARL) (312) or PTEN induced 
putative kinase 1 (PINK1) (313). Drugs used to 
induce Parkinsonism in zebrafish include rotenone, 
paraquat, 6-hydroxydopamine and 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP) (319, 
320). MPTP’s active metabolite [1-methyl-4-
phenylpyridinium (MPP+)] selectively accumulates 
in dopaminergic neurons where it inhibits complex 
I, inducing neuronal cell death (248). Zebrafish is 
susceptible to MPTP/MPP+ toxicity through 
reduction of dopaminergic neurons in the posterior 
tuberculum and, presumably, serotonergic neurons 
in the paraventricular organ and hypothalamus 
(435). However, characterization of zebrafish 
locomotor changes induced by MPP+ is currently 
scarce. MPTP decreased tail reflexes (257, 258), 
travelled distance, swimming period (259) and 
speed (319). 
Ubiquinone (coenzyme Q10) has been studied 
as neuroprotective agent in mouse models of 
MPTP/MPP+ toxicity, attenuating dopaminergic 
degeneration (436). Mito-Q10, a positive-charged 
UQ analogue, inhibited the MPTP- and MPP+-
induced neurotoxicity in mouse and cellular models 
(437), but as far as we could find, there are no 
published studies with idebenone and other 
ubiquinone analogues in MPTP-induced Parkinson 
models. Regarding KDACi, VPA, sodium butyrate, 
suberoylanilide hydroxamic acid, phenylbutyrate 
and TSA decreased MPTP/MPP+ toxicity in mouse 
and/or cellular models (438). The main objectives 
of this work were to: characterize the locomotor 
profile and mitochondrial function of the zebrafish 
MPP+ Parkinson model; validate HDAC1 and 
HDAC6 as targets by monitoring their expression in 
zebrafish and by confirming their respective in vivo 
inhibition with MS-275 and tubastatin A. 
Additionally, we tested the rescuing potential of 
ubiquinone analogues (idebenone and 
decylubiquinone) and KDACi (MS-275 and 
tubastatin A) upon the MPP+-induced Parkinsonian 
phenotypes in zebrafish.  
 
Methods 
 
Drugs, solvents and solutions  
The 1-methyl-4-phenylpyridinium (MPP+), UQ 
analogues (idebenone and decylubiquinone), 
tricaine methanesulfonate and mitochondrial 
complex inhibitors (rotenone, sodium malonate and 
antimycin A) were from Sigma-Aldrich (St. Louis, 
MO, USA). Tubastatin A and MS-275, which are 
selective inhibitors of HDAC6 (439) and HDAC1 
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(440) respectively, were from Selleckchem (Munich, 
Germany). EX-527 and AGK2, which are selective 
inhibitors of SIRT1 (441) and SIRT2 (442) 
respectively, were from Tocris Bioscience 
(Abingdon, UK). MPP+ stock solution was prepared 
in water, idebenone stock solution was prepared in 
methanol and stock solutions for other drugs were 
prepared in dimethyl sulfoxide (DMSO). The 
maximal concentration of solvents used was 0.1% 
and the solvent effects in all assays were studied 
(Figure 3.4.S1). 
 
Zebrafish maintenance and drug treatments 
Adult wild-type zebrafish (Danio rerio) were 
maintained at 28 ± 1ºC, on a 14h:10h light:dark 
cycle, and handled for egg production as we 
previously described (443). Briefly, on the day 
before egg collection adults (7 females and 14 
males) were placed in a 30 L breeding tank and the 
time of egg collection (1.5h after starting the light 
period) was registered as zero hours post 
fertilization (hpf).  
At 3 days post fertilization (dpf), hatched larvae 
were randomly distributed into multi-well plates and 
maintained at the same temperature and light 
conditions of the adults. According to the number of 
larvae per condition required for each experiment, 
two types of plates were used: 12-well plates with 
15-30 larvae in 1 mL per well, or 48-well plates with 
5 larvae in 0.5 mL per well. Solutions in wells 
containing larvae (water with or without solvent or 
drugs) were renewed daily (half volume). Larvae 
were continuously exposed to drugs from 3 dpf 
onwards. Exceptions were the survival tests with 
rotenone pre-exposure, where treatment with 0.3 
µM rotenone started at 1 dpf to precede the 500 
µM MPP+ exposure starting at 3 dpf. No food was 
added to larvae throughout the experiments. 
Larvae were imaged daily with an inverted 
microscope (Eclipse TE300, Nikon, Tokyo, Japan) 
and scored as normomorphic (no apparent 
abnormality), dysmorphic (one or more 
abnormalities) or dead, using previously described 
normal development as reference (292). Dead 
larvae were removed daily during the readings.  
 
Neuromast labeling 
Control larvae and MPP+-treated larvae at 6 dpf 
were incubated for 30 min with 100 nM 
MitoTracker® Green FM. After incubation, larvae 
were anesthetized with 0.8 mM tricaine 
methanesulfonate. Fluorescent images were 
captured at 10x magnification with 488 nm 
excitation and > 510 nm emission using an inverted 
epifluorescence microscope (Eclipse TE300, Nikon, 
Tokyo, Japan), a monochromator (Polychrome II, 
TILL Photonics, Martinsried, Germany), a CCD 
camera (C6790, Hammatsu, Photonics, 
Hamamatsu, Japan) and a computer with the 
Aquacosmos 2.5 software (Hammatsu Photonics). 
 
Behavioural evaluation 
Behavioural evaluation (sensorimotor reflex and 
locomotion profile) was initially assessed daily in 
control larvae from 3-7 dpf, identifying 6 dpf as the 
suitable time period for analysis of maximal 
responses (Figure 3.4.3B and Table 3.4.2). 
Subsequently, 10 larvae per condition (in duplicate 
wells: 5+5) were treated from 3 to 6 dpf and the 
behavioural profile of normomorphic larvae 
assessed at 6 dpf. 
 
Sensorimotor reflex (Touch responses). 
Normomorphic larvae capable of spontaneous 
swimming were distributed into 12-well plates (1 
larvae per well) and allowed to acclimate for at 
least 1 min. When larvae were spontaneously 
immobilized, they were gently touched with a 
micropipette tip (20 µL) in the head or tail for the 
recording of either positive (immediate swimming) 
or negative reflexes (no movement upon touch).  
 
Locomotion profile (Spontaneous swimming). 
Normomorphic larvae were distributed into 12-well 
plates (1 larvae per well), allowed to acclimate for 5 
min, and their locomotor profile recorded for 10 min 
at 28 ± 1ºC with a HD digital camera (C525, 
Logitech). Native videos with 15 frames per second 
(fps) were converted into 5 fps with iWisoft Free 
Video Converter (www.iwisoft.com/videoconverter) 
before analysis with the Image J particle tracker 
plugin ((444); http://mosaic.mpi-cbg.de/Particle 
Tracker/). We determined the following parameters: 
total travelled distance, time in movement, 
movement speed (total travelled distance divided 
by time in movement), number of initiations and 
time in movement per initiation. We also 
determined the movement distribution throughout 
the well, the number of circles, and the time in 
centre. For these last three parameters, we divided 
the well into virtual quadrants (Figure 3.4.3A). A 
low or high standard deviation (SD) of the time per 
quadrant reports, respectively, a homogeneous or 
heterogeneous movement distribution. Larvae 
complete one circle when they pass sequentially 
through four sequenced quadrants in either 
clockwise or in counter-clockwise direction (Figure 
3A, Left). The central division out of 9 was used to 
determine “time in centre” (Figure 3.4.3A, Right). 
Locomotion profiles were scored as uniform, 
circular, one-sided, and others (Figure 3.4.3Ciii). 
All larvae analysed were capable of swimming, 
although a few did not move during the 10 min 
recording period (scored together with “others” in 
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Figure 3.4.1.Structure, expression and activity of zebrafish KDACs (HDAC1 and HDAC6). A, HDAC1 (i) and HDAC6 
(ii) homology comparison: Human, Homo sapiens; great apes (bonobo, Pan paniscus; chimpanzee, Pan troglodytes; gorilla, 
Gorilla gorilla); macaque, Macaca mullata; marmoset, Callithrix jacchus; galago, Otolemur garnettii; mouse, Mus musculus; 
rat, Rattus norvegicus; zebrafish, Danio rerio; fly, Drosophila melanogaster; nematode, Caenorhabditis elegans; yeast, 
Saccharomyces cerevisiae. Percentages of identity vs. human are shown for the entire protein (% in front of species name), 
deacetylase domains (DD) and zinc-finger ubiquitin-binding domain (Znf-UBP). (iii) Amino acid comparison of the serine-
glutamate tetradecapeptide (SE14) region for the indicated mammals. B, Developmental expression of zebrafish KDACs by 
qPCR. Data are mean ± SEM, relative to 18S expression, of n independent experiments: (i) HDAC1, n=3-8; (ii) HDAC6, 
n=3-8; (iii) SIRT1, n=3-7; (iv) SIRT2, n= 3-6. C, KDAC inhibitors (KDACi)-induced changes in histone and tubulin 
acetylation in 6 dpf zebrafish by Western blotting. Larvae treatment (3-6 dpf) with 10 µM MS-275 or 1 µM tubastatin A 
induced acetylation in histone H3 (H3K9) or α-tubulin, respectively. β-Actin was used as loading control. 
 
 
 
locomotion profile). 
 
Activity of mitochondrial respiratory 
complexes 
 
Sample preparation. At 6 dpf, 30 whole larvae per 
treatment condition were sonicated (Sonics Vibra-
cell) in ice-cold lysis buffer (250 mM sucrose; 20 
mM HEPES; 3 mM EDTA, pH 7.5) (403) followed 
by 3 freeze-thaw cycles. Samples were then 
centrifuged at 600 g (10 min, 4ºC) and the 
supernatant re-centrifuged at 20,000 g (25 min, 
4ºC) yielding the mitochondrial pellet that was 
resuspended in ice-cold lysis buffer. For separate 
head vs. body mitochondria assays, 100 larvae per 
treatment condition were divided with a scalpel 
blade in ice-cold lysis buffer prior to sonication. 
Protein concentration in mitochondrial samples was 
quantified via Bradford method using bovine serum 
albumin (BSA) standards (445). 
 
Citrate synthase. Citrate synthase activity was 
determined by measuring 5-thio-2-nitrobenzoate 
absorvance, spectrophotometrically at 405 nm in a 
microplate reader (Biotek Synergy HT®). Kinetic-
readings were performed at 30ºC in 30s intervals, 
in 96-well plates containing 25 µL of mitochondrial 
suspension (approximately 3 µg of protein) and 
200 µL of assay buffer [10mM Tris-HCl, 500 µM 
5,5'-dithiobis-(2-nitrobenzoic acid), pH=8.1] with 
200 µM acetyl coenzyme A. After 5 min of basal 
readings, 1 mM oxaloacetate was added to the 
wells and changes in signal recorded for 30 min 
(446). 
 
Complex I. Complex I activity was quantified by 
monitoring 2,6-dichlorophenolindophenol (DCPIP) 
reduction (decreased DCPIP absorbance at 600 
nm). Kinetic-readings at 30s intervals were 
performed at 30ºC with a microplate reader (Biotek 
Synergy HT®). Mitochondrial suspensions (25 µL 
with approximately 3 µg of protein) were incubated 
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in 96-well plates with 150 µL of assay buffer (25 
mM KH2PO4, 5mM MgCl2, pH=7.2) supplemented 
with 3.5 mg/mL BSA, 120 µM DCPIP and 50 µM 
ubiquinone Q1, during 5 min. 125 µM β-
nicotinamide adenine dinucleotide (NADH) was 
then added and absorbance changes recorded for 
15 min, followed by rotenone (7 µM) addition to 
determine the rotenone-insensitive DCPIP 
reduction rate (taken as non-complex I mediated) 
for an additional 15 min (Figure 3.4.4B) (447). 
 
Complex II. Complex II activity was determined 
similarly to complex I (DCPIP reduction) except 
that the assay buffer was supplemented with 4 µM 
antimycin A, 7 µM rotenone, 50 µM DCPIP and 50 
µM ubiquinone Q1. Also, different from complex I 
determination was the use of 20 mM succinate and 
5 mM malonate instead of NADH and rotenone, 
respectively (403).  
 
KDAC sequence homology  
HDAC1 and HDAC6 protein sequences were 
obtained from NCBI (http://ncbi.nlm.nih.gov/protein). 
For HDAC1: Homo sapiens CAG46518.1; Pan 
paniscus XP_003828201.1; Pan troglodytes 
JAA34765.1; Gorilla gorilla XP_004025419.1; 
Macaca mulatta AFJ71458.1; Callithrix jacchus 
JAB49873.1; Otolemur garnettii XP_003801297; 
Mus musculus AAI08372.1; Rattus norvigecus 
NP_001020580.1; Danio rerio AAI65208.1; 
Drosophila melanogaster AAC61494; 
Caenorhabditis elegans O17695.1; 
Saccharomyces cerevisiae AAB20328.1. For 
HDAC6: H. sapiens NP_006035.2; P. paniscus 
XP_003807271.1; P. troglodytes JAA44515.1; G. 
gorilla XP_004064155.1; M. mulatta AFI34191.1; C. 
jacchus XP_002762913.2; O. garnettii 
XP_003799739.1; M. musculus AAH41105.1; R. 
norvigecus XP_001057931.1; D. rerio 
XP_693858.5; D. melanogaster AFI26269.1; C. 
elegans Q20296.2; S. cerevisiae CAA95883.1. 
Percentages of identity were calculated using 
BLAST (http://ncbi.nlm.nih.gov/Blast.cgi). 
 
KDAC gene transcription (qPCR) 
In each experiment, 15 larvae per condition at 3, 4, 
5 and 6 dpf were collected and stored in 
RNAlater®. RNA was extracted with illustra 
RNAspin Mini RNA isolation kit (GE Healthcare, 
Piscataway, NJ, USA), according to manufacturer’s 
instructions, and quantified spectrophotometrically 
at 260 nm. RNA purity was assessed by 260/280 
nm absorbance ratio and by agarose (1.2%) gel 
electrophoresis. cDNA were synthesized from 0.5 
µg RNA using the iScriptTM cDNA synthesis kit 
(Bio-Rad, Hercules, CA, USA), according to 
manufacturer’s instructions. KDAC expression 
levels were determined using qPCR (Bio-Rad, 
iQTM5): 4 µL cDNA diluted 1:10 was added to the 
reaction mixture containing 1x iQTM SYBR Green 
supermix (Bio-Rad) and 200 nM of each primer 
(Table 3.4.1), in a final volume of 20 µL.  qPCR 
primers for HDAC1 and HDAC6 were designed 
with Primer-BLAST (http://www.ncbi.nlm.nih.gov/ 
tools/primer-blast/) using the zebrafish KDAC DNA 
sequences available in Ensembl (http://www.en 
sembl.org/index.html). Primers were synthetized by 
Stab-Vida (Setúbal, Portugal). 18S was used as a 
reference gene (448). qPCR primers for SIRT1, 
SIRT2 and 18S were previously described in 
literature (449-451). qPCR initiated with 3 min 
denaturation at 95ºC, followed by 40 cycles of 
denaturation, annealing and extension with 
conditions summarized in Table 3.4.1 for each 
gene. A melting curve and a standard curve with 5-
fold serial dilutions of cDNA were generated in 
each qPCR reaction. PCR products were analysed 
in an agarose (1.2 %) gel electrophoresis to 
confirm the presence of single bands and the 
respective size of the amplified product (Figure 
3.4.S2). Relative gene expression was calculated 
using the 2-ΔΔCt procedure (452) and normalized to 
18S expression. 
 
Western blot 
30 Larvae per condition at 6 dpf were sonicated 
(Sonics Vibra-cell) in ice-cold lysis buffer (50 mM 
Tris-HCl, pH 7.4, 1% NP-40, 0.25% Na-
deoxycholate and 1 mM EDTA) supplemented with 
protease and phosphatase inhibitor cocktail 
(10085973, Fisher Scientific, Loures, Portugal). 
After sonication, lysates were incubated during 1h, 
at 4ºC, and then centrifuged at 12,000 g for 10 min. 
Supernatant protein concentrations were quantified 
by the Bradford method (445). Lysate samples 
were heated at 95ºC for 5 min in the presence of 
6x sodium dodecyl sulphate (SDS) sample buffer 
and 5% β-mercaptoethanol, as previously 
described (453). Equal amounts of protein (50 µg) 
were loaded into 12% SDS-PAGE (polyacrylamide 
gel electrophoresis) gel and the electrophoresis run 
at 125 V, for 70 min, using the Mini-PROTEAN® 
Tetra Cell (Bio-Rad). Proteins were then 
transferred into a nitrocellulose membrane, during 
1.5 h, at 40 V, using the Mini Trans-Blot® Cell (Bio-
Rad) (4ºC). Protein transference was assessed by 
Ponceau S staining. Membranes were blocked with 
5% non-fat dry milk in PBST [phosphate buffered 
solution (PBS) with 0.05% Tween 20], overnight, at 
4ºC. Membranes were incubated with primary 
antibodies during 1h, at room temperature: rabbit 
polyclonal anti-histone H3 (acetyl K9) (1:1000) 
(ab10812; Abcam, Cambridge, UK); mouse 
monoclonal anti-acetylated-α-tubulin (1:5000) 
(T6793; Sigma-Aldrich); rabbit polyclonal anti-β-
actin (1:5000) (ab8227; Abcam). After washing with 
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Table 3.4.1. Primer sequences and qPCR conditions during 40 cycles for the indicated genes. 
PBST, membranes were incubated with secondary 
antibodies conjugated with horseradish peroxidase 
(HRP) for 1 h, at room temperature [donkey 
polyclonal HRP-conjugated secondary antibody 
anti-rabbit (1:50000) (ab98503; Abcam) and 
donkey polyclonal HRP-conjugated secondary 
antibody anti-mouse (1:10000) (ab98799; Abcam)]. 
β-actin was used as loading control. Proteins were 
detected using Immun-StarTM WesternCTM 
Chemiluminescence kit (Bio-Rad) and ChemiDocTM 
MP Imaging System (Bio-Rad). 
 
Statistical analysis 
Results are shown as mean ± standard error of 
mean (SEM) from n independent experiments, 
unless otherwise stated in Figure Legends. In each 
experiment, individual larvae values were averaged 
prior to ratio calculations (e.g. time in movement 
per initiation). Survival tests of larvae treated with 
MPP+ or with MPP+ and rotenone were analysed 
via Kaplan-Meier. One-way ANOVA with post test 
for linear trend was used to evaluate concentration- 
or time-dependent effects. Results were 
considered statistically different when P < 0.05. All 
statistical analyses and graphical presentations 
were performed with GraphPad Prism version 6.0 
(San Diego, CA, USA). 
 
Results 
 
HDAC1 and HDAC6 expression in zebrafish 
KDAC inhibition, mainly as a sytrategy to modulate 
gene expression, has been investigated as a 
therapeutic approach for some diseases, including 
cancer and neurodegenerative disorders (425). 
The study of the therapeutic potential of KDACi 
requires animal models with characterised KDAC 
expression and function. Therefore, in order to 
validate zebrafish as a model for testing epigenetic 
modulatory drugs such as KDACi, we performed 
homology comparisons of zebrafish HDAC1 and 
HDAC6 with that of other species, and monitored 
their expression profile during zebrafish embryonic 
development. Using the NCBI protein database, 
zebrafish HDAC1 and HDAC6 sequences were 
compared with respective homologues in primates 
and in other species that, like zebrafish, are 
commonly used as experimental models, i.e., 
mouse, rat, fly, nematode and yeast (Figure 
3.4.1A). HDAC1 is highly conserved in the species 
analysed. Human and zebrafish HDAC1 exhibit 
92% global homology (96% at the deacetylase 
domain; DD) and both contain 4 other key 
structural elements, namely, one nuclear 
localization signal (NLS) and three nuclear export 
signal (NES) sequences. Drosophila melanogaster 
(fly), Saccharomyces cerevisiae (yeast), or 
Caenorhabditis elegans (nematode), respectively, 
lack 2, 3 or 4 of the additional structural elements 
(Figure 3.4.1Ai).  
Regarding HDAC6, there is a higher variability 
between species. Human HDAC6 is constituted by 
two DD (DD1 and DD2), two NES sequences, one 
NLS, one dynein motor binding (DMB) sequence, 
one zinc-finger ubiquitin-binding protein domain 
(Znf-UBP) and one serine-glutamate 
tetradecapeptide repeat domain (SE14). Yeast 
HDAC6 homologue, HDA1, which presents one DD, 
has only 39% of percentage of identity in relation to 
human HDAC6, while zebrafish presents 50% 
(Figure 3.4.1Aii). The inter DD domain sequence 
described as dynein motor binding (DMB) in human 
HDAC6 (454) lacks homology (according to BLAST, 
NCBI), with the respective inter DD sequence of 
non-mammalian organisms, rendering uncertain 
the existence of a functionally equivalent DMB 
domain in these species. Additionally, known NES 
and NLS sequences were also absent from the 
HDAC6 protein of zebrafish, fly, nematode and 
yeast, meaning that their relative HDAC6 cellular 
distribution may differ from human HDAC6 (Figure 
3.4.1Aii). SE14 is suggested responsible for stable 
HDAC6 cytoplasmic retention (455) and present in  
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Figure. 3.4.2. Survival and neuromast labelling in MPP+-treated zebrafish larvae. A, Time-dependent survival of control 
larvae vs. MPP+ treatment (0.1 – 3 mM) starting at 3dpf. Each treatment condition was assessed in 26-39 individual larvae, 
randomly sampled from a synchronized multiparental clutch. B, Normomorphic (white circles), dysmorphic (grey triangles) 
and dead (black circles) larvae, at 6 dpf, after 3 days of treatment (3-6 dpf) with MPP+ at the indicated concentrations. Data 
are mean ± SEM of 3-9 independent experiments. C, Representative neuromast labelling in control and MPP+- treated 
larvae (1 mM from 3 to 6 dpf). Both images were taken at 6 dpf. 
 
 
higher primates. Marmoset and galago present 
only 5 and 1 SE14 repetitions, respectively, while 
higher primates present 8, being uncertain whether 
this domain is functional in marmoset and galago 
(Figure 3.4.1Aiii).  
Zebrafish expressed HDAC1 and HDAC6 
during the studied period: 1-6 dpf (Figure 3.4.1B). 
HDAC6 expression is almost constant during the 
embryonic development, whereas HDAC1 
expression decreases from 3 to 6 dpf. In order to 
better characterize the KDAC expression, the 
SIRT1 and SIRT2 expression were also studied 
during zebrafish embryonic development: SIRT1 
and SIRT2 showed a robust increase in expression 
until 4 dpf, and subsequently declined. We tested 
whether KDAC inhibitors (HDAC1, 10 µM MS-275; 
HDAC6, 1 µM tubastatin A; SIRT1, 10 µM EX-527; 
SIRT2, 1 µM AGK2) would induce compensatory 
changes in transcription of their target enzyme, but 
found no changes in larvae treated from 3 to 6 dpf 
(Figure 3.4.S3). In spite of structural differences 
between zebrafish and human HDAC6, the 
selective HDAC6 inhibitor, tubastatin A, increased 
acetylation of zebrafish α-tubulin K40, a HDAC6 
target (439) (Figure 3.4.1C). Similarly, MS-275, a 
selective inhibitor of human HDAC1 (440), 
increased acetylation of zebrafish histone H3K9 
(Figure 3.4.1C).  
 
MPP+ induced locomotor abnormalities in 
zebrafish 
MPP+ is a known dopaminergic neurotoxin (248), 
previously tested in zebrafish, but with limited 
characterization of associated locomotor changes 
(257-259, 319). For MPP+ concentration selection 
we tested different concentrations in a larvae 
survival test without feeding. Control larvae 
survived until 10 dpf. MPP+ treatment, starting at 3 
dpf, accelerated larval death in a concentration-
dependent manner, with 100 µM being the highest 
concentration where survival was no different from 
control (Figure 3.4.2A). Considering the 
experimental time period 3-6 dpf, 1 mM (1000 µM) 
MPP+ was the highest concentration without 
significant changes in dysmorphic or dead embryos 
(Figure 3.4.2B), and it also did not affect 
neuromast labelling at 6 dpf (Figure 3.4.2C). 
Neuromasts are sensory structures, rich in 
mitochondria (456), which help in evaluating the 
MPP+ selective toxicity to central nervous system 
(CNS). 
Sensorimotor reflexes (tail and head touch 
responses) and locomotor profiles monitored daily 
from 3-7 dpf under control conditions highlighted 6 
dpf as the best period for these behavioural 
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Figure 3.4.3. Behaviour analysis in control and MPP+–treated larvae. A, Virtual quadrant (Q) division for automated 
locomotion analysis in microplate wells. B, Developmental-dependent (3-7dpf) changes in time in movement (white circles; 
right Y axis; 0-600 seconds), and sensorimotor reflexes evoked by tail- (grey circles) or head-touch (black circles) in % of 
control normomorphic larvae (left Y axis). Data are mean ± SEM, of 5 independent experiments, each performed with 10 
larvae. C, (i) Representative time (s) vs. distance (mm) profile of control and MPP+-treated (3-6 dpf) larvae at the indicated 
concentrations, with readings at 6 dpf; (ii) time in movement, tail and head reflexes; (iii) locomotion patterns scored as 
uniform, circular, one-sided and others, according to representative tracings shown in (iv). Data are mean ± SEM, of 3-8 
independent experiments, each with at least 10 larvae per treatment condition. *P<0.05, One-way ANOVA with post test for 
linear trend: (ii) time in movement, tail and head reflex; (iii) uniform profile. 
 
 
analyses. More than 95% of larvae presented a 
positive tail reflex at 3 dpf, whereas only about 56% 
presented head reflex, the latter reaching 
maximum at 4 dpf (Figure 3.4.3B). Locomotor 
parameters were maximal at 5–6 dpf (Table 3.4.2), 
as represented by ‘time in movement’ (Figure 
3.4.3B). Higher locomotion corresponded to 
increased time in movement, travelled distance, 
number of described circles, time in centre and 
higher time in movement per initiation (Table 3.4.2). 
We stress that the number of initiations must be 
analysed together with other parameters (e.g. time 
in movement), as initiations can be low for larvae 
with very low motility, as well as for those with high 
motility that do not stop. Higher locomotion was 
also associated with lower SD for movement 
distribution (Table 3.4.2), meaning uniform 
movement (Figure 3.4.3Civ, Top Left) across the 
well’s quadrants (Figure 3.4.3A, Left). We thus 
chose 6 dpf as the time for behavioural evaluation. 
We started treatments at 3 dpf, not only because 
hatched larvae avoid chorion permeability issues, 
but also because at 3 dpf their CNS is significantly 
developed and with a spatial distribution of 
dopaminergic neurons similar to that found in adult 
zebrafish (316). 
MPP+ (100, 500 and 1000 µM; from 3-6 dpf) 
concentration-dependently induced behavioural 
abnormalities at 6 dpf (Figure 3.4.3C; Table 3.4.2). 
100 µM MPP+ changed little or none of the 
parameters vs. control, whereas 500 and 1000 µM 
MPP+ significantly affected multiple parameters. 
We thus focused on 500 µM MPP+, as the minimal 
effective concentration (Figure 3.4.3C, Table 
3.4.2) and with arguably selective dopaminergic 
toxicity at 6 dpf (no effect on survival, morphology 
or neuromasts; Figure 3.4.2). 500 µM MPP+ 
selectively decreased the head touch response, 
without affecting the tail response (Figure 3Cii, 
black vs. grey circles, as % of total normomorphic 
larvae – Left Y axis). Interestingly, MPP+ did not 
change movement speed, but increased the 
number of initiations (or stops) albeit swimming for 
shorter periods, thus resulting in decreased total 
distance, total time in movement, and time in 
movement per initiation (Table 3.4.2). Also, 500 µM 
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Table 3.4.2. Locomotor parameters of control and drug-treated larvae at the indicated dpf. Drug treatment was from 3 
to 6 dpf. Larvae locomotion was analysed during 600s. Data are mean ± SEM of 3-8 independent experiments, each with at 
least 10 larvae per treatment condition.  
 
 
MPP+ decreased the number of circles and 
movement uniformity (increased SD for quadrant 
permanence – Table 3.4.2, and decreased % 
larvae with uniform movement – Figure 3.4.3Ciii, 
iv). 
 
MPP+ inhibited zebrafish complex I activity. 
MPP+ toxicity is typically associated with complex I 
inhibition (248). To verify this assumption in the 
zebrafish model and test for additional MPP+ 
mitochondrial effects, we assessed the activity of 
mitochondrial complex I, complex II, and citrate 
synthase, together with the quantification of the 
total mitochondrial protein per larvae. Larvae 
treated with MPP+ (100, 500 or 1000 µM) from 3 to 
6 dpf exhibited no change in complex I, complex II 
and citrate synthase activity nor in total 
mitochondrial protein per larvae (Figure 3.4.4A). In 
contrast, low concentrations of the complex I 
inhibitor rotenone (0.1 µM from 3-6 dpf) sufficed to 
decrease complex I activity by 49.3 ± 25.4 %, and 
also decreased mitochondrial protein by 32.2 ± 
5.32 % (Figure 3.4.4A). We then tested whether 
MPP+ (100, 500 and 1000 µM from 3-6 dpf) 
differentially affected head (enriched in brain 
mitochondria) vs. body (enriched in muscle) 
mitochondria (Figure 3.4.4C). When corrected for 
total mitochondrial protein, complex I, complex II 
and citrate synthase activity were lower in head vs. 
body mitochondria under control conditions, 
possibly due to functional differences between 
brain and muscle mitochondria. The positive 
control rotenone (0.1 µM) strongly reduced 
complex I but not complex II or citrate synthase 
activity, with a modest reduction in both head and 
body mitochondria protein per larvae (Figure 
3.4.4Ci-iv). Interestingly, MPP+ at 100 and 500 µM 
exhibited a trend towards increased complex I and 
II activity in head, but not body mitochondria, that 
disappeared at 1000 µM together with a trend for 
decreased citrate synthase activity (Figure 3.4.4Ci-
iii). 
Given the modest changes observed in 
mitochondrial extracts from MPP+ exposed larvae, 
we tested the effects of directly adding MPP+ to 
control mitochondrial extracts. Direct MPP+ addition 
to mitochondrial extracts concentration-
dependently inhibited complex I but not complex II 
activity, with 1 mM and 5 mM, respectively, 
reaching 41.0 ± 5.63 % and 62.3 ± 9.50 % 
inhibition, One-Way ANOVA with test for linear 
trend P < 0.05 (Figure 3.4.4D). While substantial 
complex I inhibition in mitochondrial extracts was 
only achieved with high MPP+ concentration, lower 
concentrations added to live larvae are likely to 
accumulate selectively in dopaminergic neurons via 
dopamine transporter uptake (258). Moreover, 
mitochondrial membrane potential (Δψm)-
dependent MPP+ accumulation should substantially 
increase the actual concentration in the vicinity of 
mitochondrial complexes (261). We thus tested 
whether combined chronic exposure of MPP+ (500 
µM) with rotenone (0.3 µM; aiming to depolarize 
mitochondria) would modify larvae survival. In co-
exposure, the mean survival of rotenone plus MPP+ 
(CI 95% = 8.3-8.7 days) overlapped that of MPP+ 
alone (CI 95% = 8.0-8.7 days). In pre-exposure 
experiments, however, rotenone (starting at 1 dpf) 
combined with MPP+ (starting at 3 dpf) allowed for 
a modest increase in mean survival (CI 95% = 8.3-
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Figure 3.4.4. Mitochondrial parameters in control, MPP+-, and rotenone-treated larvae. A, Complex I (i), complex II (ii) 
and citrate synthase (iii) activity and mitochondrial protein (iv), at 6 dpf, in larvae treated with MPP+ (white bars) or 0.1 µM 
rotenone (black bars), in % of control. Data are mean ± SEM of 4 independent experiments, each with at least 30 larvae per 
treatment condition. B, Representative graph of complex I activity assessment, shown as DCPIP consumption (nmol) over 
time (s). Reaction started with NADH addition at 300s and stopped with rotenone at 1200s. C, Complex I (i), complex II (ii) 
and citrate synthase (iii) activity and mitochondria protein (iv), at 6 dpf, in MPP+ and 0.1 µM rotenone treated-larvae, 
separated into head (white bars) and body (black bars) prior to measurements. Data are mean ± SEM of 3-5 independent 
experiments, each with at least 100 larvae per treatment condition, expressed in % control (mean value between control 
head and tail data = 100%). A, C, Larvae treatment occurred from 3 to 6 dpf. D, Complex I and II activity quantification in 
control mitochondrial extracts acutely exposed to MPP+ at the indicated concentrations. Data are mean ± SEM in % control 
(no MPP+) of 4-5 independent experiments, each with at least 30 larvae per treatment condition. *P< 0.05, One-way ANOVA 
with post test for linear trend. E, Time-dependent survival in larvae treated with MPP+ (500 µM) with or without rotenone (0.3 
µM) co-exposure (Left; i) or pre-exposure (Right, ii). Data are from 30-45 larvae per treatment in rotenone pre-exposure 
assay and 26-39 larvae per treatment in rotenone co-exposure assay, randomly sampled from a synchronized multiparental 
clutch. 
 
-8.6 days) vs. MPP+ alone (CI 95% = 7.9-8.2 days) 
(Figure 3.4.4E). Thus, these findings are compatible 
with the hypothesis that MPP+ toxicity for zebrafish 
larvae is Δψm-dependent. 
 
Discussion 
 
Zebrafish express HDAC1 and HDAC6 with 
deacetylase activity 
KDAC inhibitors are putative neuroprotective 
compounds (457), and have the potential to 
modulate mitochondrial dynamics (425). Here we 
investigated the impact of HDAC1 or HDAC6 
inhibition upon the MPP+-induced Parkinsonian 
phenotype in zebrafish. HDAC6 partakes in several 
mechanisms often impaired in neurodegenerative 
disorders, e.g. microtubule transport, misfolded-
protein degradation and autophagy (425, 458). 
Human HDAC6 has a preferential cytoplasmic 
localization where it deacetylates targets such as 
α-tubulin, cortactin or heat shock protein 90 
(HSP90). In higher mammals, HDAC6 has a 
serine-glutamate tetradecapeptide (SE14) domain 
(459) promoting its stable cytoplasmic retention in 
a leptomycin B resistant manner (455). Leptomycin 
B inhibits nuclear export by alkylating the NES 
receptor, CRM-1 (chromosome region 
maintenance 1) (460). Mice, and possibly most 
animals other than higher primates, lack the SE14 
domain in their HDAC6 homologue (Figure 
3.4.1Aii-iii), with leptomycin B promoting mouse 
HDAC6 nuclear localization (461). Despite the 
SE14 absence, mouse HDAC6 is also 
predominantly cytoplasmic, which is reported to be 	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Figure 3.4.5. Sensorimotor reflexes and locomotor profile in 6 dpf zebrafish following drug-treatment. Larvae were 
treated from 3 to 6 dpf without (white bars) or with (black bars) 500 µM MPP+, in co-exposure with solvent (control), 10 µM 
MS-275, 1 µM tubastatin A (TUB), 3 µM idebenone (IDB) or 10 µM decylubiquinone (DCB). A, Head (i) and tail (ii) reflex 
expressed in total normomorphic percentage. B, Time in movement (i), time in movement per initiation (ii), standard 
deviation of quadrant permanence (iii) and number of circles (iv). Data are mean ± SEM of 3 independent experiments, 
each with at least 10 larvae per treatment condition.  
 
 
 
 
 
Figure 3.4.6. Effect of KDAC inhibitors and ubiquinone analogues upon zebrafish mitochondrial parameters. 
Complex I, complex II (i) and citrate synthase activity and mitochondrial protein (ii) of 6 dpf larvae, treated from 3 to 6 dpf 
with 10 µM MS-275, 1 µM tubastatin A (TUB), 3 µM idebenone (IDB) or 10 µM decylubiquinone (DCB). Data are mean ± 
SEM of 3-5 independent experiments, each with at least 30 larvae per treatment condition. 
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due to the first NES that is also found in other 
mammals (461).	  
Zebrafish and Drosophila HDAC6 homologues 
lack a known NES or NLS (Figure 3.4.1Aii), but 
Drosophila HDAC6 is nevertheless preferentially 
cytoplasmically located (462). Subcellular 
localization of human HDAC6 is also regulated by 
acetylation, which favours cytosolic retention by 
preventing NLS interaction with importin-α (463). 
HDAC6 dynein motor binding domain (DMB) 
assists trafficking and clearance of ubiquitinated 
proteins by agressome formation: HDAC6 DMB 
binds dynein whereas the Znf-UBP domain binds 
ubiquitin (464). Zebrafish HDAC6 lacks a known 
DMB, with uncertain functional consequences. 
Currently, little is known about HDAC6 in zebrafish. 
HDAC6 seems necessary for zebrafish 
angiogenesis, an effect dependent of cortactin 
deacetylation (465). Thus, by lacking NES, NLS 
and DMB, the precise nature and mechanisms of 
zebrafish HDAC6 subcellular distribution and 
activity remain uncertain. Still, as with Drosophila 
HDAC6, the zebrafish homologue may also be 
preferentially cytosolic, and its cytosolic 
deacetylase activity is supported both by domain 
homology (Figure 3.4.1Aii) as well as by our 
current data showing enhanced α-tubulin K40 
acetylation with tubastatin A treatment (Figure 
3.4.1C). 
HDAC1 is evolutionarily more conserved, and 
more extensively studied than HDAC6 in zebrafish. 
Unlike HDAC6, mammalian HDAC1 is 
predominantly nuclear (466), regulating the 
expression of a wide variety of genes. Zebrafish 
neurogenesis requires HDAC1 that regulates 
several genes associated with neuronal 
specification and CNS patterning (467). 
Additionally, zebrafish heart, exocrine pancreas, 
liver, retina, craniofacial cartilage and pectoral fin 
development (468-470), melanocyte differentiation 
(471) and haematopoiesis (472), all require HDAC1.  
We show that HDAC6 gene expression is relatively 
stable throughout zebrafish development, whereas 
HDAC1 expression decreases after 3 dpf (Figure 
3.4.1B), possibly coincident with completion of 
HDAC1-dependent organogenesis. Zebrafish 
HDAC1 and HDAC6 are functionally active, with 
selective pharmacological inhibition increasing 
physiological substrate acetylation (Figure 3.4.1C). 
Structurally, zebrafish HDAC1 exhibits all key 
domains of the human isoform, some of which are 
absent from fly, nematode and yeast models. All 
non-primate models fail to fully recapitulate key 
human HDAC6 features. Even though mice and 
rats possess the DMB domain absent from 
zebrafish HDAC6, all these models lack the SE14 
domain, as do other key small organism models 
also lacking DMB  (fly and nematode) or even one 
deacetylase domain (yeast). Nevertheless, our 
data suggests that cytosolic localization and at 
least tubulin deacetylase activity are conserved in 
zebrafish HDAC6. 
 
Mitochondrial and behavioural deficits in the 
zebrafish MPP+ Parkinson model 
The similarity between zebrafish and mammalian 
nervous systems, particularly dopaminergic 
neuronal network organization (292), has 
supported its use as PD model (259, 403). We 
used the dopaminergic toxin MPP+ instead of the 
pre-toxin MPTP, due to higher handling safety, but 
also because MPP+ activity is monoamine oxidase 
(MAO) independent (Figure 3.4.7) (248), thus 
overcoming the reported potential problem of 
MPTP being a weak substrate to zebrafish MAO 
(473). Nevertheless, studies with zebrafish 
embryos (1-4 dpf) have reported equal 
susceptibility to MPP+ or MPTP (259). 
Here we report a detailed analysis of the MPP+-
induced behavioural changes (locomotion + 
sensorimotor reflexes) in zebrafish larvae (Figure 
3.4.3 and Table 3.4.2). MPP+ (500 µM)-treated 
larvae presented a locomotor profile characterised 
by short periods of acceleration, pausing more 
frequently than control larvae (Figure 3.4.3Ci). 
Thus, MPP+-treated larvae are in movement during 
less time and present a higher number of initiations. 
This profile resembles PD motor symptoms, where 
patients may present unwanted accelerations, 
rigidity, postural instability, and freezing of gait 
(474). Additionally, MPP+-treated larvae showed an 
uneven movement distribution (Figure 3.4.3Ciii, iv), 
possibly due to disorientation. MPP+ also reduced 
sensorimotor reflexes, specifically the escape 
response induced by head touch, without affecting 
the tail touch response (Figure 3.4.3Cii). Different 
neuronal circuits are involved in these responses. 
The head reflex requires trigeminal sensory 
neurons, whereas the tail reflex requires the spinal 
Rohon-Bead sensory neurons (475). As far as we 
could find, there is no evidence that MPP+ 
selectively targets trigeminal vs. Rohon-Bead 
sensory neurons. MPP+ may, however, 
delay/impair maturation of neuronal pathways 
involved in the head reflex, since the percentage of 
MPP+-treated larvae without head reflex at 6 dpf 
resembles that of control larvae at 3 dpf (when 
MPP+ treatment started) (Figure 3.4.3B, Cii). The 
delayed maturation hypothesis is supported by 
previous studies showing rescue of zebrafish 
larvae motor profile following 48h MPTP washout 
(259). There are, however, studies suggesting that 
MPTP induces dopaminergic and some 
serotoninergic neurodegeneration in transgenic 
zebrafish with GFP labelled monoaminergic 
neurons, where decreased in situ tyrosine 
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Figure 3.4.7. Mechanisms of drug-induced changes in mitochondrial bioenergetics and dynamics. MPP+, the active 
metabolite of MPTP, selectively accumulates in dopaminergic neurons via the dopamine transporter (DAT) (248). MPP+ is 
driven to mitochondria in a Δψm-dependent manner, inhibiting complex I, and possibly complexes III and IV (264). 
Mitochondrial and cytosolic dehydrogenases reduce ubiquinone analogues (idebenone, IDBH2 and decylubiquinone, 
DCBH2) that in turn transfer electrons to complex III (9). MPP+ increases mitochondrial fission (476) and autophagy (477), 
processes that might be affected by MS-275 (478) and tubastatin A (TUB) (425), respectively. Both tubastatin A and MS-
275 promote mitochondrial trafficking (425, 479), while MPP+ induces microtubule fragmentation, thus impairing 
mitochondrial transport (480). 
 
 
  
hydroxylase hybridization also suggested 
neurodegeneration (435). Rescued locomotion 
following MPTP washout may thus involve the high 
capacity of zebrafish for axonal or even neuronal 
regeneration after local lesions (300). Significantly, 
16 regions capable of neurogenesis are reported in 
zebrafish, contrasting with two particularly involved 
in formation of new neurons in mammals (481). 
Neuromast labelling was unaffected in MPP+-
treated zebrafish larvae (Figure 3.4.2C). 
Neuromasts are sensory structures arranged in the 
lateral line and head, detecting nearby vibrations 
and thus assisting behaviours such as schooling, 
prey capture, and predator escape (482). Positive 
neuromast labelling suggests that MPP+ 
impairments in the head reflex are not due to an 
abnormal lateral line, a condition that could also 
impair escape behaviour (483). Moreover, the 
neuromast core of sensory hair cells (482), highly 
enriched in mitochondria (456), should have 
displayed decreased MitoTracker labelling if MPP+ 
was acting globally via its main mechanism of 
complex I inhibition (248). Also, mitochondrial 
complex I activity was unaffected in MPP+-treated 
zebrafish, either in whole larvae or even in head vs. 
body mitochondrial extracts (Figure 3.4.4A, C). 
Nevertheless, MPP+-treated zebrafish showed 
locomotor defects, suggesting that MPP+ (500 µM) 
is selectively targeting dopaminergic neurons 
[estimated less than 1% of total human brain 
neurons (484)], thus explaining lack of complex I 
inhibition in whole mitochondria extracts. In higher 
concentrations, however and when directly 
exposed to mitochondrial extracts, MPP+ inhibited 
complex I but not complex II (Figure 3.4.4D). 
MPP+ is a cation that accumulates inside 
polarized mitochondria, whereby disruption of Δψm 
may avoid the MPP+ mitochondrial accumulation 
and consequently its effects (Figure 3.4.7) (261), 
which explains the higher MPP+ toxicity verified in 
intact mitochondria vs. submitochondrial particles 
(263). Therefore, rotenone, which causes a 
complex I inhibition and consequently disruption of 
Δψm (320), could decrease the MPP+ toxicity. In 
fact, when larvae were treated with a moderate 
concentration of rotenone able to inhibit complex I 
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before of MPP+ exposure, there was a slight 
increase of larval mean survival in relation with 
larvae treated alone with MPP+ (Figure 3.4.4E). 
Summing up, MPP+ induced a locomotor 
phenotype that may be compared with motor 
symptoms present in PD without detectable non-
selective effects. 
 
Effect of ubiquinone analogues and lysine 
deacetylase inhibitors upon MPP+ behavioural 
deficits 
KDACi and UQ analogues were reported 
neuroprotective in several neurodegenerative 
diseases models	   (427, 428, 432-434). In addition 
to respiratory chain dysfunction via complex I 
inhibition, MPP+ has also been associated with 
disturbed mitochondrial dynamics, namely 
enhanced fission (476) and decreased microtubule 
dynamics with specific disruption of mitochondrial 
axonal transport (480) (Figure 3.4.7). Given the 
KDACi potential for modulating mitochondrial 
dynamics (425) and the electron carrier properties 
of UQ analogues capable of enhancing 
mitochondrial respiratory chain activity (9, 135), we 
tested whether these compounds could 
prevent/rescue MPP+-induced behavioural   
phenotypes. No protection from MPP+, however, 
was detected in larvae co-treated with ubiquinone 
analogues or KDACi (Figure 3.4.5 and Table 
3.4.2). 
Tubulin acetylation enhances axonal transport 
(425) whereby selective tubulin deacetylase 
(HDAC6) inhibition with tubastatin A (439) might in 
principle rescue MPP+-induced impairment in 
axonal transport (480) (Figure 3.4.7). However, 
HDAC6 presents other key homeostatic roles in 
neurons, namely regulating autophagy and 
misfolded protein degradation (454), whose 
inhibition might explain lack of tubastatin A 
protection against MPP+. In fact, autophagy is 
reportedly increased in the presence of MPP+ (477), 
possibly as a protective response since autophagy 
induction with rapamycin rescued MPP+-induced 
toxicity in mice (485).  
HDAC1 inhibition with MS-275 has been 
associated with several biological responses that 
might afford protection against MPP+. MS-275 
improved axonal transport in neuronal cultures 
(479); MS-275 induced mitochondrial elongation 
through fission inhibition (478) (Figure 3.4.7), a 
process reportedly protective against MPP+ in 
human neuronal cell lines (486); and MS-275 
increased mitochondrial biogenesis in mice skeletal 
muscle and adipose tissue (487), a process 
reported protective against MPTP in in vitro (SH-
SY5Y cells) and in vivo (mice) models (488, 489). 
Nevertheless, our data with 10 µM MS-275 showed 
no protection and even worsening of MPP+ effects 
in zebrafish larvae, with 10 µM MS-275 alone 
impairing locomotion (Figure 3.4.5 and Table 
3.4.2). 
In spite of studies showing beneficial effects of 
KDACi in PD models (490, 491, these are not 
consensual findings. A higher prevalence of 
Parkinsonism was reported in patients treated with 
valproate {Jamora, 2007 #608). Additionally, the 
pan-KDACi, TSA, decreased rat, mouse and 
human neuronal cell line survival at nanomolar 
range, increasing apoptosis and neurotoxicity 
induced by MPTP and rotenone (492). Paraquat, 
another dopaminergic toxin, induced histone H3 
acetylation in the rat N27 neuronal cell line, 
decreasing the total KDAC activity. Paraquat 
toxicity was reduced by inhibition of acetylation by 
anacardic acid, a histone acetyltransferase inhibitor 
(493). As far we could find, contradictory 
information exists about MPTP-induced histone 
acetylation in mouse models. Despite different 
doses, treatment period and analysed tissue: no 
increase of histone H3 acetylation was found on 
frontal cortex (490), whereas increased histone H3 
acetylation was reported for the striatum of MPTP-
treated mice (494). Furthermore a slight increase of 
acetylated tubulin was observed in striatum and 
substantia nigra of MPTP-treated mice (495). 
We previously reported that UQ analogues, 
idebenone and decylubiquinone, delayed rotenone 
induced cardiac failure (443). This effect was 
attributed to the electron carrier properties of UQ 
analogues, transferring electrons from 
mitochondrial or cytosolic dehydrogenases to 
complex III (9). However, MPP+ may inhibit other 
mitochondrial complexes beyond complex I, 
disrupting the electron respiratory chain without an 
alternative pathway to oxidative phosphorylation 
energy production. Mitochondrial complex III and IV 
inhibition by 200 µM MPP+ was previously shown in 
isolated mice brain mitochondria (496) (Figure 
3.4.7). Furthermore, considering that MPP+ activity 
depends on Δψm (261), drugs that maintain/ 
increase Δψm may boost MPP+ accumulation and 
thus its toxicity. Previous studies support the 
beneficial effect of KDACi on mitochondrial activity. 
Pan- and class I-specific KDACi preserve 
mitochondrial function and ATP levels in neurons 
subjected to hypoxia and glucose deprivation (497). 
Idebenone protected a rodent retina ganglion cell 
line against complex I inhibition (120); while 
decylubiquinone increased mitochondrial complex I 
and II activities in synaptosomes (135) and 
restored respiratory chain activity in yeast 
mitochondria lacking endogenous ubiquinone (117). 
Thus, it is conceivable that by improving 
mitochondrial function and holding Δψm KDACi or 
ubiquinone analogues may fail to rescue or even 
aggravate MPP+ toxicity. 
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Concluding remarks  
The present work shows that HDAC1 and HDAC6 
are expressed and display functional deacetylase 
activity in zebrafish. While zebrafish HDAC1 is 
similar to mammalian HDAC1, more studies are 
needed to clarify some questions about HDAC6, 
namely whether zebrafish HDAC6 binds to dynein. 
MPP+ induced a locomotor phenotype resembling 
PD motor symptoms. However, Δψm-dependent 
MPP+ toxicity may at least partly explain the lack of 
protection verified with UQ analogues and HDAC1 
or HDAC6 inhibitors. In future studies, it will be 
valuable to assess UQ analogues and KDACi 
ability to rescue genetic PD models in zebrafish, 
namely those displaying Parkin/Pink1 mutations/ 
deficits. 
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Figure 3.4.S1. Solvent controls. A, Time-dependent survival vs. control (water) in larvae treated with DMSO (i) or 
methanol (ii) at the indicated concentrations (% solvent / water volume). Data are from 30-45 larvae per condition, randomly 
sampled from a synchronized multiparental clutch. B, HDAC1 (i) and HDAC6 (ii) expression in 0.1% DMSO-treated larvae 
vs. control (water) from 3 to 6 dpf. Data are mean ± SEM, relative to 18S expression, of 3 independent experiments, each 
with at least 15 larvae per treatment condition. C, Head (i) and tail (ii) reflex at 6 dpf in 0.1% DMSO and 0.1% methanol-
treated larvae from 3-6 dpf vs. control (water), without (white bars) or with (black bars) 500 µM MPP+. Data are mean ± SEM 
of 4 independent experiments, each with at least 10 larvae per treatment condition. D, Complex I vs. complex II activities (i); 
Citrate synthase activity and mitochondrial protein (ii) in 0.1% DMSO and 0.1% methanol-treated (3-6 dpf) larvae at 6 dpf. 
Data are mean ± SEM of 5 independent experiments, each with at least 30 larvae per treatment condition. E, Locomotor 
parameters at 6 dpf of 0.1% DMSO or 0.1% methanol-treated larvae (3-6 dpf) with or without 500 µM MPP+. Larvae 
locomotion was analysed during 600 s. Data are mean ± SEM of 3 independent experiments, each with at least 10 larvae 
per treatment condition.  
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Figure 3.4.S2. qPCR products from KDAC expression study. Representative agarose electrophoresis gel (1.2%) of 
qPCR products derived from KDAC gene transcription quantification and theoretical size product attending to gene 
sequence and primers used. BP, base pairs.  
 
 
 
 
Figure 3.4.S3. KDAC expression in zebrafish treated with the respective enzyme inhibitor over the time. A, HDAC1 
expression in 10 µM MS-275-treated larvae. B, HDAC6 expression in 1 µM tubastatin A-treated larvae. C, SIRT1 
expression in 10 µM EX-527-treated larvae. D, SIRT2 expression in 1 µM AGK2-treated larvae. Larvae treatment started at 
3 dpf. Data are mean ± SEM, relative to 18S expression, of 3-5 independent experiments, each with at least 15 larvae per 
treatment condition. 
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Table 3.4.S1. Normomorphic, dysmorphic and dead larvae at 6 dpf under control vs. the indicated drug 
concentrations from 3 to 6 dpf. Data are mean ± SEM of the relative proportions (% total), from n=3-8 independent 
experiments, each with at least 10 larvae per treatment conditions. 
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4. General Discussion 
  
 Quinones are compounds with multiple biological activities. In this thesis, 
naphthoquinones and ubiquinone analogues were the main object of study. Attending to 
all known biological activities of naphthoquinones, their potential in the modulation of 
immune system remained underexplored. Ubiquinone analogues are benzoquinones with 
high biological interest, since they act as electron carriers potentially rescuing 
mitochondrial ETC dysfunction (9). Ubiquinone analogues in models of mitochondrial 
dysfunction were thus also studied in this thesis. 
 
 
4.1. Naphthoquinones  
 
 
4.1.1. Modulation of the immune system 
 
The immune system is essential for protection against infectious agents (140). 
However, immune system deregulation is linked to several pathological conditions, 
including autoimmune diseases, chronic inflammation and allergic disorders. While 
inflammation may be required against an infectious agent, allergy can be qualified as an 
undesirable process. Little information exists on naphthoquinones’ anti-inflammatory or 
anti-allergic activity. The majority of the available literature on naphthoquinones’ anti-
inflamatory activity is focused on shikonin and β-lapachone (see General Introduction). 
This thesis, therefore, addresses the anti-infllammatory and anti-allergic properties of 1,4-
naphthoquinones (diosquinone, juglone, menadione, naphthazarin and plumbagin), and 
the anti-allergic activity of diospyrin. 
Both anti-inflammatory and anti-allergic activities were studied using cell systems: 
RAW 264.7 macrophages for inflammation and RBL-2H3 basophils for allergy. For both 
studies, naphthoquinones’ non-toxic concentration was determined using the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction assay. In both 
RAW 264.7 and RBL-2H3 cells, menadione and juglone were the least toxic compounds, 
while naphthazarin was the most toxic one, with the maximal non-toxic concentration of 
0.1 µM (Table 4.1). The same order of toxicity was previously reported in primary rat 
hepatocytes, which was related with reduced glutathione depletion (498). Öllinger and 
Brunmark (498) justified the highest naphthazarin toxicity with its highly stabilized 
semiquinone form (Figure 4.1).  
 
GENERAL DISCUSSION 
 	  
110 
Table 4.1. Naphthoquinones’ maximal non-toxic concentrations for RAW 264.7 and 
RBL-2H3 cells and concentrations lethal for 50% of a population (LC50) of zebrafish 
embryos. LC50 values as shown as mean ± standard error of the mean (SEM). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1. Stabilization of naphthazarin’s semiquinone radical.  
 
 
Naphthoquinones 
Maximal non-toxic 
concentration (µM) LC50 (µM) 
RAW 264.7 RBL-2H3 Zebrafish 
Diospyrin N.T. 1 2.00 ± 0.06 
Diosquinone 1.5 1 0.54 ± 0.17 
Juglone 5 10 0.62 ± 0.03 
Menadione 10 5 1.56 ± 0.25 
Naphthazarin 0.1 0.1 4.85 ± 0.37 
Plumbagin 1 1 0.51 ± 0.08 
N.T. Not tested    
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Electron resonance stabilizes naphthazarin’s semiquinone radical (Figure 4.1), 
thus increasing the probability of autoxidation with ROS generation (498). Other work 
confirmed a direct relation in ROS generation and naphthoquinones cytotoxicity, indicating 
that higher ROS production induces higher toxicity (346). ROS generation has also been 
reported as a mechanism by which naphthoquinones have antitumoral effects, since cell 
death is reverted by the presence of antioxidants (499, 500). 
The anti-inflammatory screening of naphthoquinones was based in the reduction of 
NO production by LPS-induced macrophages (Figure 4.2).  
 
 
Figure 4.2. LPS induces an increase of NO, IL-6 and TNF-α levels through NF-κB 
activation. LPS promotes phosphorylation of IκB through activation of IKK complex. IκB 
phosphorylation induces its degradation, allowing the translocation of NF-κB dimer (e.g. 
P50-P65 dimer) to the nucleus, where the transcription of genes linked to inflammation 
occurs.  
 
Besides being an ubiquitous intercellular messenger regulating several physiologic 
processes, NO is also an important non-specific host defence, being highly toxic towards 
infectious agents (501). In addition, NO has vasodilator properties and regulates the 
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function of host immune cells	   (502). NO reduction also contributes to allergy modulation: 
NO promotes Th2 responses (169) that are associated to allergic disorders and helminthic 
infections (166). Also, NO may be synthetized by cells involved in allergic responses, such 
as eosinophils and mast cells	  (503). Therefore, anti-inflammatory drugs may also have an 
interesting application in allergic disorders. In fact, allergy and inflammation are not 
completely separated pathologies, the first being considered a chronic inflammatory 
disease (504): in an IgE-mediated allergic reaction, the recruitment and activation of 
inflammatory cells starts an inflammatory process, which is characteristic of the late phase 
(172).  
Diosquinone was the only tested naphthoquinone that reduced NO release without 
cell toxicity (Figure 3.1.4 and 3.1.7). However, NO reduction alone is not a good 
parameter for anti-inflammatory screening, because superoxide generated during 
oxidative stress or naphthoquinones’ redox cycle may react with NO, reducing its 
bioavailability (Figure 4.3). The reaction of NO with superoxide is irreversible, forming 
peroxynitrite (a very toxic oxidant), possibly the main responsible for NO attributed toxicity 
(501). Nitration of tyrosine residues (Figure 4.3) is a hallmark of peroxynitrite toxicity (501).  
 
 
Figure 4.3. 3-Nitrotyrosine formation from superoxide (O2-) and nitric oxide (NO).  
 
Quantification of superoxide and 3-nitrotyrosine was made after cell treatment with 
diosquinone, to evaluate if the observation of reduced NO release was a consequence of 
oxidative stress. Since neither superoxide (Figure 3.1.8) nor 3-nitrotyrosine increased 
(Figure 3.1.9), diosquinone might be interfering with the LPS pathway (Figure 4.2) (74). 
NF-κB is a transcription factor that regulates expression of cell proliferation and 
inflammatory genes, including iNOS and inducible cytokines (74). Contrarily to the 
degranulation process that is preceded by a calcium influx, iNOS is not calcium activated, 
and is continuously active (503). We found no previous studies on the inhibition of NF-κB 
by diosquinone, but NF-κB might be inhibited by diosquinone, since other 
naphthoquinones [shikonin (73), β-lapachone (78) and plumbagin (85)] are known NF-κB 
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inhibitors. NF-κB inhibition is interesting in allergy management because NF-κB activation 
was found in the airway epithelium of patients with allergic asthma (505), and because 
allergens may activate NF-κB through IκB degradation (506). 
The anti-inflammatory activity of diosquinone was also assessed by reduced TNF-
α and IL-6, two pro-inflammatory cytokines enhanced by LPS (Figure 4.2) (507). TNF-α 
plays several inflammatory roles: NF-κB transcriptional regulation, production of IL-6 and 
other cytokines (508), and expression of COX-2, pro-coagulant proteins and adhesion 
molecules (509). However, TNF-α is also involved in allergy, promoting Th2 cell response 
to allergens (510). TNF-α may be produced by mast cells, the first line of response to IgE-
mediated allergy (503). Increased TNF-α was observed in human lung samples after IgE-
treatment (511). Furthermore, anti-TNF-α antibodies reduced allergic symptoms, 
eosinophilic infiltration, IgE levels, adhesion molecules expression and Th2 type cytokines 
transcription in mouse model of allergic rhinitis (512). On the other hand, IL-6 is 
considered the major stimulus for acute-phase protein synthesis, whose serum levels 
increase in acute and chronic inflammation. IL-6, in particular, promotes B cell 
differentiation into antibody-producing cells (513). Similarly to TNF-α, IL-6 promotes Th2 
cells differentiation, determining the type of adaptative immune response (514). IL-6 
release causes dysfunction of allergic asthmatic airways, through an inflammation-
independent process (514). Additionally, IL-6 associates with allergen cutaneous 
response in atopic individuals (515).  
Regarding anti-allergic activity, naphthazarin was the only naphthoquinone 
reducing IgE-antigen complex mediated degranulation (Figure 3.2.2), inhibiting a step 
upstream to intracellular calcium increase, since naphthazarin was unable to avoid 
calcium ionophore mediated degranulation. Conceivably, naphthazarin acts 
mechanistically similarly to shikonin, another naphthoquinone with 5,8-dihydroxy-1,4-
naphthoquinone core. Shikonin inhibited spleen tyrosine kinase (Syk), downstream of 
FcεRI activation by IgE-antigen complex (372). Unlike naphthazarin, diospyrin reduced 
calcium ionophore-stimulated-basophils’ degranulation (Figure 3.2.3), suggesting that 
naphthazarin and diospyrin have different mechanisms of action.  
Despite being weak hyaluronidase inhibitors, naphthoquinones inhibited soybean 
lipoxidase (Figure 3.2.6A), used to model the structurally similar human 5-, 12- and 15-
lipoxygenases (377). Naphthoquinones may inhibit lipoxidase through competition with 
endogenous lipophilic substrates, since higher inhibitory activity correlated with higher 
lipophilicity (i.e. menadione and the dimeric naphthoquinones diospyrin and diosquinone). 
Leukotrienes inhibition in cells was only confirmed for menadione. Effective menadione 
concentrations for reducing LTC4 in cells (0.005 – 5 µM) (Figure 3.2.6C) were lower than 
for in vitro lipoxidase inhibition (IC50, 128 ± 9.38 µM). Menadione may reduce leukotriene 
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production in IgE-antigen complex-induced cells by inhibiting 5-lipoxygenase and/or by 
reducing arachidonic acid availability (Figure 4.4). Menadione is a known ROS generator 
and the associated oxidative stress was reported for similar concentrations to those 
required for leukotriene reduction (380). Menadione-generated ROS may thus react with 
arachidonic acid forming oxidized lipids (Figure 4.4)	  (379). Eosinophils, macrophages and 
monocytes are also important sources of cysteinyl leukotrienes (169). Since leukotrienes 
are pro-inflammatory (516),  menadione-related drugs may help understand the role of 
leukotriene reduction  in non-allergic inflammatory conditions. 
 
      
Figure 4.4. Menadione reduces leukotriene production. Menadione may directly inhibit 
5-lipoxygenase and it may produce ROS, which induces arachidonic acid oxidation, 
reducing its bioavailability. 
 
 
 4.1.2. Naphthoquinones’ toxicity profile in an in vivo model  
 
Little information exists concerning the effects of naphthoquinones in zebrafish. In 
zebrafish embryos: menadione was studied as ROS generator (517) and as anti-cancer 
drug (518). β-lapachone and plumbagin were also studied as anticancer drugs (518) and 
dehydro-α-lapachone was identified as anti-vascular drug (519). Additionally, β-
lapachone-induced cardiovascular toxicity was previously evaluated in 24 hpf zebrafish 
(520). Naphthoquinones’ toxicity profile in zebrafish (in vivo model) was different than that 
obtained in cell lines (RAW 264.7 and RBL-2H3). Except for naphthazarin and diospyrin, 
naphthoquinones’ LC50 values in zebrafish were lower than their toxic concentrations for 
RAW 264.7 macrophages and RBL-2H3 basophils (Table 4.1). This difference of 
concentrations is probably related with the zebrafish embryonic development: during 
embryonic development, cells are highly susceptible to oxidative stress or other 
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mechanisms that may interfere with signalling pathways. In addition, the order of less toxic 
naphthoquinones to more toxic ones in zebrafish was naphthazarin, diospyrin, menadione, 
juglone, diosquinone and plumbagin. Curiously, naphthazarin that was the most toxic 
naphthoquinone in cell culture was the less toxic for zebrafish embryos, at 80 hpf (Table 
4.1). Naphthazarin induced an all or none effect, allowing directly killing normomorphic 
embryos, as indicated by the LC50/NC50 ratio (naphthazarin LC50/NC50 = 1.0 ± 0.04). When 
LC50/NC50 ratio  ~1, the concentration required to kill 50% embryos equals that required to 
halve normomorphic embryos, without dysmorphic embryos. Since naphthazarin was the 
most hydrophilic naphthoquinone it may lack chorion permeability at low concentrations. 
In contrast, plumbagin and menadione were the only naphthoquinones inducing 
abnormalities, which may be related with these naphthoquinones being the most lipophilic 
of the monomeric ones. Possibly, their lipophilicity allows gradual chorion permeation, 
allowing the progressive toxicity required for inducing non-lethal abnormalities.  
Menadione mainly induced hypochromic anaemia in zebrafish (Figure 3.3.4H), 
decreasing erythocytes and their red colour, possibly by decreases haemoglobin or even 
erythrocyte production. A short exposure (24-32 hpf) sufficed to induce hypochromic 
anaemia. Exposures excluding the 24-32 hpf period allowed normally coloured 
erythrocytes at 80 hpf. Thus, menadione’s effect on haematopoiesis is not acute. Instead, 
menadione impairs haematopoiesis in the specific period known as transient 
haematopiesis in zebrafish (400). Menadione may act by complex I inhibition (414), 
compromising Δψm that is required for producing the iron-sulfur cluster in haemoglobin 
(415). Menadione’s toxicity to erythrocytes is consistent with menadione inducing 
haemolysis in people with glucose-6-phosphate dehydrogenase deficiency (413). 
Other naphthoquinones such as atovaquone, β-lapachone and lapachol were also 
tested in zebrafish in the present thesis. Atovaquone is a synthetic naphthoquinone 
therapeutically used against Plasmodium spp. and Pneumocystis jiroveci infections, since 
its toxicity is selective to parasites vs. human cells (521). In fact, atovaquone LC50 for 
Plasmodium falciparum (0.001 ± 0.0002 µM) (522) is muchs lower than that for 
mammalian cells (15-30 µM) (523). Atovaquone induced progressive toxicity in zebrafish 
embryos, characterized by oedema without significant bradycardia and focal lesions 
(necrosis and bleedings/clots) (Figure 3.3.4A). Despite lapachol being a β-lapachone 
isomer (Figure 1.8), they presented different toxicity patterns. Lapachol induced a wide 
range of zebrafish abnormalities, most frequently decreased pigmentation, head defects, 
gastrula arrest and oedema. β-Lapachone did not induce abnormalities, but had a lower 
LC50 than lapachol for zebrafish (Figure 3.3.4F, I and Table 3.3.2). 
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4.2. Ubiquinone analogues 
 
 
4.2.1. UQ analogues in a mitochondrial dysfunction model 
 
Idebenone and decylubiquinone were tested in zebrafish, in order to study the 
modulation of respiratory chain by UQ analogues. We found no previous information 
about UQ analogues’ effects in zebrafish. Idebenone and decylubiquinone were less toxic 
than naphthzarin, the naphthoquinone with lower toxicity. Despite differing only in one 
functional group, idebenone was 4x more lethal than decylubiquinone, at 80 hpf (Table 
3.3.2). The toxicity of decylubiquinone increased abruptly at 80 hpf, coinciding with peak 
hatching, suggesting that it may be dependent on increased chorion 
permeability/dysruption. 
 
4.2.1.1. Mitochondrial dysfunction-induced toxicity in zebrafish 
 
To allow the study of UQ analogues upon the modulation of respiratory chain 
dysfunction, the effects of mitochondrial complexes inhibitors were characterized in 
zebrafish. Rotenone (complex I inhibitor) and 3-nitropropionic acid (complex II inhibitor) 
induced abnormalities, while myxothiazol and antimycin A (complex III inhibitors) directly 
induced embryonic death without previous abnormalities (Figure 4.5). Strong complex III 
inhibitor toxicity results from lack of alternative pathways for downstream electron flow in 
the mitochondrial ETC. ATP synthase inhibition (oligomycin) arrested embryonic 
development at the gastrula stage, revealing the strict dependence of mitochondrial ATP 
at or past zebrafish gastrulation.  
Atovaquone also a complex III inhibitor (521), showed a distinct toxicity profile from 
myxothiazol and antimycin A, suggesting that atovaquone has additional effects beyond 
complex III inhibition. In fact, it was previously described that atovaquone inhibits UQ 
synthesis in Pneumocystis spp. by reducing 4-hydroxybenzoate incorporation into UQ 
(Figure 4.6) (62). Consistently, 4-nitrobenzoate, another UQ synthesis inhibitor (411), 
induced a similar toxicity profile to that described to atovaquone. Therefore, the main 
mechanism of action of atovaquone in zebrafish may not be the mitochondrial complex III 
inhibition, but rather the inhibition of UQ biosynthesis. This hypothesis was strenghtened 
by rescuing atovaquone’s decrease in normomorphic embryos with the UQ precursor 4-
hydroxybenzoate (Figure 3.3.6B) (62). Significantly, 4-hydroxybenzoate failed to rescue 
the toxicity of other complex III inhibitors (myxothiazol and antimycin A), and also that of 
4-nitrobenzoate. However, lack of protection against 4-nitrobenzoate is probably related to 
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the use of very different molar concentrations (5 µM 4-hydroxybenzoate - the highest 
concentration without toxicity vs. 10 mM 4-nitrobenzoate - the lowest toxic concentration). 
It is worth mentioning that 4-hydroxybenzoate toxicity precluded equimolar concentration 
testing vs. 4-nitrobenzoate.  
 
 
 
Figure 4.5. Main effects of mitochondrial complex inhibitors in zebrafish embryonic 
development. 
 
 
 
 
Figure 4.6. Atovaquone’s mechanisms of action. Atovaquone inhibits mitochondrial 
complex III and the ubiquinone (UQ) biosynthesis. 
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4.2.1.2. Mitochondrial dysfunction rescue by UQ analogues  
 
While UQ analogues did not rescue chronic complexes I, II or III inhibitor toxicity, 
they delayed the circulation and heart beat arrest induced by acute complex I inhibition 
(Figure 4.7). Again, no rescue of acute mitochondrial complex III dysfunction was 
observed with UQ analogues (Figure 3.3.7). As previously stated, no alternative way to 
complex III exists to energy production, which explains the lack of protection against 
complex III toxicity inhibition. However, idebenone and decylubiquinone may be reduced 
by several dehydrogenases, including cytosolic dehydrogenases, directly feeding complex 
III and, consequently, allowing ATP production even when complex I was inhibited. 
Idebenone and decylubiquinone-induced protection against acute complex I inhibition was 
possibly due to increased ATP production, because rotenone asystole was also delayed 
by oligomycin (prevents ATP consumption upon rotenone induced ATP synthase reversal) 
(Figure 3.3.7). Therefore, lipophilicity of UQ analogues is a likely advantage vs. 
endogenous UQ10, because UQ analogues may be present in cytosol or in mitochondria, 
crossing biological membranes. Haefeli and collaborators suggested that the same does 
not occur with UQ10, which failed to restore the ATP levels following complex I inhibition 
(9). 
 
 
Figure 4.7. Ubiquinone analogues’ effects in zebrafish embryos acutely and 
chronically treated with rotenone. UQ analogues induced protection against acute 
rotenone exposure, but not against chronic exposure. 
 
UQ analogues were also expected to protect against acute complex II inhibition. 
However, it was not possible to test this hypothesis, because no bradycardia and 
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circulation/heartbeat arrest were verified in a short period of time using with 3-
nitropropionic acid. Additionally, chronic and simultaneous inhibitions of complex I and II 
did not induced any additive or synergic toxicity (Figure 3.3.6C), as expected if zebrafish 
had a low dependence of complex I and II to feed complex III. This hypothesis is also 
supported by other observed evidences: a) LC50 of 3-nitropropionic acid in zebrafish was 
10 times higher than the LC50 described for rat neurons, suggesting that mitochondrial 
complex II has a lower contribution to energy production (Table 3.3.2); b) dysmorphic 
embryos treated with rotenone or 3-nitropropionic acid survived beyond gástrula (Figure 
3.3.1), which is not possible without mitochondrial ATP, as it was verified using oligomycin. 
Thus, in zebrafish early embryonic development, oxidative phosphorylation is perhaps 
highly dependent on other dehydrogenases beyond complex I and II, such as 
dihydroorotate dehydrogenase, electron transfer flavoprotein dehydrogenase or glycerol-
3-phosphate dehydrogenase. The last two are involved in lipid metabolism, which is 
expected to be increased during early embryonic development, given the high lipid 
content of the zebrafish yolk (524). This lack of complex I and II dependence in early 
embryogenesis may explain why no rescue of chronic complex I and II inhibition was 
verified with UQ analogues, being also possible that chronic toxicity with rotenone and 3-
nitropropionic acid may involve off-target effects. 
Another explanation for acute complex I-induced toxicity’s rescue verified with UQ 
analogues and not against chronic toxicity is related with NQO1 expression. NQO1 is 
reported by Haefeli and collaborators to reduce UQ analogues, allowing them to restore 
ATP levels in a model of complex I dysfunction (9). NQO1 expression in zebrafish needs 
clarification; however, it is known that NQO1 is expressed in zebrafish’s cardiovascular 
system and that its inhibition by dicoumarol decreases β-lapachone [predicted to be 
bioactivated by NQO1	   (401)]-induced cardiovascular toxicity in embryos at 24 hpf (520). 
However, considering whole embryos, dicoumarol-induced NQO1 inhibition did not reduce 
β-lapachone toxicity, neither increase the menadione toxicity (Figure 3.3.4J), which is 
detoxified by NQO1 (402). Furthermore, NQO1 is known to have an essential role in 
zebrafish melanogenesis (406), being expected that NQO1 inhibition induces 
pigmentation abnormalities. In fact, dicoumarol and lapachol (also known NQO1 inhibitor) 
induced a pigmentation decrease, having been lapachol the most potent. However, 
attending to lapachol [IC50 = 150 nM (407)] and dicoumarol [IC50 = 10 nM (408)] IC50 for 
NQO1, it would be expected that dicoumarol would be more potent than lapachol 
concerning toxic effects from NQO1 inhibition, whereby lapachol effects may be, perhaps, 
due to the inhibition of other enzyme, such as dihydroorotate dehydrogenase, for which 
lapachol is more potent than dicoumarol (409, 410). Together, these findings suggest that 
NQO1 levels in whole zebrafish embryos may be low. Considering that NQO1 reduces 
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naphthoquinones into hydroquinones, generally more stable than the oxidized form (8), 
low NQO1 activity may also explain higher naphthoquinones’ toxicity to zebrafish vs. RAW 
264.7 and RBL-2H3 cells (Table 4.1). 
  
 
 4.2.2. Ubiquinone analogues in a Parkinson model 
  
 Despite the study of UQ analogues in several neurodegenerative disorders, 
including Friedrich’s ataxia (126) or Leber’s hereditary optic neuropathy (130), fewer 
studies have been done regarding PD. Idebenone increased lifespan and improved motor 
function of mice with mitochondrial dysfunction induced by knockout of HtrA2, a 
mitochondrial protease linked to PD (428). In order to test the UQ analogues as possible 
therapeutic option for PD, a parkinsonian phenotype was created in zebrafish using the 
neurotoxin MPP+.  
 
 
4.2.2.1. MPP+-induced Parkinsonian phenotype in zebrafish 
 
MPP+ is a selective dopaminergic toxin, whose main mechanism of action is 
mitochondrial complex I inhibition (248). MPP+, at 500 and 1000 µM, induced locomotor 
abnormalities without apparent morphological changes in zebrafish. MPP+-induced 
phenotype in zebrafish was characterized by a modest increase in the number of 
initiations, a decrease in travelled distance, and in time in movement (Table 3.4.2). 
Therefore, MPP+-induced a locomotor profile characterized by accelerations intercalated 
by pauses. Additionally, MPP+-treated larvae movement lacked uniformity, possibly due to 
lack of orientation. MPP+ also compromised sensorimotor reflexes (Figure 4.8), namely 
reducing the number of larvae with head reflex. Since the tail reflex was not affected, 
MPP+ may exert toxicity in specific neurons required to head reflex and not to tail reflex, 
such as trigeminal sensory neurons (475), but this lacks experimental demonstration. On 
the other hand, MPP+ may delay zebrafish development, since at 6 dpf the proportion of 
MPP+-treated larvae without head reflex resembled the proportion of control larvae wihout 
head reflex at 3 dpf (when MPP+ treatment started) (Figure 3.4.3).  
MPP+ did not change zebrafish neuromast labelling (Figure 3.4.2). Neuromasts 
are sensory structures in the lateral line that detect surrounding water movements, 
contributing to fish navigation (482). Thus, some alterations in fish movement, such as an 
abnormal escape response, may be related with neuromast abnormalities (483). Moreover, 
neuromasts are constituted by a core of sensory cells, named hair cells that are rich in 
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mitochondria (456). Therefore, neuromast labelling is a simple technique that helps 
evaluating a possible non-selective toxicity of MPP+.  
 
 
 
Figure 4.8. MPP+-induced effects in zebrafish larvae. UQ analogues did not induced 
protection against MPP+-induced phenotype. 
 
In order to confirm complex I inhibition by MPP+ in zebrafish, the quantification of 
complex I activity was made in MPP+-treated larvae at 6 dpf. Nevertheless, as it is 
estimated that dopaminergic neurons are less than 1% of the total neurons in human 
brain (484), the use of whole larvae may dilute the possible complex I inhibition by MPP+, 
since no inhibition of complex I was verified in MPP+-treated embryos (Figure 3.4.4). In 
order to overcome this problem, quantification of complex I was made in head vs. body of 
MPP+-treated larvae. Again, no inhibition of complex I was verified, but it should be 
highlighted that mitochondrial data from sectioned larvae typically presented high 
standard deviations, possibly due to the inherent variability of the sectioning-associated 
procedure. However, when higher MPP+ concentrations were added to the control larvae 
mitochondrial extracts, MPP+ inhibited complex I but not complex II. Complex I inhibition 
by MPP+ may depend on Δψm, because MPP+ is a cation that accumulates in polarized 
mitochondrion (261). This hypothesis is supported by higher MPP+ toxicity to intact 
mitochondria than submitocondrial particles (263) and by a modest increase in MPP+-
treated larvae mean survival in the presence of rotenone (reducing Δψm) (Figure 3.4.4E). 
Additionally, mitochondrial complexes III and IV inhibition was previously proposed for 
MPP+ (264). 
 
 
4.2.2.2. UQ analogues in MPP+-induced Parkinsonism 
 
Idebenone (3 µM) and decylubiquinone (10 µM) per se did not modify zebrafish 
locomotion (Table 3.4.2). Attending to the protection provided by UQ analogues against 
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rotenone-induced acute complex I inhibition, it would be expected that idebenone or 
decylubiquinone could rescue the MPP+ toxicity, since this compound is also a complex I 
inhibitor. However, no protection against MPP+ was verified with UQ analogues (Table 
3.4.2). In addition, results suggest an increase of MPP+ toxicity in presence of idebenone, 
attending to reduced travelled distance, time in movement, and number of circles. The 
possibility of MPP+ inhibiting complex III and IV (525) precludes the activity of UQ 
analogues as electron carriers, transporting electrons directly to complex III. Furthermore, 
and attending to the fact that MPP+ may need a polarized mitochondrion to inhibit the 
respiratory chain, if UQ analogues increase the efficacy of electron transference, 
enhancing Δψm (9, 115, 137), they may contribute to higher MPP+ mitochondrial 
accumulation. According to this hypothesis, MPP+ has further limitations as a PD-
modeling drug. However, a recent study reported that lycopene protects cells against 
MPP+-induced cytotoxicity and maintains mitochondrial function (526). Therefore, more 
studies are needed to explore this question and to explain how idebenone increases 
MPP+ toxicity. Related with this point, it is known that oxidized idebenone inhibits complex 
I activity in vitro (119) and promotes mPTP opening (134). However, mPTP opening 
seems to be cell-type dependent, because UQ0 inhibited mPTP opening in isolated 
hepatocytes and clone-9 cells (non-cancerous hepatocyte cells), while enhancing mPTP 
opening in MH1C1 cells (cancerous hepatocyte cells) (527). Nevertheless, oxidized 
idebenone could avoid MPP+ accumulation in mitochondrial matrix, by decreasing Δψm. 
On the other hand, the oxidized/reduced idebenone equilibrium depends on several 
factors, including NQO1 activity. If dopaminergic neurons have low NQO1 activity, UQ 
analogues may not be sufficiently reduced to feed mitochondrial complex III and bypass 
MPP+-induced complex I inhibition. In fact, NQO1 expression in human substantia nigra 
from normal individuals was found mainly in astroglial and endothelial cells, being less 
frequently found in dopaminergic neurons (244). 
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5. Conclusions 
 
Experimental results from this thesis allowed the following conclusions: 
 
1. Diosquinone was the only tested naphthoquinone that reduced NO from LPS-
stimulated cells. The anti-inflammatory activity of diosquinone includes inhibition of 
inflammatory cytokines release (TNF-α and IL-6). 
2. In RAW 264.7 macrophages, diosquinone did not induce oxidative stress, as 
evaluated by quantifying superoxide and 3-nitrotyrosine levels. 
3. Naphthazarin and diospyrin were the only tested naphthoquinones that inhibited 
basophils’ degranulation. 
4. Naphthazarin and diospyrin likely have different mechanisms of action: 
naphthazarin inhibited IgE-antigen complex-induced degranulation, whereas 
diospyrin inhibited calcium ionophore-induced degranulation. 
5. Naphthoquinones are weak hyaluronidase inhibitors. 
6. Most tested naphthoquinones inhibit soybean lipoxidase. 
7. Menadione, diospyrin and diosquinone, the most lipophilic tested 
naphthoquinones, presented the highest lipoxidase inhibitory activity, with the 
proposed mechanism being competition with endogenous lipophilic substrates. 
8. Menadione decreased leukotriene C4 release in IgE-antigen complex-induced 
basophils, possibly by a mechanims involving 5-lipoxygenase inhibition and 
decreased arachidonic acid bioavailability. 
9. With the exception of naphthazarin and diospyrin, tested naphthoquinones showed 
higher toxicity to zebrafish embryos than to RAW 264.7 or RBL-2H3 cell lines. 
10. Menadione induced hypochromic anaemia in zebrafish embryos, possibly by 
disrupting haematopoiesis. 
11. Rotenone and 3-nitropropionic acid induced abnormalities in zebrafish embryos, 
while antimycin A and myxothiazol directly killed embryos. 
12. Mitochondrial ATP is required for zebrafish embryonic development past the 
gastrula stage, as verified with oligomycin. 
13. Since the atovaquone’s toxicity profile differs from other complex III inhibitors, but 
resembles that of 4-nitrobenzoate, and atovaquone’s toxicity is partially rescued by 
4-hydroxybenzoate, the main mechanism of atovaquone toxicity in zebrafish might 
be UQ biosynthesis inhibition. 
14. Idebenone and decylubiquinone failed to protection against mitochondrial complex 
III inhibition in zebrafish. 
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15. Idebenone and decylubiquinone failed to protect against chronic complex I 
inhibition during embryonic development. 
16. Idebenone and decylubiquinone delayed circulation and heartbeat arrest induced 
by acute mitochondrial complex I inhibition. Direct feeding of mitochondrial 
complex III by reduced UQ analogues may underlie the observed protection.  
17. Early zebrafish embryonic development appears to lack a strong dependency on 
mitochondrial complexes I and II. Other dehydrogenases, mainly those involved in 
lipid metabolism, may thus be responsible for most complex III feeding. 
18. NQO1 activity in whole embryo should be low, because its inhibition by dicoumarol 
neither potentiated menadione toxicity nor decreased β-lapachone toxicity 
(compounds respectively bioactivated or detoxified by NQO1), 
19. MPP+ induced locomotor abnormalities and abnormal head reflexes in zebrafish 
larvae. 
20. MPP+ did not induce detectable toxicity in neuromasts. 
21. High MPP+ concentrations were required to inhibited zebrafish complex I in 
mitochondrial extracts. Results support the hypothesis that MPP+-induced 
mitochondrial complex I inhibition depends on mitochondrial membrane potential. 
22. Idebenone and decylubiquinone failed to rescue MPP+-induced locomotor 
phenotype. 
 
Conclusions concerning naphthoquinones and UQ analogues are summarized in Table 
5.1. 
 
Table 5.1. Main findings related with each compound. 
Quinone Main findings 
Diospyrin Reduced Calcium mobilization-induced degranulation 
Diosquinone Anti-inflammatory properties: reduced nitric oxide, IL-6 and TNF-α release 
Juglone  No significant results obtained 
Menadione 
Lipoxidase inhibition and reduced leukotrienes synthesis in cells 
Possible haematopoiesis impairment 
Naphthazarin Inhibited IgE-antigen complex-induced degranulation 
Plumbagin No significant results obtained 
  
Idebenone  Delayed acute rotenone cardiovascular toxicity in zebrafish embryos 
Decylubiquinone Lack of protection against MPP+-induced locomotor phenotype in zebrafish 
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